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Abstract
This thesis describes the development of bioorthogonal chemical tools — originally designed
to form bonds cleanly and selectively in living systems — on gold nanoparticles (AuNPs) as
a model reactive nanomaterial template to showcase chemical modifications in a facile and
robust manner. To achieve this goal, new methodologies to cleanly incorporate strained
alkyne (SA) and cargo-bearing triarylphosphine derivatives onto AuNPs were developed.
The protocols described herein provide well-defined reactive AuNP interfaces that undergo
bioorthogonal bond-forming and breaking reactions cleanly, selectively, and rapidly to
enable chemical tuning of their properties and function.
In order to circumvent the high reactivity of SAs, which hindered their incorporation onto
AuNPs, a cyclopropenone-caging strategy was employed to successfully mask the SA until
post-AuNP incorporation. Interfacial cyclopropenones were photochemically decarbonylated
using ultraviolet A (UV-A) irradiation, which proceeded cleanly and rapidly, to afford the
unmasked SA moieties. This versatile reactive AuNP template exhibited rapid reactivity with
azides (via strain-promoted alkyne-azide cycloaddition, SPAAC) and nitrones (via strainpromoted alkyne-nitrone cycloaddition, SPANC) to form robust covalent bonds with the
partner molecule, which provides an efficient and reliable route towards derivatizing AuNP
surfaces.
To further expand the scope of bioorthogonal chemistry on AuNPs, cargo-bearing
triarylphosphines were used to demonstrate the release of molecules off AuNPs via the
Staudinger-Bertozzi ligation (SBL) with azides. It was shown that functionalized AuNPs
undergo SBL in a highly specific manner to release a Rhodamine B dye — a model cargo —
from its surface. The release event was monitored from immediate turn-on of fluorescence
upon treatment with an azide. Building on this “click-to-release” design, a dualbioorthogonal molecular tool was developed to feature unprecedented versatile reactivity on
AuNPs. Four bioorthogonal transformations (SPAAC, SPANC, SBL, and a modified
perfluoroaryl Staudinger reaction, PFAA-SR) were deployed on AuNP surfaces to
demonstrate the clean and versatile reactivity this new chemical tool offers.
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In total, this thesis work describes innovative strategies to successfully incorporate
bioorthogonal functionalities onto AuNPs, methods to quantitate and follow their interfacial
chemistry, and the creation of versatile reactive AuNP templates that can be chemically
modified with ease under mild and biocompatible conditions.
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Chapter 1

1

Introduction – Bioorthogonal Chemistry for Materials
Modification

1.1 Bioorthogonal Chemistry
Over the last century, chemists and biologists have shared a common interest in
developing chemical tools to study biological molecules and processes within their native
environment. In 2008, the Nobel Prize in Chemistry was shared between Shimomura,
Chalfie, and Tsien to recognize their pioneering work that led to “the discovery and
development of the green fluorescence protein, GFP.”[1-2] The development of genetically
encoded GFP revolutionized the tracking and detection of native proteins in living
systems; however, GFP’s large size can cause significant perturbations to a target
protein’s structure — and consequently, function — and lacks amenability to biological
reporters that are not genetically encoded such as lipids, glycans, and nucleic acids. To
address this deficiency, an alternative tool for tagging biomolecules has emerged from
the chemical biology community — the bioorthogonal chemical reporter.[3-6]
A bioorthogonal chemical reporter strategy involves two distinct steps: (1) incorporation
of a unique chemical motif, often as small as a single functional group, into the target
biomolecule using the living system’s own biosynthetic metabolism; (2) this motif,
termed the chemical reporter (blue circle, Figure 1.1), must react selectively with a probe
(yellow star) bearing the complementary chemical moiety (blue arc) while avoiding side
reactions with nontarget biomolecules (grey shapes).[3] This bond-forming transformation
between two components, along with its stringent requirements, is known as a
bioorthogonal reaction.[4-7] A prototypical bioorthogonal reaction must satisfy most if not
all of the following requirements:
1. The chemical reporter and its partner must be mutually and selectively reactive
within a physiological setting (in H2O, 37 °C, pH 6–8) while remaining inert to
the myriad of functionalities found in living systems;
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2. The covalent reaction should be rapid, unaided by additional reagents, to form a
stable adduct with innocuous (or no) byproducts;
3. The chemical reporter and its installation process should be tolerated
enzymatically and not result in the perturbation of a biomolecule’s native
structure or function. As such, a small abiotic functional group that goes
‘unnoticed’ by biosynthetic pathways, such as the azide, is often employed.

Figure 1.1. The bioorthogonal chemical reporter strategy. A chemical reporter (blue
circle) linked to a substrate (light green box) is introduced into a target biomolecule
through cellular metabolism. In a second step, the reporter is covalently tagged with an
exogenously delivered probe (blue arc). Both the chemical reporter and exogenous probe
must avoid side reactions with nontarget biomolecules (grey shapes). Figure and caption
reproduced with permission from Ref. [3].
These stringent requirements, along with the fact that nucleophiles, oxidants, and
reductants are ubiquitous in living systems, means that suitable moieties for this covalent
reaction are far from obvious. Despite these challenges, in the last two decades, a handful
of bioorthogonal reactions have been developed.

1.1.1

Development of Bioorthogonal Reactions

In 2001, Sharpless introduced to the world the concept of ‘click chemistry’.[8] Although
at times loosely defined, click reactions share some common characteristics[9-11]:
1. The reaction should be rapid, high yielding, and wide in scope to generate a stable
adduct;
2. The transformation should proceed in simple reaction conditions and, ideally, is
insensitive to water and oxygen;
3. The reaction should generate only inoffensive (or no) byproducts that, if present,
can be removed without chromatography.
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The fact that these characteristics are similar to that of bioorthogonal chemistry is no
coincidence — bioorthogonal reactions are simply a subset of click reactions with the
added constraint of biocompatibility.[11] Therefore, the development of click and
bioorthogonal reactions often occurred concurrently. An obvious starting point was the
organic azide (R–N3), underscored by its small size, inert nature to many chemical and
biological functionalities while remaining energy-rich, and flexible reactivity.[11-13]

1.1.1.1

Huisgen Cycloadditions to Alkynes

The potential of the organic azide to act as a dipole for forming stable bonds was
popularized by Huisgen in 1963, although its discovery dates back to the late 1800s.[14]
Considered to be one of the most useful in the cycloaddition family of reactions, the
cycloaddition of azides and acetylenes to give stable triazoles features high functional
group tolerance and extraordinary stability towards H2O and O2. However, this
transformation is sluggish even at elevated temperatures and affords a mixture of 1,4- and
1,5-disubstituted triazoles (Scheme 1.1).[14] Sharpless and Meldal brought the acetyleneazide Huisgen cycloaddition back into the spotlight in 2002 with their independent
reports detailing the discovery that copper(I) salts catalyze the reaction, which proceeds
at room temperature and features “near perfect regioselectivity” to afford 1,4disubstituted 1,2,3-triazoles in markedly improved yields (Scheme 1.1).[15-16] This
discovery established the Cu(I)-assisted alkyne-azide cycloaddition (CuAAC) as the click
reaction benchmark and immediately led to a renaissance of Huisgen cycloadditions and
their application in synthetic organic chemistry, medicinal chemistry, materials and
biomaterials science. Namely, the CuAAC enabled the construction of more advanced
and complex structures that were previously difficult or impossible to obtain, such as the
development of diverse polymer architectures,[17-18] biomaterials,[19] drug discovery,[20]
and functional nanoparticles.[21] However, its use in living systems was limited due to the
cytotoxicity of excess Cu(I) that mediates the generation of reactive oxygen species
(ROS), which degrades delicate biomolecules.[22-24] Therefore, the CuAAC precluded
applications wherein cells must remain viable.
Alkyne-azide cycloadditions (AACs) that are activated via other mechanisms were
investigated by the synthetic community to circumvent the obstacle of Cu(I) cytotoxicity.
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Scheme 1.1. Early development of alkyne-azide cycloadditions.
Ju and coworkers demonstrated that the activation of alkynes by electron-withdrawing
substituents (such as an ester, 1.6) enabled the AAC to occur at ambient temperatures in
water without the need of Cu(I) additives (Scheme 1.2).[25] However, these compounds
were susceptible to Michael additions with biological nucleophiles. Instead, Bertozzi and
coworkers explored the activation of alkynes by means of ring strain, which later became
a landmark discovery known as the strain-promoted alkyne-azide cycloaddition (or
SPAAC, Scheme 1.2).[26] Wittig and Krebs first noted such reactivity between neat
cyclooctyne and phenyl azide, which “proceeded like an explosion to give a single
product”.[27] This unusual high reactivity, when compared to linear alkynes, is due to the
massive bond angle deformation of the acetylene to 163° when incorporated in a
cyclooctyl ring, which accounts for 18 kcal/mol of ring strain.[26] This destabilization of
the ground state provides a dramatic rate acceleration compared to unstrained alkynes. [28]
Bertozzi employed this unique reactivity to demonstrate SPAAC between 1.8 and 1.9,
unaided by Cu(I), to afford an equimolar mixture of triazoles 1.10 (Scheme 1.2). The
authors measured bimolecular rate constants (k2) ranging from 10-4 to 10-3 M-1s-1 in
CD3CN, which is several orders of magnitude slower than those observed for CuAAC.[4]
Despite having only moderate rates, they successfully employed the SPAAC for selective
modification of biomolecules and living cells with no negative effects on cell viability,
i.e. it was bioorthogonal. This represented the onset of rapid advancement in the
development of new alkyne reagents that feature increased reactivity towards azides.
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Scheme 1.2. Early examples of AACs without the use of Cu(I) additives.
Efforts to enhance cyclooctyne reactivity towards SPAAC focused on two key design
features: 1) addition of fluorine groups as electron-withdrawing substituents or 2) fusion
of pendant ring systems onto the cyclooctyne core and/or sp2 hybridization of ring atoms
to increase strain energy.[4,29-32] Additionally, considerations regarding synthetic
accessibility and availability, shelf and aqueous stability, and lipophilicity — which can
lead to nonspecific “sticking” to other biomolecules and insertion into cell membranes —
needed to be made.[4,29] To this end, a library of cyclooctynes, all featuring chemical
handles for functionalization, have been developed for use in living systems (Figure 1.2).
Figure 1.2 is not meant to be exhaustive in representing all available cyclooctyne reagents
in literature, but illustrative of key developments in the structural and kinetic tuning of
alkynes since Bertozzi’s original cylooctyne (1.9).[29] Furthermore, although less
extensively studied, electronic tuning of azide reagents was also developed to feature k2
values up to 2.0 M-1s-1 with bicyclononyne 1.18 (Figure 1.2) in CH3CN/H2O, which is
comparable to those observed for CuAAC.[33]
The addition of alternative 1,3-dipoles to strained alkynes was also explored. Pezacki and
van Delft groups independently pioneered the use of nitrones for 1,3-dipolar cyloaddition
with cyclooctynes, known as the strain-promoted alkyne-nitrone cycloaddition (SPANC),
to afford stable isoxazolines.[34-36] The authors demonstrated rapid and clean reactivity as
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Figure 1.2. Structurally modified cyclooctyne reagents for SPAAC. Figure partially
reproduced with permission from Ref. [32] with 1.18 BCN structure added from Ref.
[33]. The second-order rate constants are for the reaction with benzyl azide 1.8 in CH3CN
(1.9, 1.11, 1.12, 1.13, 1.15), methanol (1.14, 1.16, 1.17), or 3:1 CH3CN/H2O (1.18). OCT
= cyclooctyne (1st generation); ALO = “aryl-less octyne”; MOFO = monofluorinated
cyclooctyne; DIFO = difluorinated cyclooctyne; DIBO = dibenzocylooctyne; BARAC =
biarylazacyclooctynone;
DIBAC
=
dibenzoazacyclooctyne;
TMDIBO
=
tetramethoxydibenzocylooctyne; BCN = bicyclononyne.
well as its amenability for live cell imaging and protein modification.[35-36] Although not
as widely employed as its azide counterpart due to synthetic challenges and its larger
size, nitrones can potentially offer additional utility due to its rapid reactivity (k2 up to 60
M-1s-1) and their ability to bear up to three R-groups.[37]

1.1.1.2

Staudinger Ligation

It was nearly a century ago that Staudinger discovered that organic azides and trivalent
phosphines undergo imination to afford iminophosphoranes (Scheme 1.3).[38-39] Now
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known as the Staudinger reaction, this imination usually proceeds smoothly and
quantitatively via a two-step process: initial electrophilic addition of an azide (e.g. 1.8) to
a PIII center (e.g. 1.19) to give a phosphazide intermediate (1.20), which undergoes
intramolecular rearrangement (via a 4-membered ring transition state) and N2 elimination
to afford the iminophosphorane 1.21 (Scheme 1.3).[39-40] Bertozzi recognized several key
features of this transformation that satisfy the bioorthogonality criteria. Firstly, phosphine
and azide react with each other rapidly in water at room temperature in high yield.
Secondly, only N2 is produced as a byproduct. Last and most importantly, both reactive
partners are abiotic and essentially unreactive towards biomolecules inside or on the
surface of cells.[41] The only drawback is that the covalent adduct, iminophosphorane
1.21, is unstable and hydrolytically cleaves to afford phosphine oxide 1.22 and amine
1.23 (Scheme 1.3). Although synthetically useful for the reduction of azides to amines,[4243]

the Staudinger reaction did not provide the means to robustly tag chemical reporters in

living systems.
Bertozzi and coworkers resolved this problem by designing a phosphine that would
enable rearrangement of the unstable intermediate iminophosphorane to a stable covalent
adduct. In their seminal work,[41] the authors demonstrated that an appropriately situated
electrophilic trap — a methyl ester — within the phosphine structure would capture the
nucleophilic iminophosphorane via intramolecular cyclization and ultimately lead to the
formation of a stable amide bond rather than hydrolysis products 1.22 and 1.23. This
revision of the classic Staudinger reaction became known as the Staudinger-Bertozzi
ligation (or simply Staudinger ligation) and represented the first truly bioorthogonal
reaction. Soon after, Bertozzi and coworkers elucidated the mechanism of this
bioorthogonal transformation (Scheme 1.3).[40] Proceeding similarly to the Staudinger
reaction for the imination steps, iminophosphorane 1.26 results from the reaction between
azide 1.8 and phosphine 1.24. Unlike intermediate 1.21, which is unstable and hydrolyzes
in H2O, iminophosphorane 1.26 cyclizes intramolecularly to give the cyclic intermediate
1.27 and the methoxide anion (CH3O‾). In the presence of water, 1.27 hydrolyzes to
afford the stable adduct 1.28 and methanol (CH3OH). Using this new ligation strategy,
Bertozzi successfully demonstrated that cell surface azides — preinstalled via the cell
metabolism of synthetic azidosugars — could be used for cell surface engineering with
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Scheme 1.3. Mechanistic depiction of the prototypical Staudinger reaction and
Staudinger-Bertozzi ligation between benzyl azide 1.8 and triarylphosphines 1.23 and
1.26.
triarylphosphine probes via the formation of stable amide bonds.[41]
Further developments of the Staudinger-Bertozzi ligation (SBL) focused on accelerating
the transformation. Initial efforts showed that substituents on the phenyl ring of the
phosphine (1.29a-c, Scheme 1.4) had a pronounced effect on the overall rate.[40] It was
found that electron-donating substituents accelerated the SBL (i.e. rates of reaction with
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benzyl azide for 1.29c > 1.29b > 1.29a) as it favoured nucleophilic attack of the
phosphine on the azide, the rate determining step. However, increased electron density on
the phosphorous atom rendered the more reactive substrates to rapidly oxidize in air to
phosphine oxides, which are unreactive and diminished their utility.[32] Alternatively,
Bertozzi demonstrated that electronic modification of the azide partner to aryl azides with
varying substituents (1.31a-c, Scheme 1.4) resulted in iminophosphoranes that were too
stable and exhibited slow amide formation.

Scheme 1.4. Substituent effects on the rate of the SBL.
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In contrast to the reaction between benzyl azide 1.8 and phosphine 1.24, in which
phosphazide formation was rate limiting, reactions between 1.24 and aryl azides 1.31a-c
converted to intermediates 1.32a-c rapidly in <5 min. Instead, the intramolecular amide
bond-forming step became rate limiting and required up to 48 hours for complete
conversion to the ligation products (1.33a-c).[40] Presumably, resonance stabilization of
iminophosphoranes 1.32a-c reduced their reactivity and nucleophilicity relative to that
generated between benzyl azide and phosphine 1.24.
Despite challenges with improving the intrinsic kinetics of the SBL, other developments
to enhance their utility were made and reinforced the SBL as the bioorthogonal reaction
of choice for many years. Examples include the development of “traceless”[44] and lightactivated variants[45-47] that either excludes the unnatural phosphine oxide moiety from
the ligated product or improves stability towards air oxidation and enables spatiotemporal
resolution, respectively.

1.1.1.3

Other Bioorthogonal Reactions

Despite such stringent requirements as those outlined in bioorthogonality, the creation of
SPAAC and SBL methodologies inaugurated the field of bioorthogonal chemistry and
thus initiated the search for other chemical functionalities that fit these criteria. Over the
last two decades, a number of bioorthogonal reactions have been successfully developed
that have shown excellent biocompatibility and selectivity in living systems.[4,48-49] Lin
and coworkers demonstrated a mild, photoactivated 1,3-dipolar cycloaddition through in
situ generation of nitrile imines from tetrazoles using 302 nm light, which reacts rapidly
with dipolarophiles to afford stable polysubstituted pyrazolines (Scheme 1.5).[50] Termed
the tetrazole photoclick, the authors later demonstrated its use in the robust labelling of
proteins in biological media, which yielded fluorescent pyrazoline adducts and allow for
in situ monitoring.[51] Rutjes and coworkers demonstrated that azides react with
oxanorbornadienes via tandem [3+2] cycloaddition – retro Diels-Alder to eliminate furan
and form stable triazoles (Scheme 1.5).[52] Although it was shown to be effective for the
bioconjugation of radiolabeled probes to peptides,[53] in vivo studies were never reported.
Furthermore, tetrazines exhibit unique [4+2] Diels-Alder cycloadditions with strained
olefins (e.g. transcyclooctene[54] and norbornene[55]) followed by rearrangement to
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eliminate N2 and form stable adducts (Scheme 1.5). This tetrazine ligation features k2
values ranging from 101 to 103 M-1 s-1 and is among the fastest in bioorthogonal
chemistry. In addition to those described above, new chemical ligation strategies are
reported every year,[49] which offers exciting applications as these methodologies are
further investigated and refined. However, among those in the bioorthogonal toolkit, the
SPAAC and SBL are considered the most mature in the field and commercially relevant.
Due to their high synthetic accessibility and small size, the catalog of organic azides —
ranging from small molecules to large biomolecules — available commercially is by far
the most extensive compared to other bioorthogonally reactive functionalities. Thus, this
thesis examines these two transformations in focus.

Scheme 1.5. Prototypical representations of other bioorthogonal reactions.

1.1.2

Applications of Bioorthogonal Chemistry in Living Systems

Our understanding of living systems is refined by the chemical tools available for
labelling and tracking biomolecules and their associated processes. The development of
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bioorthogonal ligation strategies enabled the robust tagging of proteins, nucleic acids,
lipids and glycans in real time. Since Bertozzi demonstrated cell surface glycan labeling
using the SBL,[41] many other applications have emerged in chemical biology. Several
examples are highlighted below.
Boons and coworkers utilized the SPAAC reaction on metabolically installed azidosugars
to track relative quantities of sialic acid in living cells that have defects in
glycosylation.[56] Their investigation revealed that cells with defects in the conserved
oligomeric Golgi complex are impacted more greatly on O-glycan sialylation than
galactosylation. Kim and coworkers reported the successful pretargeted labelling of
tumour cells utilizing the SPAAC reaction in live mice with a
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F-labeled azide.[57]

Positron emission tomography (PET) imaging confirmed high tumor uptake of the
radioprobe compared to the control, which was enabled by the in vivo SPAAC reaction.
Bertozzi and coworkers reported noninvasive imaging of glycans in live developing
zebrafish using in vivo SPAAC with azide-bearing fluorescent probes.[58] Remarkably, by
employing a multicolour labelling strategy to resolve temporally distinct glycan
populations, the authors were able to visualize and differentiate cell-surface glycans
developed in the first 60 hours post-fertilization (Figure 1.3, orange fluorescence) and
those developed between 61–63 hours post-fertilization (Figure 1.3, green fluorescence).
This spatiotemporal analysis of glycan expression and trafficking, enabled by rapid
SPAAC reactivity, allowed for the identification of development patterns that would be
undetectable with conventional molecular imaging approaches. Recently, Carrico and
coworkers described a photoinitiated bioorthogonal ligation in live zebrafish.[45]
Triarylphosphines were uncaged — removal of photoprotecting group — in vivo under
focused irradiation and underwent SBL with cell-surface glycans, which resulted in
effective visualization of regions of interest in zebrafish larvae.
Unsurprisingly, the extensive application of bioorthogonal chemistry to form robust
linkages in chemical biology quickly attracted the attention of material scientists as a
viable chemical tool for the assembly of materials with more functional or complex
architectures.
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Figure 1.3. Brightfield (A, C, E) and fluorescence (B, D, F) images of zebrafish during
development. A = frontal view; B = mouth region; C = lateral view; D = pectoral fin; E,F
= embryo. Temporally distinct glycan populations resolved using two colour labelling.
Scale bars in A, C, E, F = 100 μm; B, D = 10 μm. Image reproduced partially with
permission from Ref. [58].

1.2 Nanomaterials Chemistry
Over the last three decades, scientists have witnessed explosive growth in the field of
nanotechnology. Interest in nanomaterials — defined as materials with at least one
dimension in the nanoscale — stems from their unique properties that are distinct from
small molecules and bulk materials of similar composition. Perhaps more importantly,
these properties change significantly with size and shape, and differently depending on
the material (e.g. semiconductors vs. noble metal particles).[59] Thus, two related
subfields of nanotechnology were born: 1) the synthesis of new nanostructures of
different sizes and shapes and investigation of their structure-property relationships;[59] 2)
the application of nanomaterials across scientific disciplines ranging from catalysis,[60-62]
bioimaging and sensing,[63-65] to its appearance in commercial products.[66] The next
sections focus on the latter and demonstrate how the engineering of appropriate surface
functionalities on materials is often critical to their use.

14

1.2.1

Application of Nanomaterials

Owing to their diverse sizes, shapes, composition, and thus unique intrinsic properties,
the potential applications of nanomaterials are seemingly endless. In scientific literature,
the term “nano” is ubiquitous: nano- particles (or dots),[67] clusters,[68] rods, [69] tubes,[70]
stars,[71] pyramids,[72] and sheets[73] have been reported. Their applications utilize one or
more of (but is not limited to) the following properties:
1. The material absorbs light efficiently and may be emissive or able to convert this
energy into localized heat.
2. The material’s size or shape enables its components to function as nanocarriers
for drugs, imaging probes, or biomolecules either on its surface or internally.
3. The material functions as a semiconductor.
4. The material features desirable macro properties such as tensile strength, high
surface area, or low density (lightweight).
In addition, nanomaterials provide a platform for the integration of multiple
functionalities within a single construct, which permits their use in complex
environments that require specific interactions at their interface (for example, in chemical
biology) or to assemble nanocomposite materials. Several such applications are
highlighted below.
Jung and coworkers reported a two-step pretargeting approach to cell labelling and drug
delivery using 120 ± 30 nm nanoemulsions — lipid vesicles — that utilize leucine zipper
pairs (ZE and ZR) that have an exceptionally high binding affinity and forms a stable
ZE/ZR heterodimer complex in solution (Figure 1.4).[74] In their methodology, a ZRcontaining, fluorescently-labelled antibody (4D5-FITC) was first immobilized onto the
target antigen overexpressed in tumour cells (“diagnosis”); healthy cells remained
unlabelled due to lack of the target antigen. Cells were then treated with either rhodamine
dye- or doxorubicin-containing vesicles that display ZE (“therapy”). The authors
observed successful binding of ZE-containing rhodamine-vesicles onto pretargeted
tumour cells (SKBR3), which displayed the fluorescence of FITC (from antibody) and
rhodamine (from vesicle). In the case of healthy cells (MCF10A), no fluorescence from
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the antibody or vesicles was observed, which validated their two-step pretargeted
labelling strategy. Furthermore, cell viability studies showed a significant increase in the
delivery of doxorubicin using pretreatment of tumour cells with the antibody-ZE
conjugate, whereas the absence of the conjugate (and thus pretargeting) led to no
observed cytotoxicity of drug-containing vesicles.

Figure 1.4. Left panel: Schematic representation of the two-step pretargeting approach to
cell labelling using leucine zipper pairs (ZR and ZE). A fluorescently-labelled antibody
(4D5-FITC) containing ZR first binds the target antigen overexpressed on the tumour cell
surface; normal cell is not labelled. Vesicles displaying surface ZE recognize antibodyZR conjugate and binds to form a stable ZE/ZR complex. Right panel: Fluorescence
images of MCF10A (normal human breast epithelial cells) and SKBR3 (human breast
cancer cells) after pretreatment with ZR-4D5-FITC (a, d) followed by treatment with ZErhodamine-vesicles (b,e). The overlay image (c,f) was generated by merging two signals,
where green = FITC; red = rhodamine; blue = DAPI nuclear stain. Scale bars = 10 μm.
Figures reprinted with permission from Ref. [74].
Simon and coworkers reported long-term, multicolour imaging of live cells using
emissive CdSe/ZnS quantum dots (QDs).[75] The authors demonstrated that antibodyconjugated QDs could be used to specifically label extracellular proteins of interest on
live HeLa cells, which enabled fluorescence imaging and tracking of their cell growth
and development. Over the period of one week, they observed no effect on normal
growth and development in their manipulations, which represented a non-invasive and
reliable way to label live cells. Duda and coworkers more recently demonstrated a similar
method using antibody-conjugated CdSe/CdZnS, CdSe/CdS, and InAs/CdZnS QDs in
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mice.[76] The authors observed high photostability, specific binding, and long circulation
half-life of conjugated QDs in mice blood vessels, which offers new possibilities to study
single-cell interactions and their microenvironments in live animals.
Even in the absence of drug additives, nanoconstructs can be therapeutic. Vo-Dinh and
coworkers developed a protocol to prepare cell-penetrating peptide (CPP)-functionalized
gold nanostars (NS) and demonstrated their use in plasmonic photothermal therapy.[77]
The authors observed that CPP-NS assemblies entered breast cancer cells significantly
more than bare or PEGylated NS. In addition to enhanced intracellular delivery, they
demonstrated efficient photothermolysis of tumour cells at an ultralow irradiance using
an 850 nm pulsed laser, which allows for deep tissue penetration and spatially resolved
ablation of cancerous tissue.
An alternative to photothermal therapy is photodynamic therapy (PDT), which utilizes
nontoxic photosensitizers that, when activated by a light source, generate reactive oxygen
species (ROS, 1O2) to trigger cell death. Tan and coworkers utilized the fact that carbon
nanotubes (CNTs) quench 1O2 generation of photosensitizers that are attached to its
surface to design a targeted PDT system.[78] In their design, a photosensitizer was
attached to one end of a protein-binding aptamer that wrapped onto the CNT surface
(Scheme 1.6). In the absence of thrombin, the target protein, 1O2 generation was
quenched. In the presence of its target, the CNT-aptamer binding was disturbed to favour
aptamer-target binding, which concomitantly liberates the photosensitizer from the CNT
surface to regenerate 1O2 generation. This represented the first targeted PDT system
based on 1O2 generation quenching on CNTs and is amenable to other aptamer-protein
pairs to target different proteins of interest.
Desirable properties of nanomaterials can be combined into composite materials to
further enhance their utility. Javey and coworkers fabricated CNT-hydrogel polymer
composites that feature reversible thermal and optical responsivity.[79] By utilizing
poly(N-isopropylacrylamide) (pNIPAM) loaded with CNTs in hydrogels, the authors
demonstrated that the abrupt strain change in the polymer hydrogel above the lower
critical solution temperature (LCST) could be used to actuate the folding of low density
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Scheme 1.6. Schematic of aptamer-photosensitizer-CNT complex and the regulation of
1
O2 generation upon target binding: (I) aptamer-photosensitizer and CNTs were mixed
together to form a complex where the ssDNA aptamer is wrapped on the CNT surface,
which brings the photosensitizer close to the CNT to quench 1O2 generation. (II) Target
binding with aptamers disturbs aptamer-CNT interactions, resulting in liberation of
photosensitizer from CNT surface and thus restoration of 1O2 generation. Figure
reproduced with permission from Ref. [78].

Figure 1.5. Programmable cubes – a folding cube based on thermal responsive CNThydrogel polymer actuator. Figure reprinted with permission from Ref. [79].
polyethylene (LDPE) strips (Figure 1.5). They observed a 5-fold enhancement in
response time — time required to reach a folding angle of 90° from 180° (flat) —
through the incorporation of CNTs into the polymer matrix versus without CNTs. The
authors proposed that the enhanced mass transport of water molecules through CNT
fluidic channels is the mechanism by which the response time is increased by CNTs. In
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addition to enhanced water diffusion, CNTs provide optical responsivity to near-infrared
(near-IR) irradiation. Excitation by a 785 nm laser, to which pNIPAM is transparent,
resulted in hydrogel shrinking in the irradiated area due to localized heat generation from
CNTs, which was followed by ultrafast (0.3 s) swelling to its original state after the laser
was turned off. This conversion of thermal and optical stimuli to mechanical energy,
enabled by the joint (and synergistic) properties of nanoscale materials, highlights the
potential of these programmable composites as actuators in smart devices or tissue
connectors in biological media.
In addition to the examples described above, new applications utilizing nanomaterials are
developed every year, made possible only by the unique optical, electronic, and physical
properties offered in the nanoscale.[63,65,80] Such innovations, as exemplified in the
applications described previously, require careful consideration and engineering of
surface functionalities to determine how these materials interact with and respond to their
intended environment of use. Thus, the development of functionalization methodologies
that are reliable and robust is critical to the utility of nanoscale materials.

1.2.2

General Methods of Modification

Derivatization of material surfaces with target functionalities or molecules can be
achieved in a many number of ways, ranging from weakly electrostatic interactions to the
formation of robust, covalent bonds. This section offers a brief overview of existing
methodologies that consider material composition (organic vs. metal) and their
amenability towards the incorporation of chemical handles.
Self-assembly of organic monolayers onto metal surfaces has been established and wellstudied for decades,[81-83] thus offering the most obvious method of introducing further
function onto metal-based nanomaterials. In addition, organic monolayers feature
compatibility with a wide scope of donor ligands (N, O, S, and P-based)[81,84-88] and serve
to passivate and stabilize metallic colloids from aggregation. Most commonly,
engineering of metal surfaces is achieved via treatment with thiol ligands carrying the
desired functional group, which can range from small chemical handles (-OH, -NH2, COOH)[89-90] to be used for further modification, to large biomolecules such as proteins
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via binding of their cysteine group(s).[91-92] More recently, organic reactions are
performed on terminal moieties in the monolayer to achieve the desired functionality; one
popular method uses

1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC)/N-

hydroxysuccinimide (NHS) or N-Hydroxysulfosuccinimide (sulfo-NHS) to form stable
amide bonds with the target molecule.[93-94]
Functionalization of carbon-based nanomaterials feature greater complexity due to the
inertness of their graphitic network. However, methods to chemically oxidize defect sites
using harsh (extensive ultrasonic treatment in a mixture of concentrated nitric and
sulfuric acid) or mild conditions (refluxing in nitric acid) can be used to generate surface
-OH and -COOH, among other oxygen-containing groups, that can be elaborated into
amide or ester bonds.[95-96] An alternative method relies on the use of reactive species
(e.g. radicals, carbenes, nitrenes) for direct insertion of functional groups into the πconjugated carbon framework.[96-97] It has been shown that direct covalent attachment of
functional moieties onto CNT sidewalls strongly enhances their solubility, which
improves their processability and utility.
Modification of glass or Si-based nanoparticles is most commonly achieved via treatment
with trialkoxysilanes (R–Si(OR)3) via condensation, which can be used to introduce basic
chemical functionalities (e.g. amines) that can be utilized for further surface
modification.[98-100] An alternative method uses hydrosilylation reactions of hydrideterminated silicon surfaces with terminal alkenes and alkynes to afford alkyl- and
alkenyl-substituted surfaces, respectively.[101-102]
Although not exclusive, the protocols outlined above represent general methods of
functionalizing nanoscale materials of different composition by using their intrinsic
surface chemistry. Due to limitations with compatibility and stability, it is becoming
increasingly popular to first introduce more general chemical handles followed by
subsequent organic reactions on the surface, rather than employing the materials surface
chemistry directly to introduce the target functionality. In alignment with our group’s
interest in developing organic and photochemical tools for nanomaterial modification,

20

this thesis explores different methods to enable clean and reliable reactivity on gold
nanoparticles as a model nanomaterial surface.

1.3

Gold Nanoparticles

For thousands of years, colloidal gold was used throughout Europe in stained glass
windows of cathedrals, by the Chinese to colour vases and other ornaments, and by
Indians in gold-containing ashes for medicinal use.[67,103] It was not until recent decades
that researchers began to exploit their interesting optical properties and rich surface
chemistry for applications in materials science and chemical biology. This next section
provides an overview of gold nanoparticles (AuNPs) to describe their properties,
synthesis, characterization, applications, and methods of surface derivatization.

1.3.1

Physical and Chemical Properties

Previously (and aptly) known as monolayer-protected Au clusters, AuNPs are comprised
of a metallic core of gold atoms and an organic ligand shell — usually thiolates — that
passivates and stabilizes the metal core to prevent aggregation of individual
nanoparticles. Although commonly depicted as spherical for simplicity, the Au core is
polyhedral, characterized by a face-centered cubic lattice in which Au atoms occupy
terrace, edge, and vertices (Figure 1.6).[104-105] High resolution transmission electron
microscopy (HRTEM) images of dodecanethiolate-capped AuNPs, depicted in Figure
1.6B, show individual gold atoms making up the metal core. Decahedral, icosahedral, and
truncated octahedral Au core structures, among others, have been proposed and vary with
the size of AuNPs.[105]
Due to the strong affinity between sulfur and gold, combined with the lateral van der
Waals and dipole interactions between thiolated ligands and their end groups,[106] AuNPs
are generally very stable and can be stored indefinitely with no consequence. However,
strongly basic and acidic conditions, or high temperatures, can result in nanoparticle
aggregation due to desorption of thiolates under harsh conditions.[107] In this case,
exposed core regions can coalesce to give aggregated and insoluble structures. In
addition, the decomposition of AuNPs can be induced chemically by molecular iodine
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(I2) or cyanide ions (CN–),[108] which allows for analysis of decomposition products to
determine the original composition.

Figure 1.6. A) Cartoon representations of thiolate-stabilized gold nanoparticles. B)
HRTEM micrographs of 4.1 nm dodecanethiolate-capped AuNPs. (a) fcc clusters, (b-c)
decahedra, (d-f) multidomain. HRTEM micrographs reprinted with permission from Ref.
[105].
Perhaps their most intriguing physical property, the interaction of AuNPs with light has
been extensively studied and utilized. While smaller AuNPs (< 3 nm) do not exhibit a
distinct maximum absorption in their ultraviolet-visible (UV-vis) spectra, larger AuNPs
(8–100 nm) show a broad but detectable peak between ~510–580 nm, known as the
surface plasmon resonance (SPR) band. This SPR band, caused by the collective
oscillation of the free conduction electrons when interacting with incident light, is
responsible for the very intense colour of AuNPs.[109] The position of the SPR band
depends on various parameters, with significant (and often predictable) effects of size,
shape, surface chemistry, and dielectric constant of the suspending medium. For example,
it has been shown that increasing the AuNP core diameter from 9 nm to 99 nm can shift
λmax of the SPR band from 517 nm to 575 nm in water, respectively (Figure 1.7).[109]
Moreover, altering the aspect ratio of Au colloids from quasi-spherical to rod-like
nanostructures shifts the SPR band remarkably to give surface plasmon absorption
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maxima between 600 and 1300 nm,[110] which falls within the optical therapeutic window
where light has its maximum depth of penetration in tissue. Furthermore, AuNPs can act
as “light-activated nanoscopic heaters” due to their ability to convert absorbed light
energy into localized heat, termed the photothermal effect, which enabled the
development of many therapeutic applications.[65]

Figure 1.7. UV-vis absorption spectra of AuNPs of various core sizes obtained in water.
Figure reprinted with permission from Ref. [109].
Lastly, an important attribute of AuNPs is their low cytoxicity and biocompatibility when
their surfaces are properly engineered. Although AuNPs are typically stable under
standard storage conditions or in solvent, their multitude of complex interactions within
biological environments necessitate additional considerations regarding adequate
biological stability. For example, the use of poly(ethylene glycol) is commonly employed
as a surface ligand on AuNPs to effect hydrophilicity, increase circulatory half-life, and
block the nonspecific adsorption of proteins.[111] This methodology, coupled with the
design of appropriately functionalized end groups (charged molecules, biomolecules,
etc.) has led to many biocompatible applications of AuNPs in medical diagnostics and
therapy.
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1.3.2

Synthesis of AuNPs

Since Michael Faraday observed in 1857 that “fine particles” — formed by the aqueous
reduction of gold chloride by phosphorus — could be stabilized by the addition of carbon
disulfides to afford a “beautiful ruby” colour, many synthetic methods following a similar
strategy have been developed.[111] In the typical bottom-up synthesis of AuNPs, a
solvated gold salt is reduced in the presence of a surface-capping ligand. Modern
procedures can be classified into two major methods: the Turkevich citrate-mediated
method and the Brust-Schiffrin synthesis (Scheme 1.7).

Scheme 1.7. Modern methods of synthesizing AuNPs. A) Turkevich method to yield 10–
150 nm citrate-stabilized AuNPs. B) Brust-Schiffrin synthesis of 1–3 nm thiolatestabilized AuNPs. TOAB = tetraoctylammonium bromide, TOA = tetraoctylammonium.
In the Turkevich method, an aqueous solution of HAuCl4 is chemically reduced at 75°C
by trisodium citrate, which acts as both the reductant and stabilizing ligand. Following a
two-step process of rapid nucleation then successive growth, Au(III) ions are reduced to
Au(0) to afford citrate-passivated AuNPs with moderate size distribution.[112] The size of
AuNPs produced by this method can vary from 10 to 150 nm depending on the
HAuCl4:citrate ratio, reaction temperature, and order of reagents added. Weakly bound
citrate ions provide water solubility and means of displacement with ligands that strongly
bind Au (e.g. thiols), thus offering a method to prepare functionalized AuNPs directly
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from this “blank” template. However, AuNPs prepared this way typically feature poor
stability and greater size distribution and is therefore less widely used compared to the
Brust-Schiffrin synthesis.
In the Brust-Schiffrin two-phase synthesis, aqueous HAuCl4 is first transferred into
toluene by a phase-transfer agent (tetraoctylammonium bromide, TOAB), followed by
the addition of thiol to reduce Au(III) to the Au(I)-thiol polymeric form, [(Au(I)SR)n].[113]
Consumption of Au(III) can be evidenced by decolourization of the organic layer. Upon
addition of NaBH4 as a reductant, rapid conversion of [(Au(I)SR)n] into AuNPs can be
observed via the development of a dark brown colour corresponding to AuNPs of 1–5 nm
core size. Like the Turkevich method, core size can be tuned by varying the HAuCl4:RSH
ratio, reaction temperature, and rate of thiol or NaBH4 addition. Modifications to this
method to prepare water-soluble AuNPs in a single phase, without the need of TOAB,
have also been reported.[114]

1.3.3

Characterization of AuNPs

The popularity of AuNPs as a nanoplatform can be attributed to, in part, the large number
of characterization techniques available to determine their size and composition.
Transmission electron microscopy (TEM) and HRTEM provides structural information
regarding the size, shape, and morphology of the metal core.[67,105] X-ray photoelectron
spectroscopy (XPS) can be used to elucidate the oxidation state of gold atoms and those
belonging to the ligand shell. Typical XPS analysis of AuNPs shows peaks corresponding
to Au (4f), (4d), and (4p), C (1s), and S (2s) binding energies. Furthermore,
thermogravimetric analysis (TGA) can be used to measure the mass ratio of organic
ligands vs. metal as a function of mass loss over temperature.[115] In the case of mixed
monolayers of ligands that differ significantly in chemical structure, it is possible to
resolve the mass loss of individual components via deconvolution and peak fitting of the
TGA derivative plot. Lastly, dynamic light scattering (DLS) and zeta potential
measurements can be used to determine their hydrodynamic radius and surface charge,
thus providing insight into their stability and surface interactions in different media.[115]
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In addition to enhancing processability, AuNP solubility in both organic solvents and
water permit their characterization via traditional techniques used for molecules. That is,
nuclear magnetic resonance (NMR) spectroscopy, perhaps the most important tool in
modern synthetic organic chemistry for determining chemical structure, can be used to
determine AuNP purity and composition. However, the assembly of tightly-packed
ligands onto the AuNP surface implies that the frequency of signals is not only
determined by the chemical structure of themselves, but also by the neighbouring ligands
and environment. A key characteristic of the NMR spectra of dissolved AuNPs is the
presence of broad signals.[116] Figure 1.8 illustrates the 1H NMR spectra of tiopronin and
tiopronin-AuNPs obtained in D2O. Several differences can be observed between the
spectra: significant broadening and moderate shifting of the peaks once bound onto the
AuNP core. In addition, broadening of peaks is often asymmetric and results in the
appearance of peak shoulders.

Figure 1.8. 1H NMR spectrum of tiopronin (a) and tiopronin-AuNPs (b) obtained in D2O.
Spectra reprinted with permission from Ref. [116].
The mechanism by which broadening occurs has been extensively studied and many
factors can affect the degree of broadening and direction of peak shifts. First, the
heterogeneity of Au-S binding sites (edge, vertex, or terrace on the polyhedral core) and
the associated difference in packing density of neighbouring ligands is an important linebroadening mechanism. Secondly, slow rotational diffusion of bulky AuNPs, compared
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to their analogous “free” ligand, results in additional broadening and scales with AuNP
core size (i.e. larger AuNPs exhibit broader signals).[117-119] As these effects are most
pronounced for protons (and other nuclei) closest to the core, signals resulting from
terminal functional groups that are most distant are typically sharper. Despite this
broadening of signals, NMR spectra of AuNPs provide important information regarding
their structure and composition, especially when compared to the spectra obtained from
the corresponding unbound molecules. In fact, NMR broadening can be used to identify
the presence of impurities, as unbound molecules in solution appear as sharp signals in
the spectrum.
Lastly, Fourier transform-infrared (FT-IR) and UV-vis spectroscopies can be used to
characterize AuNPs. FT-IR spectroscopy provides structural information regarding the
functional groups present in the nanoassembly and may be useful in identifying the
presence of unbound thiols due to a characteristic, albeit weak, S-H absorbance in the
2550–2600 cm-1 region. As described previously, UV-vis spectroscopy is an important
tool for determining Au core size. In addition, attached chromophores can be identified in
their UV-vis spectrum and compared with that obtained for the unbound thiol, to
independently confirm AuNP composition alongside other spectral techniques (NMR,
IR).[120]

1.3.4

Application of AuNPs

Active research surrounding their synthesis and characterization techniques enabled the
widespread production of stable AuNPs of various sizes and shapes with well-defined
interfaces. The simplicity of their preparation, and their commercial availability by
popular vendors, allowed researchers from across disciplines to utilize them for
applications in diagnostic imaging, therapeutics, and catalysis. A Web of Science search
for “gold nanoparticles” results in over 95,000 published articles and review articles, with
over 80,000 from the last decade alone. Several recent examples of these applications
will be highlighted.
Many applications using AuNPs center around their ability to absorb light. El-Sayed and
coworkers recently demonstrated the synthesis of 29 ± 3 nm AuNPs functionalized with
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thiolated poly(ethylene glycol), a modified RGD peptide (known to target overexpressed
receptors on cancer cells), and a nuclear localization signal (NLS) peptide (Figure
1.9).[121] By using the combination of RGD and NLS peptides, the authors demonstrated
enhanced cellular uptake and localization in the nuclear region, which was confirmed by
dark field microscopy. Irradiation of internalized AuNPs using a near-IR (NIR) laser
triggered photothermal heating and resulted in cell death. Surface enhanced Raman
spectroscopy (SERS), conducted within a single cell, was used to monitor protein and
lipid structures in real-time during the irradiation process. Thus, they presented a method
to both induce and monitor the cell death mechanism within single cells in real-time
using actively targeted AuNPs.

Figure 1.9. A) Cartoon representation of nuclear-targeted AuNPs; where PEG =
poly(ethylene glycol), RGD = RGDRGDRGDRGDPGC peptide, and NLS =
CGGGPKKKRKVGG peptide. B) Schematic demonstrating photothermal heating of
targeted cells caused by NIR irradiation of AuNPs, leading to cell death as evidenced by
dark field microscopy. Figures reproduced with permission from Ref. [121].
Gold nanoparticles also represent excellent delivery vehicles due to their rich surface
chemistry, high ligand density, and biocompatibility. Dai and coworkers reported the use
of 11.2 ± 0.1 nm AuNPs to carry vascular endothelial growth factors (VEGF) across the
skin barrier.[122] The authors demonstrated that negatively charged AuNPs coupled to
VEGF exhibited ideal transdermal delivery efficacy, which is important for promoting
angiogenesis and wound repair in skin injuries. Recently, Kanaras and coworkers
reported a remarkable multiplex sensing and drug delivery system using DNA-AuNP
dimers (Figure 1.10).[123] AuNPs (15 ± 1.5 nm) featuring “sense strands” of DNA were
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Figure 1.10. Multiplex sensing and drug delivery system using DNA-AuNP dimers. A)
Multiplex sensing strategy: when the target mRNA binds to the sense strand, a short
oligonucleotide strand is released resulting in an increase in fluorescence emission, which
was previously quenched by AuNP core. B) Multiplex drug delivery strategy: when the
target mRNA binds to the sense strand, intercalated drug molecules (doxorubicin or
mitoxantrone) are released. As both drugs are fluorescent, and previously quenched by
AuNP, release also leads to turn-on signal of emission. Reproduced from Ref. [123].
assembled into dimers via DNA hybridization of single oligonucleotides (linker strands 1
and 2, Figure 1.10) and subsequent copper-free click chemistry. The sense strands,
initially hybridized to short oligonucleotides bearing a fluorophore (flare strands), can
detect mRNA targets via hybridization, resulting in the release of the flare strands and
“turn-on” of the previously AuNP-quenched fluorescence to give a response signal
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(Figure 1.10A). The authors built on this design by demonstrating a similar sensing
strategy to release intercalated anticancer drugs (doxorubicin or mitoxantrone) in live
cells that carried the target mRNA (Figure 1.10B). Through cell viability studies that
compared the toxicity of drug-loaded targeted AuNPs versus nontargeted AuNPs (socalled scrambled dimers), they demonstrated significant specificity of targeted AuNPs in
releasing the drugs to induce cell death.
Although bulk gold is chemically inert, it is well known that AuNPs exhibit good
catalytic performances.[124] Deng and coworkers recently showed that 4 nm AuNPs
supported in magnetic yolk-shell mesoporous silica microspheres can be used to catalyze
the epoxidation of styrene using tert-butylhydroperoxide (TBHP) as an oxidant (Scheme
1.8).[125] They reported excellent catalytic performance, high conversion, and
recyclability of the catalyst due to the ability to isolate the nanoassemblies using an
externally applied magnetic field. The authors proposed that the hollow spaces of these
yolk-shell microspheres help reactants contact with highly confined AuNPs, thus leading

Scheme 1.8. Synthesis of magnetic yolk-shell mesoporous silica microspheres with
supported AuNPs and its catalysis of styrene epoxidation. Scheme reproduced with
permission from Ref. [125].
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to greater catalytic efficiency.
In addition to those described above, new applications of AuNPs are developed every
year.[111,124,126] In nearly all cases, the choice of surface functionalities is crucial to their
function as it dictates how AuNPs interact with and respond to their intended
environment of use, their stability and their properties. Thus, the rich surface chemistry of
AuNPs has been investigated extensively over the years to offer multiple
functionalization routes.

1.3.5

Surface Derivatization of AuNPs

Although amine- and phosphine-based capping groups are feasible and have been
reported, thiolates are by far the most commonly used and studied due to their high
affinity for gold and tight packing to form stable monolayers.[86] This section highlights
how AuNP surface chemistry with thiols can be used to introduce the desired
functionality via three routes: direct synthesis, ligand displacement, and interfacial
reaction.

1.3.5.1

General Methods to Synthesize Functionalized AuNPs

As the Brust-Schiffrin synthesis of AuNPs incorporates the added thiol into its ligand
shell, it represents the most direct way to introduce the desired terminal functional group
onto AuNPs (Scheme 1.9A). This method, termed direct synthesis, provides access to a
range of functionalities (e.g. alkyl, –OH, –NH2, –COOH) that are compatible with the
reducing conditions required for the synthesis. However, the utility of this method is
limited by the fact that 1) functionalities that do not remain intact in the presence of
NaBH4 cannot be used and 2) functionalities that are susceptible to nucleophilic attack
(e.g. Michael acceptors) cannot be stably obtained due to self-reactivity of the required
thiol. In addition, while there are established protocols for obtaining AuNPs of discrete
sizes and narrow size distribution using inert or “non-functional” (e.g. alkyl) thiols, the
use of functional thiols can lead to varied sizes and broader size distribution.[104,113]
To overcome the limitations with the direct synthesis route, ligand displacement reactions
can be employed. In this method, inert or non-functional AuNPs are first synthesized
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Scheme 1.9. Methods to derivatize AuNPs with the desired functionality. A) Direct
synthesis of AuNPs using a thiol carrying the desired functionality. B) Ligand
displacement onto inert or “non-functional” (e.g. alkyl or ethylene glycol) terminated
AuNPs using a thiol carrying the desired functionality. C) Interfacial reaction between an
intermediate reactive functionality (e.g. -COOH, azide, alkyne) on AuNPs and a reactive
partner carrying the desired functionality.
using an established Brust-Schiffrin protocol. In the second step, a thiol containing the
desired terminal functionality is used to displace non-functional thiolates from the surface
to afford a mixed monolayer (Scheme 1.9B). The overall rate and extent of displacement
from the incoming thiol are affected significantly by core size, electronic charge of the
AuNPs, structure of the incoming ligand, and sterics.[127-128] For example, ligand
displacements are initiated at AuNP surface sites where monolayer packing is less dense
(and therefore more accessible), such as the edges and vertices, and diffuse into the
terrace sites until an equilibrium state is reached. These parameters allow for the finetuning of desired ligand concentrations (functional versus non-functional) and provides
greater control over the AuNP composition. Furthermore, by first using a non-functional
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AuNP template of discrete size, a library of functional AuNPs can be accessed that
feature the same core diameter and size distribution. This reproducibility is highly
important due to the size-dependent properties associated with AuNPs. However, the
issue of introducing functionalities that are incompatible with the thiol moiety persists in
this method. In addition, in the presence of multiple thiol moieties (as in many peptides
and proteins), it is often unpredictable where binding occurs and how the binding mode
can affect the overall surface function. Lastly, due to the need for high concentrations of
incoming thiol for ligand displacement to be effective, this method can be inefficient and
uneconomical if the thiol ligand is expensive or difficult to synthesize.
The synthesis of thiol derivatives is often challenging or, in many cases, ineffective due
to incompatibility with the desired functionality. The last and arguably most useful
method overcomes this challenge by employing synthetic organic chemistry to modify
the AuNP monolayer interfacially (Scheme 1.19C). Termed interfacial reactions, these
transformations allow for the formation of robust covalent bonds using AuNPs as a
macromolecular-type reagent to introduce the desired functionality. However, common
reaction conditions such as high temperature, highly basic or acidic environments, or the
use of catalysts that affect AuNP stability cannot be used. Therefore, finding reactions
that proceed efficiently and cleanly under mild conditions to offer well-defined interfaces
remains a challenge in the derivatization of AuNPs. Many methods have been developed
and extensively used, such as EDC/NHS (or sulfo-NHS) coupling,[93-94] but more recently
our group has focused on utilizing click chemistry to achieve these modifications.

1.3.5.2

Interfacial Click and Bioorthogonal Reactions on AuNPs

By revisiting the criteria for a reaction to be considered a click reaction — clean, fast,
selective, and high yielding reactivity under mild conditions — it becomes immediately
evident why these transformations are of interest for engineering well-defined AuNP (and
other material) surfaces. In particular, use of a bioorthogonal reaction features the added
advantage of biocompatibility, which enables the reaction to proceed in vivo, if
necessary, for the targeted delivery of AuNPs in complex biological media. This section
highlights several existing methods for employing click and bioorthogonal chemistry on
AuNPs.
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Perhaps the most widely used in the click reaction toolkit, the CuAAC represents a fast
and clean method to form covalent bonds using chemical functionalities that are small,
chemically inert, and easy to introduce. Most systems employ azide-functionalized
AuNPs followed by Cu(I)-mediated reaction with a terminal alkyne bearing the desired
functionality

(Scheme

1.10).[129-131]

While

it

has

been

shown

that

tris(3-

hydroxypropyltriazolylmethyl)amine (THPTA) and similar derivatives can be used as an
additive to intercept ROS generated by excess Cu(I) during CuAAC,[132-133] copper
catalysts are generally cytotoxic and have limited utility in living systems. Additionally,
the requirement of additives (either catalyst or stabilizing agents) compromises and
weakens the cleanliness and simplicity that are key characteristics of click chemistry.

Scheme 1.10. Generalized scheme depicting alkyne-azide cycloadditions on AuNPs.
To overcome this, SPAAC can be employed, which requires no additives and generates
no byproducts. For example, our group and others have demonstrated the use of strained
alkyne reagents to modify azide-AuNPs.[131,134-135] Although effective and cleaner than
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CuAAC, the incorporation of strained alkynes into the target functionality can be
synthetically challenging and tedious, often requiring multiple protection-deprotection
steps.[135] Moreover, the low commercial availability and high cost of strained alkyne
reagents acts as an additional barrier to researchers who wish to explore a library of
functionalities on AuNPs and other surfaces. Thus, the complementary system that
utilizes alkyne-AuNPs that react with azido-bearing functionalities represents a superior
method to employing SPAAC (Scheme 1.10). However, the synthesis of such alkynylAuNPs remains a challenge due to the instability of strained alkynes towards
nucleophiles. Thus, methods of alkyne incorporation onto AuNPs require further
investigation.
In addition to CuAAC and SPAAC, maleimide-based click chemistry has been
extensively studied on AuNPs (Scheme 1.11). Our group has demonstrated reversible
Diels-Alder and Michael addition reactivity on AuNPs in recent years and showed its
applicability in the assembly of hybrid nanomaterials, bioimaging, and potential drug
delivery.[136-141] Due to the reversibility of maleimide chemistry, it represents an excellent
platform for the development of drug delivery and sensing applications. However,
maleimide reactivity features several drawbacks: 1) maleimides are susceptible to
hydrolysis in basic aqueous conditions[140]; 2) the use of nucleophiles as the reaction
partner for Michael additions limits its use in vivo, due to the abundance of amine and
thiol functionalities in biomolecules; 3) the need for high temperature or pressure for
Diels-Alder reactions limits its utility in living systems or in the conjugation of sensitive
molecules.
Lastly, there are no reported systems that utilize SBL — the original bioorthogonal
reaction for forming stable amide bonds — on AuNPs until our group’s recent work. We
successfully demonstrated that a triarylphosphine-bearing thiol ligand can be synthesized
and used to reliably modify AuNPs to afford phosphine-AuNPs with a well-defined
interface (Scheme 1.12).[142] These AuNPs featured clean and quantitative reactivity with
an azide-bearing RGD peptide to afford the first AuNP-bioconjugate synthesized using
the SBL. As the SBL remains a powerful and versatile bioorthogonal transformation that
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features chemical ligation and release, further investigation into its utility on AuNPs is
necessary.

Scheme 1.11. Generalized scheme depicting maleimide-based click chemistry on AuNPs;
Michael addition (top) and Diels-Alder cycloaddition (bottom) shown.

Scheme 1.12. Generalized scheme depicting the Staudinger-Bertozzi ligation of azides
onto AuNPs.
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1.4 Scope of Thesis
The reliable modification of nanomaterial surface functionalities is critical to their
application as it governs how the nanoassembly interacts with and responds to the
intended environment of use. This is true for AuNPs, which have found applications in
drug delivery, bioimaging, photothermal therapy, and catalysis. Thus, it is of critical
importance that methodologies to derivatize their surfaces under mild conditions are
developed. The birth of bioorthogonal chemistry has allowed chemical biologists to
reliably form bonds even in the most complex biological environments, wherein they
must forfeit all control of reaction parameters such as temperature, solvent, pH, and the
presence of reductants, oxidants, and nucleophiles. The careful choice of reaction
partners enables fast, clean, and selective reactivity despite often unpredictable
conditions. Indeed, the reliability and robustness of these chemical tools should not be
excluded to applications in chemical biology. Thus, this thesis examines methods to
utilize these transformations on AuNPs as a model nanomaterial.
The transposition of bioorthogonal chemistry to AuNPs began in our group only recently,
with few examples demonstrating SPAAC reactivity on AuNPs and a preliminary study
on SBL reactivity in our seminal work. Due to the reactivity of strained alkynes toward
thiols, a reliable method for the incorporation of cylooctynes onto AuNPs has yet to be
realized. In addition, SPANC reactivity on alkyne-AuNPs has not been explored. Thus,
this thesis aims to address these deficiencies through:
1. The development of well-defined methodologies for the incorporation of strained
alkynes and triarylphosphine derivatives onto AuNPs.
2. The exploration of combinatorial functionality of bioorthogonal moieties on
AuNPs.
3. Demonstrating

quantitative

and

qualitative

determination

of

chemical

functionalities on AuNPs.
4. Demonstrating simple, clean, and reliable reactivity on AuNPs under mild
conditions.
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Chapter 2, published in Chem. Eur. J. 2017, 23, 1052–1059, focuses on the development
of cyclopropenones as a photochemical caging strategy for strained alkynes, which
enabled the direct incorporation of strained alkyne precursors onto AuNPs. This chapter
describes the synthesis of cyclopropenone AuNPs, their photochemical decarbonylation
reactivity, and 1,3-cycloaddition reactivity. The methodology for determining AuNP
composition is also outlined. A library of derivatized AuNPs was synthesized.
Chapter 3, published in Langmuir, 2017, 33, 1908–1913, describes the investigation of
the SBL as a dual-purpose transformation on AuNPs that permits chemical ligation and
release. A modified triarylphosphine thiol ligand carrying a Rhodamine B cargo was
synthesized and incorporated onto AuNPs through ligand displacement. Quantitative
determination of the cargo concentration on AuNPs is outlined. Finally, its reactivity
towards a water soluble azide to trigger cargo release was examined and monitored via
fluorescence spectroscopy. Control experiments were conducted in the absence of active
phosphine and its sensitivity to displacement by glutathione was examined.
Chapter 4, published in Bioconjugate Chem. 2019, 30, 1140–1149, highlights the
development of a dual-bioorthogonal molecular tool that permits the use of four
bioorthogonal transformations interchangeably to attach, release, and replace molecules
on the AuNP surface. Bioorthogonal reactivity of model molecules via two routes —
“click-to-release” or “double-click” —is described. Incorporation of the molecular tool
onto AuNPs, quantitative analysis, and execution of the interfacial chemistry is discussed.
Finally, the use of this chemistry for the preparation of multifunctional AuNPs and their
application for targeted cell labelling is examined.
Chapter 5 summarizes the conclusions of this work and provides a commentary on the
contribution of this investigation to the field of materials chemistry.
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Chapter 2

2

Photo-induced Interfacial Unmasking of Strained
Alkynes on Small Water Soluble Gold Nanoparticles

Reprinted with permission from Chem. Eur. J. 2017, 23, 1052–1059, with minor
formatting changes to maintain consistency throughout thesis. Figure S2.X refers to
Supporting Information (Section 2.6).

2.1 Introduction
In the last decade, owing to rapid advances in nanotechnology and materials chemistry,
there has been special emphasis on the modification of material surfaces. As a result, the
search for efficient functionalization protocols via covalently bound mono- or multilayers
has become the central focus of much research. In this regard, click chemistry is of
particular relevance because of its high yields, mild reaction conditions, and ease of posttreatment.[1] The strain-promoted alkyne-azide cycloaddition (SPAAC), designed as a
tool for in vivo imaging and tracking of biomolecules,[2] is an indispensable member of
the family of bioorthogonal click reactions owing to its rapid reaction kinetics,
chemoselectivity, and biocompatibility.[3] Since its discovery, the SPAAC reaction has
been used for the synthesis and/or modification of many materials, including dendrons
and dendrimers,[4] topological polymers,[5] organo-micelles and liposomes,[6-7] micro- and
nanoparticles.[8-12] as well as other material surfaces.[13-16] More recently, Tsukruk and
coworkers prepared branched polyhedral oligomeric silsesquioxane nanoparticles via
interfacial SPAAC reaction.[17] Yi and coworkers reported chitosan-poly(ethylene glycol)
microparticles featuring azadibenzocyclooctynes (ADIBO) and their potential to undergo
bioconjugation via SPAAC reaction with azide-modified proteins and antibodies to afford
biosensing platforms.[18] Gobbo et al. prepared nanomaterial hybrids by employing
ADIBO-functionalized single-walled carbon nanotubes and azide-decorated gold
nanoparticles.[19] Wang et al. demonstrated the post-synthetic modification of metalorganic framework (MOF) thin films using the SPAAC reaction to achieve nearly
quantitative yields and to overcome Cu(I) ion contaminants commonly found in MOFs
modified with the copper-assisted alkyne-azide cycloaddition (CuAAC) reactions.[20]
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As the SPAAC reaction is becoming a popular choice of chemistry in the materials
chemistry domain for building and engineering functional materials, the development of
methodologies for the incorporation of reactive strained alkynes onto nanomaterial
surfaces is becoming important. The evolution of strained alkyne chemistry in the last
decade has led to the design of fluorinated and aryl-fused cyclooctynes that are
significantly more reactive at the C–C triple bond.[21-22] Although fast reaction kinetics
are certainly desirable, this poses challenges relating to the chemistries that are suitable
for the chemical attachment of strained alkynes onto material surfaces or other molecular
systems, i.e. the presence of functional groups that would react with the strained alkyne
(e.g. amines, thiols, azides, etc.) are prohibited. This limits the scope and utility of the
SPAAC reaction on nanomaterials, especially in cases where nucleophilic groups are
required to introduce the strained alkyne.
One such challenge is the incorporation of strained alkynes onto gold nanoparticles
(AuNPs). Among all nanomaterials, AuNPs are often regarded as one of the most
promising templates for biomedical applications such as medical diagnostics,
therapeutics, and drug delivery because of their low toxicity, chemical stability, and
tuneable optical and chemical properties.[23-28] However, incorporation of strained
alkynes directly onto the gold core via a thiol-bearing strained alkyne ligand is unsuitable
(shown in Scheme 2.1) due to the self-reactivity of the ligand by nucleophilic attack of
the thiol end onto the strained C–C triple bond.[29-31] The Workentin group has made
efforts to prepare water soluble AuNP templates that can undergo interfacial SPAAC (iSPAAC) reaction for the facile post-synthetic modification of the gold core. Recently, we
reported ADIBO-derivatized water-soluble AuNPs that were synthesized via a postsynthetic interfacial amide coupling reaction between carboxy-terminated AuNPs and an
ADIBO-amine (Scheme 2.1).[32] Although these ADIBO-modified AuNPs demonstrated
efficient i-SPAAC reactivity and water solubility, their synthesis requires an interfacial
coupling reaction that did not proceed to completion. This led to impurities that
complicated the determination of interfacial ADIBO concentration. In addition, the
loading of ADIBO moieties at the AuNP interface was governed by the number of
carboxy-terminated ligands present on the AuNP surface, which had to be kept low to
preserve the organic solvent solubility of the COOH-terminated AuNPs required for the
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Scheme 2.1. Previous strategy towards the synthesis of strained alkyne incorporated
AuNPs via interfacial amide coupling.
amide coupling reaction step. This resulted in low loading of the interfacial strained
alkyne. To overcome these limitations, an improved methodology must be developed to
1) simplify the preparation of strained alkyne derivatized AuNPs, 2) achieve higher
loading of interfacial strained alkynes onto AuNPs and 3) reduce or eliminate the
generation of impurities to provide more accurate quantitative characterization of the
resulting nanomaterial.
Recently, we reported a protection-deprotection strategy of strained alkynes via the
formation of a dicobalt-hexacarbonyl complex.[33] We demonstrated that chemistry can
be

performed

on

the

Co2(CO)6-protected

bicyclononyne

(BCN)

for

further

functionalization of the complex, which can then undergo subsequent deprotection to
regenerate the modified-BCN. Although this is an effective protection strategy suitable
for a variety of chemistries, it was not employed for incorporation onto AuNPs due to the
reactivity of alkyne-Co2(CO)6 complexes towards thiols.[34] Instead, we turned our
attention to cyclopropenones, a photochemical precursor of linear and cyclic alkynes. [3536]

The Popik group reported a cyclopropenone-masked dibenzocyclooctyne (DIBO) that

undergoes clean decarbonylation under ultraviolet A (UV-A) irradiation to afford
DIBO.[37] They’ve also demonstrated the application of these cyclooctyne precursors in
the surface functionalization of patterned polymer brush films.[38-41] However,
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derivatization of AuNPs or Au surfaces with cyclopropenone-masked DIBO moieties has
never been reported. Such masked cyclooctynes are unreactive towards azides or
nucleophiles in the absence of UV light, thus making it the ideal precursor for
incorporation onto AuNPs to overcome the limitations previously described.
The power of this moiety lies in its exceptional stability, clean photoreactivity, and the
opportunity for spatial and temporal control of the SPAAC reaction. However, it has
never been applied to gold substrates thus presenting certain challenges to executing such
chemistry on these surfaces.
For the first time, we describe herein an improved methodology towards the synthesis of
strained alkyne-functionalized AuNPs via the direct incorporation of a cyclopropenonemasked DIBO (hνDIBO), a strained alkyne precursor, onto AuNPs. These hνDIBOAuNPs undergo clean and quantitative photochemical decarbonylation under UV-A
irradiation to afford the final DIBO-derivatized AuNP product, which requires no further
purification or post-synthetic treatment. By employing this cyclopropenone-based
strategy, we were able to simplify the preparation of strained alkyne-modified AuNPs
and achieve higher loading of interfacial DIBO in addition to cleaner and quantitative
reactivity. DIBO-AuNPs were found to have excellent chemical stability and reacted
cleanly and efficiently with various 1,3-dipoles via i-SPAAC and interfacial strainpromoted alkyne-nitrone cycloaddition (i-SPANC) reactions under mild conditions.
Remarkably, hνDIBO- and DIBO-modified AuNPs display excellent solubility in both
organic solvents and aqueous media despite the strong hydrophobic nature of the
interfacial moieties, which provides invaluable opportunities for applications of these
materials in chemical biology and materials science. More importantly, these AuNPs
preserve the rapid reactivity of strained alkynes when ‘unmasked’ while offering
exceptional chemical stability in its ‘masked’ form, thus providing a facile and general
route towards the modification of AuNP surfaces with spatial and temporal control. For
these reasons, the synthetic strategy reported here not only serves to overcome synthetic
challenges towards strained alkyne-derivatized AuNPs, but offers a photoswitchable
AuNP platform based on photo-‘click’ chemistry that broadens the scope of practical
applications in biochemistry, medical diagnosis, drug delivery, and material sciences.
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2.2 Results and Discussion
The approach chosen for the introduction of DIBO precursors onto AuNPs required the
synthesis of a thiol-modified cyclopropenone-masked DIBO ligand (Scheme 2.2).
Briefly, the first step involved the double Friedel-Crafts alkylation of diphenylethane
derivative 1 with tetrachlorocyclopropene followed by immediate in situ hydrolysis of the
intermediate dichlorocyclopropene to afford the TBS-protected cyclopropenone-masked
DIBO, 2 Deprotection of 3 by tetra-N-butylammonium fluoride (TBAF) in THF followed
by substitution with tosylated trityl-protected thiol 4 afforded the S-trityl protected ligand
5. The S-trityl protecting group of 5 was cleaved cleanly in a 5% trifluoroacetic aciddichloromethane solution, leading to the desired hνDIBO-thiol ligand 6. As expected,
ligand 6 was found to be remarkably stable towards self-reactivity by either nucleophilic
attack or disulfide formation under standard ambient conditions. In addition, it can be
stored at -20 °C and remain stable for months, thus highlighting the efficacy of this
precursor strategy. Details of the ligand synthesis can be found in the Supporting
Information (Section 2.6).

Scheme 2.2. Synthesis of cyclopropenone-masked DIBO bearing thiol ligand 6. (a)
C3Cl4, AlCl3, CH2Cl2, then 5% HCl(aq); (b) TBAF, THF; (c) 4, K2CO3, DMF; (d) TFA,
TIPS, CH2Cl2.
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hνDIBO-AuNPs were prepared through a place-exchange reaction (Scheme 2.3) of thiol
6 onto triethylene glycol monomethyl ether AuNPs (MeO-EG3-AuNPs) in CH2Cl2 at
room temperature. Details of their synthesis can be found in the Supporting Information
(Section 2.6). The MeO-EG3-AuNP substrate selected has a gold core diameter of 3 ± 1
nm and features excellent organic solvent and water solubility. In addition, these AuNPs
are resistant to both strongly acidic[42] and basic conditions,[32] they can be heated to over
100 °C,[43] and can be repeatedly dried and re-dissolved in different solvents with little to
no aggregation, thus making them very resilient substrates for further modification as
well as interfacial organic chemistry. After 15 min of place-exchange under vigorous
stirring in the dark, the solvent was evaporated and the modified AuNPs were purified
from excess thiols by re-dissolving in CH2Cl2 (4 mL) and precipitating them by adding
hexanes (22 mL) in which the AuNPs are not soluble. The supernatant (containing excess
thiols and disulfides) was removed and the entire washing procedure was repeated four
times overall to afford clean hνDIBO-AuNPs. It is worth noting that the amount of thiol 6
incorporated can be tuned, to an extent, by varying the place exchange reaction time
and/or varying the ratio of 6:AuNP in the reaction mixture. The ratio of 6:AuNP (1:5) and
reaction time was carefully chosen to allow sufficient ligand exchange to occur for
characterization of the newly introduced interfacial moieties, but not such that the AuNPs
lose solubility in water due to the hydrophobicity of the hνDIBO head group. For
example, if either [thiol 6] or reaction time was doubled, the resulting AuNPs were
rendered insoluble in water, therefore limiting its potential application in chemical
biology and nanomedicine. Thus, the reaction parameters were chosen to settle on a
balance between aqueous solubility and ease of characterization. However, once the
AuNPs have been characterized, the interfacial exchange of 6 can be tuned depending on

Scheme 2.3. Strategy towards the synthesis of DIBO-AuNPs.
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the specific application of the AuNPs. These AuNPs were characterized by 1H NMR,
infrared (IR), and ultraviolet-visible (UV-vis) spectroscopy as well as by transmission
electron microscopy (TEM) and thermogravimetric analysis (TGA) (see Section 2.6).
The 1H NMR spectrum of hνDIBO-AuNPs showed the presence of broad peaks
corresponding to the newly introduced thiol ligand 6 and the triethylene glycol
monomethyl ether ligand of the AuNP substrate (Figure 2.1). The broad peaks are typical
of a clean AuNP sample, indicating that the washing procedure was effective in removing
unbound thiols and disulfides. It is worth noting that the removal of excess thiols is of
key importance to avoid any undesirable side reactivity in the later decarbonylation step.
The IR spectrum of hνDIBO-AuNPs showed an intensive carbonyl absorption band at
1844 cm-1 corresponding to the C=O of the cyclopropenone moiety, thus confirming that
ligand 6 was successfully incorporated without change to the cyclopropenone structure
(see Figure S2.2). The TEM analysis of hνDIBO-AuNPs also showed no significant
change in gold core diameter (2.9 ± 0.5 nm) following the place-exchange reaction,
which indicates that the nanoparticles are stable and do not aggregate under these

Figure 2.1. 1H NMR spectra of thiol 6 (top) and hνDIBO-AuNPs (bottom). *Denotes
residual solvent peaks. Spectra were referenced against residual CHCl3.
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conditions (see Figure 2.2A). In fact, they can be stored in solution (CH2Cl2) at -20 °C
and remain stable for months.

Figure 2.2. TEM images of A) hνDIBO-AuNPs and B) DIBO-AuNPs.
TGA of hνDIBO-AuNPs showed that 29% of the total AuNP weight corresponds to the
organic corona, i.e. MeO-EG3-S– and hνDIBO-EG4-S– (see Figure S2.4). The derivative
of the TGA curve showed that there are two ligands that decompose at distinctly different
temperatures (Figure S2.4): a larger component at 265°C and a small component at
375°C. By comparing to the TGA data with that of the MeO-EG3-AuNP starting material,
the ligand decomposing at 265 °C was assigned to MeO-EG3-S–,[32,42-44] whereas the
ligand at 375 °C was assigned to hνDIBO-EG4-S–. From the combination of 1H NMR
data, deconvolution of the TGA derivative curve, and TEM analysis, and assuming that
these AuNPs are spherical and monodispersed in size, it was possible to calculate an
approximate molecular formula of hνDIBO-AuNPs to be Au800(MeO-EG3-S)270(hνDIBOEG4-S)30. More specifically, these AuNPs contain hνDIBO-EG4-S in a concentration of
0.136 μmol mg-1 of AuNP. Details of these calculations are reported in the Supporting
Information (Section 2.6).
The photoreactivity of hνDIBO-AuNPs was then investigated using UV-vis, 1H NMR,
and IR spectroscopy. A solution of hνDIBO-AuNPs in water at a concentration of 0.25
mg/mL was irradiated with UV-A light. The UV-vis spectra of the solution before and
after irradiation showed bleaching of the 331–347 nm bands corresponding to the
precursor cyclopropenone, and appearance of 305–322 nm bands corresponding to the
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decarbonylated strained alkyne (Figure 2.3). These values are in good correspondence
with that observed in literature for similar unbound or ‘free’ DIBO molecules.[37] 1H
NMR analysis of the aromatic region of hνDIBO-AuNPs before and after UV irradiation
indicated the disappearance of the broad peak at 7.92 ppm and a decrease in the signal at
6.90 ppm of cyclopropenone, followed by appearance of broad signals at 6.77 and 7.20
ppm corresponding to the interfacial DIBO aromatic protons (Figure 2.3). Lastly, the IR
spectrum of the DIBO-AuNPs product (see Figure S2.9) showed the absence of the C=O
absorption band at 1844 cm-1 corresponding to the cyclopropenone moiety, thus
confirming quantitative decarbonylation of hνDIBO-AuNPs to afford DIBO-AuNPs with

Figure 2.3. Scheme showing the photochemical deprotection of hνDIBO-AuNPs and
subsequent i-SPAAC reaction with BnN3 7. (left). UV-vis and 1H NMR data shown for
(a) hνDIBO-AuNPs, (b) DIBO-AuNPs, and (c) triazole1-AuNPs (right). 1H NMR spectra
were recorded in CDCl3 and referenced against residual CHCl3 (denoted by *).
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no significant change to the AuNP core size as confirmed by TEM (Figure 2.2B). It is
worth noting that photochemical decarbonylation was found to proceed faster in more
dilute solutions of hνDIBO-AuNPs, which is likely due to competitive absorption of UV
light by the dark brown gold particle solution. Nevertheless, interfacial unmasking of
DIBO-AuNPs was fast (<10 min) in reasonably dilute solutions of AuNPs (0.25 mg/mL
solvent) and led to clean and quantitative yield of the strained alkyne derivatized AuNP
product, which contained 0.136 μmol interfacial DIBO mg-1 of AuNP. This is double that
of ADIBO used in the previous system shown in Scheme 2.1, thus allowing for greater
capitalization on the high load capacity of AuNPs.[32] Additionally, the only byproduct
generated (CO) is released as a gas, which avoids any impurities and the need for further
purification of DIBO-AuNPs. More importantly, it has been shown that irradiation with
UV-A light may lead to agglomerated AuNPs.[45] However, we observed no change in
AuNP core size as confirmed by TEM, thus demonstrating the overall efficacy of the
cyclopropenone-based strategy employed.
The i-SPAAC reactivity of DIBO-AuNPs was investigated with benzyl azide (BnN3) as a
model molecule and monitored through UV-vis and 1H NMR spectroscopy. BnN3 was
chosen due to its commercial availability, low cost, and use as a standard organic azide
molecule for SPAAC kinetic studies in literature.[22] When DIBO-AuNPs were treated
with excess BnN3 in CH2Cl2, the UV-vis absorption spectrum of the product showed
bleaching of the 305–322 nm bands corresponding to the interfacial DIBO, which is
consistent with quantitative formation of the triazole-AuNP product (Figure 2.3).[37] After
excess BnN3 was removed by washes with hexanes, the 1H NMR spectrum of the AuNPs
displayed additional broad peaks in the aromatic region corresponding to the phenyl
protons, and two broad singlets at 5.55 and 5.50 ppm corresponding to the benzylic
protons of the two regioisomers of the interfacial triazole product (Figure 2.3). These
results together confirm that the interfacial SPAAC reaction proceeds effectively and
quantitatively at the interface to afford the triazole-AuNP product.
Furthermore, our ability to accurately determine the concentration of interfacial DIBO on
AuNPs and the clean reactivity of these moieties with an azide counterpart allowed for
investigation into the reaction kinetics of the i-SPAAC on our nanomaterial template. The
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rate measurements of the i-SPAAC reaction of DIBO-AuNPs with BnN3 were conducted
by 1H NMR spectroscopy at 25 °C in CDCl3. Chloroform was chosen due to the high
solubility of the nanoparticles in this solvent that permitted the high AuNPs concentration
required for these kinetic experiments. A calculated amount of 11 mM BnN3 solution in
CDCl3 was added to a solution of DIBO-AuNPs in CDCl3 required to achieve an
equimolar concentration of 2.2 x 10-3 M in both BnN3 and interfacial DIBO. Reactions
were monitored through 1H NMR analysis by following the decay of the sharp singlet
signal at 4.30 ppm corresponding to the benzylic protons of the BnN3 starting material.
These reactions were carried out in triplicate and the second-order rate constant was
evaluated to be (5.3 ± 0.4) x 10-2 M-1 s-1. This is consistent with bimolecular rate
constants reported in literature for reactions of similar DIBO derivatives with BnN3 in
solution.[37] This is remarkable considering the markedly different chemical environment
presented by the nanoparticle structure and the interfacial nature of the SPAAC reaction.
In fact, previous work has showed that interfacial reactions on AuNPs can be
significantly slower than the same reaction carried out in the bulk solution, where
differences depend on the mechanistic nature of the interfacial reaction.[44,46] Thus, we
were delighted to observe no significant change in the i-SPAAC reactivity at the AuNP
interface.
Lastly, to showcase the generality of DIBO-AuNPs towards surface modification, we
reacted DIBO-AuNPs with various 1,3-dipoles shown in Scheme 2.4, which include an
aromatic azide (8), an aliphatic azide (9), and 3′-Azido-3′-deoxythymidine (AZT, 10), an
azide-bearing drug used to prevent and treat HIV/AIDS. N-phenyl-α-phenylnitrone (11)
was also used to demonstrate that DIBO-AuNPs can undergo i-SPANC in addition to the
i-SPAAC, thus offering compatibility with two mutually orthogonal functional groups for
AuNP modification.
The i-SPAAC/SPANC reacted AuNPs were characterized by 1H NMR spectroscopy. In
all cases, the purified AuNPs showed additional signals in their 1H NMR spectrum
corresponding to the interfacial clicked moieties (see Section 2.6). To confirm proper
interfacial reactivity, all reacted AuNPs were oxidized by molecular iodine to afford a
mixture of Au(I) and Au(III) complexes, which liberated the organic ligands as disulfides
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Scheme 2.4. Reaction of DIBO-AuNPs with various 1,3-dipoles.
(Scheme 2.5).[47] Each mixture of disulfides was characterized by ESI-MS to determine
the exact mass of the disulfide molecule that is most likely to form. In all cases, the
experimental m/z agreed with that calculated for each proposed disulfide, which
confirmed successful SPAAC/SPANC reactivity at the interface of AuNPs (Figures
S2.12-S2.15). More importantly, this study highlights the ease of use of DIBO-AuNPs as
a bioorthogonal nanomaterial template from which surface modification can be achieved
through simple pour and mix chemistry with various 1,3-dipoles under mild and
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Scheme 2.5. Reoxidation of reacted AuNPs by molecular iodine. ESI-MS calcd for
disulfides 12: C42H58N3O8S2 [M+H]+ 796.3665, found 796.3675; 13: C42H58N3O9S2
[M+H]+ 812.3614, found 812.3636; 14: C38H57N3NaO9S2 [M+Na]+ 786.3434, found
786.3429; 15: C45H64N5O12S2 [M+H]+ 930.3993, found 930.3983; 16: C48H61NO9S2 [M]+
859.3788, found 859.3763.
bioorthogonal reaction conditions. This is especially true in the case where AZT 10 – a
structurally complex azide molecule – was used to synthesize a drug-AuNP conjugate.
This efficient and easy-to-implement approach towards AuNP surface modification
allows for facile synthesis of AuNP-bioconjugates, nanohybrids, and functional materials
for applications across the sciences.

2.3 Conclusion
In summary, we describe an improved methodology for the introduction of strained
alkyne moieties onto AuNPs for the surface modification and engineering of functional
nanomaterials. By employing this cyclopropenone-based strategy, we were able to
simplify the incorporation of strained alkynes onto AuNPs, achieve higher loading of
interfacial strained alkynes than in our previous system, and accurately determine the
concentration of interfacial DIBO in the absence of impurities that would have otherwise
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been present if an interfacial amide coupling was employed instead. Furthermore, a major
advantage of the method reported here is that the amount of hνDIBO (and consequently,
DIBO) incorporated onto AuNPs can be tuned in a facile manner and calculated with
good precision, both of which are important for potential applications in bioconjugation,
medical diagnostics, or drug delivery. This methodology also represents a significant
advancement in the field as it addresses one of the major challenges of employing the
SPAAC reaction on AuNPs: the reactivity of the highly strained C–C triple bond towards
nucleophiles, which is normally used to bind functional ligands to gold surfaces. Instead,
our approach challenges the need to compromise between the favorable high reactivity of
strained alkynes, and the ease of use, chemical handling and/or functionalization of
strained alkynes at the interface of nanomaterials. Furthermore, cyclopropenone-masked
AuNPs offer a photoswitchable AuNP platform from which spatial and temporal control
of the photo- ‘click’ chemistry can be achieved, thus expanding the utility and scope of
applications of the i-SPAAC reaction in materials and biomaterials sciences.
Lastly, we demonstrated fast and clean i-SPAAC/SPANC reactivity of DIBO-AuNPs
with various 1,3-dipoles under mild reaction conditions. In fact, DIBO-AuNPs were even
prone to modification with structurally complex azide-bearing molecules as demonstrated
by the synthesis of an AZT drug-AuNP conjugate. Although the interfacial AZT-derived
triazole serves only as a drug model, it highlights the simplicity with which derivatization
of AuNP surfaces can be achieved. The ability to alter the surface properties of AuNPs
through the atom-by-atom control provided by this versatile AuNP template will allow
for one to tailor with ease the interactions of AuNPs with biological systems, materials
and biomaterials to help maximize the potential of this nanomaterial.
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2.6 Supporting Information
General Methods.
The following reagents, unless otherwise stated, were used as received. Anhydrous
deuterated

chloroform

(CDCl3),

anhydrous

deuterated

methanol

(CH3OD),

tetrachloroauric acid trihydrate, sodium borohydride, p-Toluenesulfonyl chloride, and
triisopropylsilane (TIPS) were purchased from Sigma-Aldrich. All common solvents,
triethylamine (TEA), magnesium sulfate, sodium sulfate anhydrous, dry methanol,
hydrochloric acid, trifluoroacetic acid, sodium hydroxide, sodium chloride were
purchased from Caledon. Ethanol was purchased from Commercial Alcohols. Glacial
acetic acid (99.7%) was purchased from BDH. Flash chromatography was performed
using 40-63 µm silica gel. Dialysis membranes (MWCO 6000-8000 Da) were purchased
from Spectra/Por. Compound 3 was synthesized according to Chem. Commun. 2014, 50,
5307–5309. Compound 11 was synthesized according to Chem. Commun. 2008, 0, 3522–
3524.
1

H and 13C NMR spectra were recorded on an Inova 400 or 600 MHz spectrometers using

CDCl3 or CH3OD as solvent and were calibrated against the residual protonated solvent.
Infrared spectra were recorded on a Bruker Vector 33 FTIR spectrometer.
Thermogravimetric analyses (TGA) were recorded by loading the sample in a 70 μL
ceramic crucible and heating from 25 ºC to 750 ºC at a rate of 10 ºC min-1. The
experiment was run under a nitrogen flow of 70 mL min-1 in a Mettler Toledo
TGA/SDTA 851 instrument. Transmission electron microscopy (TEM) images were
recorded from a TEM Philips CM10. The TEM grids (Formvar carbon film on 400 mesh
copper grids) were purchased from Electron Microscopy Sciences and prepared by
dropcasting a drop of nanoparticles solution directly onto the grid surface. The drop was
then carefully removed after 30 seconds with a soft tissue. ESI-MS spectra were recorded
on a Micromass LCT mass spectrometer in positive ion mode. UV-visible spectra were
recorded using a Varian Cary 100 bio spectrometer and 7 mm quartz cuvettes. The
nanoparticle samples were dissolved in spectroscopic grade dichloromethane. The
background was automatically subtracted from each spectrum. Photolyses were
conducted in a Luzchem LZC-4V photoreactor equipped with 14 UVA (350 nm) lamps.
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Synthesis of hνDIBO-EG4-SH ligand (6).

Scheme S2.1. Synthetic strategy for the synthesis of hνDIBO-EG4-SH ligand 6.
Synthesis of 18. To a solution of p-toluenesulfonyl chloride (22.0 g, 115 mmol) in
CH2Cl2 (200 mL) at 0 °C, was added tetra(ethylene glycol) 17 (20.3 g, 104 mmol) and
dry triethylamine (15.8 g, 156 mmol). The reaction was then stirred for 2 hours at 0 °C,
and left overnight at room temperature under inert atmosphere. The precipitate was
filtered, and the reaction mixture was then concentrated in vacuo. The crude mixture was
then purified via silica gel chromatography (hexanes: ethyl acetate 1:4) to provide
monotosyl tetra(ethylene glycol) 18 (15.3 g, 42%) as a colorless oil. 1H NMR (CDCl3,
400 MHz): δ 7.80 (d, J = 8.3 Hz, 2H), 7.34 (d, J = 4.8 Hz, 2H), 4.17 (t, J = 4.8 Hz, 2H),
3.73 – 3.59 (m, 14H), 2.45 (s, 3H).

13

C{1H} NMR (CDCl3, 101 MHz): δ 144.8, 132.8,

129.8, 127.8, 72.4, 70.6, 70.5, 70.3, 70.2, 69.3, 68.5, 61.5, 21.5.
Synthesis of 19. Triphenylmethanethiol (4.12 g, 14.9 mmol) was dissolved in a solution
of EtOH/toluene (1:1, 40 mL) and NaOH (0.596 g, 14.9 mmol) in H2O (8 mL) was
added.

To

this

mixture

was

added

a

solution

of

2-(2-(2-(2-

hydroxyethoxy)ethoxy)ethoxy)ethyl 4-methylbenzenesulfonate 18 (4.16 g, 11.9 mmol) in
EtOH/toluene (1:1, 40 mL). The reaction mixture was stirred at room temperature for 18
h. Once the reaction was completed, the mixture was poured into a NaHCO3 saturated
solution. The organic layer was washed with NaHCO3 (3x) and brine (3x). The organic
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portion was then dried over MgSO4 and concentrated in vacuo. The crude product was
then purified via silica gel chromatography (hexanes: ethyl acetate 1:1 to 1:3) to provide
19 as a colorless oil (4.44 g, 82%). 1H NMR (CDCl3, 400 MHz): δ 7.42 – 7.40 (m, 6H),
7.28 – 7.24 (m, 6H), 7.21 – 7.17 (m, 3H), 3.69 – 3.67 (m, 2H), 3.64 – 3.60 (m, 5H), 3.58
– 3.55 (m, 4H), 3.45 – 3.43 (m, 2H), 3.29 (t, J = 6.9 Hz, 2H), 2.43 (t, J = 6.9 Hz, 2H).
C{1H} NMR (CDCl3, 101 MHz): δ 144.9, 129.7, 128.0, 126.8, 72.7, 70.7, 70.5, 70.4,

13

70.2, 69.7, 66.7, 61.8, 31.7. ESI-MS calcd for C27H32NaO4S [M + Na]+ 475.1919, found
475.1914.
Synthesis of 4. To a solution of p-toluenesulfonyl chloride (1.87 g, 9.83 mmol) in
CH2Cl2 (100 mL) at 0 °C, was 1,1,1-triphenyl-5,8,11-trioxa-2-thiatridecan-13-ol (4.45 g,
9.83 mmol) and dry triethylamine (4.97 g, 49.1 mmol). The reaction was then stirred for
2 hours at 0 °C, and left overnight at room temperature under nitrogen. The precipitate
was filtered, and the solution was concentrated in vacuo. The residue was purified via
silica gel chromatography (hexanes: ethyl acetate 1:1 to 1:3) to provide compound 4
(4.92 g, 83 %) as a colorless oil. 1H NMR (CDCl3, 400 MHz): δ 7.79 (d, J = 8.3 Hz, 2H),
7.42 – 7.40 (m, 6H), 7.33 – 7.31 (m, 2H), 7.29 – 7.25 (m, 6H), 7.22 – 7.18 (m, 3H), 4.13
(t, J = 4.8 Hz, 2H), 3.66 (t, J = 4.8 Hz, 2H), 3.55 – 3.51 (m, 6H), 3.44 – 3.41 (m, 2H),
3.29 (t, J = 6.9 Hz, 2H), 2.43 – 2.40 (m, 5H).

13

C{1H} NMR (CDCl3, 101 MHz): δ

144.99, 144.97, 133.2, 130.0, 129.8, 128.2, 128.1, 126.9, 70.9, 70.73, 70.68, 70.3, 69.8,
69.4, 68.9, 66.8, 31.8, 21.9. ESI-MS calcd for C34H38NaO6S2 [M + Na]+ 629.2008, found
629.1994.
Synthesis of 5. To a solution of 3 (1.19 g, 3.70 mmol) in DMF (40 mL) was added
compound 4 (3.37 g, 5.55 mmol). Next, portionwise was added K2CO3 (0.512 g, 3.70
mmol), then the solution was stirred and heated to 80 °C for 5 hours. The reaction was
cooled to room temperature, diluted with ethyl acetate (400 mL), washed 5x with water
(75 ml), brine (100 mL), and dried over MgSO4. The organic layer was then filtered,
concentrated in vacuo, and purified via silica gel chromatography (hexanes: ethyl acetate
3:1 to CH2Cl2: MeOH 30:1) to provide 5 (2.01 g, 72% yield) as a yellow oil. 1H NMR
(CDCl3, 400 MHz): δ 7.95 – 7.92 (m, 2H), 7.42 – 7.40 (m, 6H), 7.29 – 7.25 (m, 6H), 7.21
– 7.18 (m, 3H), 6.90 – 6.88 (m, 4H), 4.18 (t, J = 4.7 Hz, 2H), 4.05 (t, J = 6.5, 2H), 3.87 (t,
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J = 4.7 Hz, 2H), 3.73 – 3.71 (m, 2H), 3.65 – 3.64 (m, 2H), 3.60 – 3.57 (m, 2H), 3.46 (t, J
= 4.7 Hz, 2H), 3.32 – 3.29 (m, 4H), 2.62 (d, J = 10.7 Hz, 2H), 2.43 (t, J = 6.9 Hz, 2H),
1.84 – 1.75 (m, 4H), 1.56 – 1.47 (m, 2H), 0.99 (t, J = 7.4 Hz, 3H).

13

C{1H} NMR

(CDCl3, 101 MHz): δ 162.8, 161.8, 154.0, 148.0, 148.0, 145.0, 142.6, 142.2, 136.0,
135.9, 129.8, 128.1, 126.9, 116.8, 116.6, 116.44, 116.39, 112.54, 112.45, 71.1, 70.9, 70.7,
70.4, 69.8, 69.7, 68.2, 67.9, 66.8, 37.38, 37.35, 31.9, 31.4, 19.4, 14.0. ESI-MS calcd for
C48H51O6S [M + H]+ 755.3401, found 755.3401.
Synthesis of 6. Compound 5 (1.45 g, 1.92 mmol) was dissolved in CH2Cl2 (20 mL) and
TFA (1.85 mL, 24.0 mmol). iPr3SiH (0.866 mL, 4.23 mmol) was added and the reaction
mixture was stirred at room temperature under argon for 3 hours. The reaction was
concentrated in vacuo and purified via silica gel chromatography (CH2Cl2:MeOH 30:1)
to provide 6 (0.910 g, 92%) as a yellow oil. 1H NMR (CDCl3, 400 MHz): δ 7.94 (d, J =
8.7 Hz, 2H), 6.92 – 6.88 (m, 4H), 4.23 – 4.20 (m, 2H), 4.05 (t, J = 6.5 Hz, 2H), 3.91 –
3.88 (m, 2H), 3.76 – 3.74 (m, 2H), 3.71 – 3.59 (m, 8H), 3.33 (d, J = 10.6, 2H), 2.62 (d, J
= 10.7 Hz, 2H), 2.87 – 2.72 (m, 2H), 1.84 – 1.77 (m, 2H), 1.60 (t, J = 7.4 Hz, 1H), 1.56 –
1.47 (m, 2H), 0.99 (t, J = 7.4 Hz, 3H). 13C{1H} NMR (CDCl3, 101 MHz): δ 162.3, 161.8,
154.0, 148.0, 142.6, 142.2, 136.0, 135.9, 116.8, 116.6, 116.43, 116.37, 112.6, 112.5, 73.1,
71.1, 70.9, 70.8, 70.4, 69.7, 68.2, 67.9, 37.39, 37.36, 31.3, 24.5, 19.4, 14.0. ESI-MS calcd
for C29H37O6S [M + H]+ 513.2305, found 513.2303.
Synthesis of MeO-EG3-AuNPs. HAuCl4·3H2O (1.46 g, 3.70 mmol, 1.0 eq.) was
dissolved in a mixture of dry methanol (503 mL) and glacial acetic acid (83 mL). To this
yellow solution was added MeO-EG3-SH (2.0 g, 11 mmol, 3.0 eq.). The bright yellow
solution was stirred vigorously for 1 h and the solution color faded slightly. A solution of
NaBH4 (1.3997 g, 37 mmol, 10.0 eq.) in nanopure H2O (96 mL) was added dropwise to
the reaction mixture under vigorous stirring. The mixture turned dark brown
immediately. After overnight stirring at ambient temperature, the solution was
concentrated and rediluted with brine. The MeO-EG3-AuNPs were extracted with toluene
while adding sodium chloride to the aqueous phase after each extraction to maintain the
saturation. The aqueous phase was eventually colorless. The combined organic phases
were then concentrated in vacuo. Evaporation of the solvent left a thin film of
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nanoparticles which was then washed with hexanes to remove excess free thiols. The
crude MeO-EG3-AuNPs were dissolved in nanopure H2O and further purified by
overnight dialysis. 1H NMR (400 MHz, CDCl3) δ 3.34 (-CH3), 3.58, 3.66 (-CH2-).
Synthesis of hνDIBO-AuNPs. To a solution of MeO-EG3-AuNPs (120 mg) in CH2Cl2
(15 mL) was added a solution of thiol 6 (24 mg, 0.05 mmol) in CH2Cl2 (15 mL) in the
dark at room temperature. The mixture was stirred for 15 min then concentrated in vacuo.
The resulting AuNP film was washed with hexanes (3x) and Et2O (3x), then redissolved
in 4 mL CH2Cl2 and precipitated out by addition of hexanes (22 mL). The resulting
suspension was placed under centrifugation at 6000 rpm for 10 min and the supernatant
was removed. This washing procedure was repeated 3x and the resulting hνDIBO-AuNPs
were dried in vacuo. hνDIBO-AuNPs were stored as a solution in CH2Cl2 at -20 °C.
Synthesis of DIBO-AuNPs. A solution of hνDIBO-AuNPs (8 mg) in CH3OH or H2O (32
mL) was irradiated with 350 nm light for 15 min. The reaction mixture was concentrated
in vacuo and the 1H NMR of the resulting AuNPs indicated quantitative decarbonylation
to afford DIBO-AuNPs.
Synthesis of triazole1-AuNPs. To a solution of DIBO-AuNPs (15 mg) in CH2Cl2 (2 mL)
was added BnN3 (50 μL, 0.38 mmol) and left to stir for 15 min. After, the mixture was
concentrated in vacuo and the resulting film was washed with hexanes (3x) to remove
excess azide. The film was remade by dissolving in CH2Cl2 followed by rotary
evaporation. This washing procedure was repeated two times, which afforded clean
triazole1-AuNPs.
Synthesis of triazole2-AuNPs. To a solution of DIBO-AuNPs (10 mg) in CHCl3 (400
μL) was added a 33 mM solution of p-azido anisole 8 in CH2Cl2 (100 μL) and left to stir
at r.t. for 4 h. After, the solvent was evaporated under reduced pressure and the reacted
AuNPs were purified by dissolving in CH2Cl2 (2 mL) and precipitation by hexanes (12
mL). This trituration procedure was repeated 3x, in which AuNPs were isolated each time
by centrifugation at 6000 rpm for 10 min, to afford pure triazole2-AuNPs.
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Synthesis of triazole3-AuNPs. To a solution of DIBO-AuNPs (10 mg) in CH2Cl2 (400
μL) was added a 33 mM solution of 3-azido-1-propanol 9 in CH2Cl2 (100 μL) and left to
stir at r.t. for 4 h. After, the solvent was evaporated under reduced pressure and the
reacted AuNPs were purified by dissolving in CH2Cl2 (2 mL) and precipitation by
hexanes (12 mL). This trituration procedure was repeated 3x, in which AuNPs were
isolated each time by centrifugation at 6000 rpm for 10 min, to afford the pure triazole3AuNPs.
Synthesis of triazole4-AuNPs. To a solution of DIBO-AuNPs (10 mg) in 1:1
MeOH:CH2Cl2 (400 μL) was added a 33 mM solution of 3′-Azido-3′-deoxythymidine 10
in 1:1 MeOH:CH2Cl2 (100 μL) and left to stir at r.t. for 4 h. After, the solvent was
evaporated under reduced pressure and the reacted AuNPs were purified by dialysis in
MeOH overnight to afford the pure triazole4-AuNPs.
Synthesis of isoxazoline-AuNPs. To a solution of DIBO-AuNPs (10 mg) in CH2Cl2 (400
μL) was added a 33 mM solution of N-phenyl-α-phenynitrone 11 in CH2Cl2 (100 μL) and
left to stir at r.t. for 4 h. After, the solvent was evaporated under reduced pressure and the
reacted AuNPs were purified by dissolving in CH2Cl2 (2 mL) and precipitation by
hexanes (12 mL). This trituration procedure was repeated 3x, in which AuNPs were
isolated each time by centrifugation at 6000 rpm for 10 min, to afford the pure
isoxazoline-AuNPs.
Kinetic measurements of SPAAC reactivity of DIBO-AuNPs. Kinetic measurements
using 1H NMR spectroscopy were performed as follows: A concentrated stock solution of
DIBO-AuNPs was prepared in CDCl3 to give a final concentration of 2.75 mM in
interfacial DIBO. To 400 μL of this AuNP solution in a NMR tube was added 100 μL of
11 mM benzyl azide (BnN3) solution to give a final equimolar concentration of 2.2 x 10-3
M in both BnN3 and interfacial DIBO. Reactions were monitored through 1H NMR
analysis at 25 °C by following the decay of the sharp singlet signal at ~4.30 ppm
corresponding to the benzylic protons of BnN3. Integrations were normalized against the
residual CH2Cl2 signal. These reactions were carried out in triplicate and the second order
rate constant was calculated from a plot of 1/[BnN3] (M-1) versus time (in seconds).
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Decomposition of AuNPs. For each reacted AuNP sample in CH3OH, excess I2 was
added to decompose the AuNPs. Insoluble solids were filtered off and the filtrate
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Figure S2.1. 1H NMR spectra of thiol ligand 6 (top) and hνDIBO-AuNPs (bottom) in
CDCl3. *Denotes residual protonated solvent. Spectra referenced against CHCl3.
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Figure S2.2. Infrared spectrum of hνDIBO-AuNPs.

Figure S2.3 UV-vis absorption spectrum of hνDIBO-AuNPs obtained in CH3OH.
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Figure S2.4. TGA characterization of hνDIBO-AuNPs.
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Calculation of the AuNP raw formula.
From a combination of the 1H NMR, TGA, and TEM data, while assuming that AuNPs
are perfectly spherical and monodispersed in size, it is possible to calculate an
approximate raw formula for hνDIBO-AuNPs. The number of gold atoms (NAu) can be
calculated using the following formula:

𝑁𝐴𝑢

𝜋𝜌𝑑 3 𝑁𝐴
=
6𝑀𝐴𝑢

Where:

 = density of face centered cubic(fcc) gold lattice (19.3 g cm-1)
d = average diameter of nanoparticles in centimeters (from TEM images)
NA = Avogadro constant
MAu = mole atomic weight of gold (196.9665 g mol-1)
The total number of thiol ligands surrounding the gold core (NL) can be calculated using
the following formula:
𝑁𝐿 =

𝑁𝐴𝑢 𝑀𝐴𝑢 𝑀𝑇𝐺𝐴
(1 − 𝑀𝑇𝐺𝐴 )(𝑀𝑊ℎ𝑣𝐷𝐼𝐵𝑂 𝑛%ℎ𝑣𝐷𝐼𝐵𝑂 + 𝑀𝑊𝑀𝑒𝑂 𝑛%𝑀𝑒𝑂 )

Where:
MTGA = organic percentage from TGA
MhvDIBO = molecular weight of hνDIBO-EG4-S- ligand
n%hvDIBO = molar percentage of hνDIBO-EG4-S- ligand
MWMeO = molecular weight of MeO-EG3-S- ligand
n%MeO = molar percentage of MeO-EG3-S- ligand
From the number of ligands per particle, the number of gold atoms per particles, and the
molar percentage of the two different ligands it is possible to obtain the nanoparticles raw
formula.
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Figure S2.5. 1H NMR spectrum of DIBO-AuNPs in CDCl3. *Denotes residual
protonated solvent. Spectrum referenced against CHCl3.

Figure S2.6. Infrared spectrum of DIBO-AuNPs.
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Figure S2.7. UV-vis absorption spectrum of DIBO-AuNPs.
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Figure S2.8. 1H NMR spectrum of triazole1-AuNPs in CDCl3. *Denotes residual
protonated solvent. Spectrum referenced against CHCl3.
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Figure S2.9. Infrared spectrum of triazole1-AuNPs.

Figure S2.10. UV-vis absorption spectrum of triazole1-AuNPs obtained in CH3OH.
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Figure S2.11. TEM images of hνDIBO-AuNPs (left), DIBO-AuNPs (center), and
triazole1-AuNPs (right).

Figure S2.12. 1H NMR spectrum of triazole2-AuNPs in CDCl3. *Denotes residual
protonated solvent. Spectrum referenced against CHCl3.
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Figure S2.13. 1H NMR spectrum of triazole3-AuNPs in CDCl3. *Denotes residual
protonated solvent. Spectrum referenced against CHCl3.

Figure S2.14. 1H NMR spectrum of triazole4-AuNPs in CDCl3. *Denotes residual
protonated solvent. Spectrum referenced against CHCl3.
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Figure S2.15. 1H NMR spectrum of isoxazoline-AuNPs in CDCl3. *Denotes residual
protonated solvent. Spectrum referenced against CHCl3.

Scheme S2.2. Re-oxidation of triazole1-AuNPs by molecular iodine. Disulfides 1A and
1B were characterized by ESI-MS. Disulfide 1A calculated 796.3665 for C42H58N3O8S2
[M+H]+, found 796.3635. Disulfide 1B calculated 1233.5769 for C70H85N6O10S2 [M+H]+,
found 1233.5784.
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Figure S2.16. ESI-MS characterization of disulfides 1A (top) and 1B (bottom).

80

Scheme S2.3. Re-oxidation of triazole2-AuNPs by molecular iodine. Disulfide 2 was
characterized by ESI-MS. Disulfide 2 calculated 812.3614 for C42H58N3O9S2 [M+H]+,
found 812.3636.

Figure S2.17. ESI-MS characterization of disulfide 2.
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Scheme S2.4. Re-oxidation of triazole3-AuNPs by molecular iodine. Disulfide 3 was
characterized by ESI-MS. Disulfide 3 calculated 786.3434 for C38H57N3NaO9S2
[M+Na]+, found 786.3429.

Figure S2.18. ESI-MS characterization of disulfide 3.
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Scheme S2.5. Re-oxidation of triazole4-AuNPs by molecular iodine. Disulfide 4 was
characterized by ESI-MS. Disulfide 4 calculated 930.3993, for C45H64N5O12S2 [M+H]+,
found 930.3983.

Figure S2.19 ESI-MS characterization of disulfide 4.
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Scheme S2.6. Re-oxidation of isoxazoline-AuNPs by molecular iodine. Disulfide 5 was
characterized by ESI-MS. Disulfide 5 calculated 859.3788 for C48H61NO9S2 [M]+, found
859.3763.

Figure S2.20. ESI-MS characterization of disulfides 5.
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Chapter 3

3

A Fluorogenic Gold Nanoparticle (AuNP) Substrate: A
Model for the Controlled Release of Molecules from
AuNP Nanocarriers via Interfacial Staudinger-Bertozzi
Ligation

Reprinted with permission from Langmuir 2017, 33, 1908–1913, with minor formatting
changes to maintain consistency throughout thesis. Figure S3.X refers to Supporting
Information (Section 3.6).

3.1 Introduction
Nanomaterials have emerged as important tools in the development of drug delivery
systems due to their vast range of structures, high load capacity of surface bound and/or
entrapped molecules, and their unique and tunable physical and chemical properties.[1-4]
The efficacy of therapeutics, when introduced in their ‘free’ form into a biological setting,
can be limited by solubility, in vivo stability, nonspecific bio-distribution, and multiple
transport barriers.[5] In this regard, the application of gold nanoparticles (AuNPs) as a
nanocarrier in drug delivery systems is a rapidly expanding field. Their inherent
nontoxicity, reproducibility and scalability of their synthesis, and well-understood surface
chemistry make them very attractive vehicles for the delivery of drugs, genetic materials,
proteins, and small molecules.[6-7] As a result, much research has been dedicated to the
development of methodologies for the controlled release of molecules from AuNP
surfaces.
Nanocarriers can be loaded with the material that is destined to be released either through
noncovalent or covalent incorporation. Due to the functional versatility of their
monolayer chemistry, AuNPs provide an excellent platform for the design of controlled
release systems. In general, AuNP-based delivery strategies rely on 1) non-covalent
hydrophobic entrapment of molecules into the AuNP monolayer,[7-8] 2) photo-regulated
release,[9-11] or 3) glutathione (GSH)-mediated release.[7,12] Although these systems
represent effective delivery strategies, the lack of specificity and/or conjugate stability in
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these ‘shotgun’-type approaches outline limits in current delivery strategies that need to
be addressed. For these reasons, there remains the need to develop more efficient
molecular delivery systems with greater target specificity and molecular-level control.
Despite the emergence of bioorthogonal chemistry and its use for in vivo imaging,
biolabelling, and bioconjugation,[13-17] there has been little to no work done employing
this family of reactions for the development of AuNP-based delivery systems. This is
surprising given the widespread application of these reactions in vivo due to their high
yielding nature, biocompatibility, chemoselectivity, and ability to proceed under
physiological conditions.[18-19]

In particular, the highly specific Staudinger-Bertozzi

ligation with azides (Scheme 3.1), initially developed for cell surface engineering via
amide bond formation, represents a dual-purpose transformation — chemical ligation and
release — that is seldom utilized for the latter purpose.[20-21] Although this bioorthogonal
ligation reaction has found applications in joining materials together covalently (e.g.
bioconjugation onto nanomaterials, biolabelling with fluorescent probes, construction of
mono- and multilayers on surfaces), the molecular cargo that is released is almost
invariably a simple alcohol such as methanol.[22-24] However, this cargo release
mechanism can be designed to carry out a function, i.e. deliver a molecular agent of
interest (e.g. drug delivery in vivo, a fluorophore, a catalyst, etc.) or develop
nanomaterial-based sensing platforms.

Scheme 3.1. Dual-purpose nature of the Staudinger-Bertozzi Ligation.
The union between bioorthogonal chemistry and materials chemistry is still a relatively
new field. The strengths of bioorthogonal chemistry are not limited to small molecule
chemistry for in vivo applications, but can be applied as a clean and fast reaction pathway
towards functional material substrates. The Staudinger-Bertozzi ligation benefits from
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high chemoselectivity, mild reaction conditions, as well as nitrogen gas being the only
byproduct, i.e. no purification is required post-reaction.
We recently demonstrated that the Staudinger-Bertozzi ligation can be employed
effectively and cleanly at the interface of organic solvent-soluble AuNPs for potential
applications in bioconjugation.25 To further expand this technology beyond ligation onto
AuNP surfaces, we set out to design a water-soluble AuNP system that fully exploits the
dual-purpose nature of this bioorthogonal reaction. By employing the ester moiety as a
functional handle for tethering a general cargo (drug, fluorophore, etc.), we capitalize on
the alcohol release mechanism off AuNPs that occurs concomitantly with ligation via
amide bond formation. The azide is becoming the most widely used tag in chemical
biology because of its small size coupled with its chemical inertness towards biological
functionalities.26 As such, a delivery strategy based on the Staudinger-Bertozzi ligation
represents an extremely attractive system with high target selectivity as it offers careful
and controlled release of the molecular cargo as a result of the high chemoselectivity of
the nanocarrier system.

3.2 Results and Discussion
As a model for AuNP-based molecular delivery, we set out to design a system that
incorporates a fluorescent dye into the AuNP monolayer. When covalently bound in close
proximity to the metallic core, efficient quenching of the dye emission is expected
(Figure 3.1a).[27-28] This provides the baseline from which the release event can be
monitored. Upon release of the dye from the nanoparticle surface into the bulk solution,
fluorescence emission is turned ‘on’, thus indicating an effective release mechanism.
Rhodamine B dye was chosen for its low cost, excellent water solubility, and
photostability. To incorporate this dye into the AuNP monolayer, a ligand was designed
to contain three key features (Figure 3.1b): (1) a thiol head for binding to the Au surface
(2) the modified triphenylphosphine moiety required for the Staudinger-Bertozzi ligation
and (3) the molecular cargo bound via an ester, which is required for release.
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Figure 3.1. (a) Cartoon demonstrating the design of a release system that exploits
fluorescence quenching of metallic nanoparticles. (b) Design of the thiol ligand bearing
the molecular cargo.
The synthesis of this thiol ligand began from commercially available 1-methyl-2aminoterephthalate, which was transformed to phosphine 1 according to a procedure
previously developed in our group (Scheme 3.2).[25] Hydrolysis of the methyl ester in 1
by a basic ethanol solution afforded the benzoic acid derivative 2, which underwent
HBTU

(2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium

hexaﬂuorophosphate)-

mediated esterification with a Rhodamine-B alcohol derivative 3 to afford ester 4.
Subsequent cleavage of the S-trityl protecting group in 4 by TFA/CH2Cl2 gave the target
thiol ligand 5. It is worth noting that the length of thiol 5 was chosen to be long enough
for the phosphine to be presented at the monolayer surface for interfacial reactivity, but
short enough to observe quenching of the dye emission upon binding onto AuNPs. Thiol
ligand 7, the P=O derivative of 5, which cannot undergo Staudinger-Bertozzi ligation,
was also prepared to serve as a control. Details of the ligand syntheses can be found in
the Supporting Information (Section 3.6).
Incorporation of thiol ligand 5 onto AuNPs was achieved via a ligand exchange reaction
with HO-EG4-AuNPs in CH3OH overnight (Scheme 3.2). Ligand exchange represents a
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Scheme 3.2. Synthesis of thiol ligands 5 and 7 (top) and Rhod-PPh3-EG4-AuNPs and
Rhod-(P=O)Ph3-EG4-AuNPs (bottom).
mild reaction pathway towards incorporating new ligands into AuNP monolayers. The
HO-EG4-AuNPs are 5 ± 1 nm in gold core diameter and were chosen for their high water
solubility (compared to MeO-EG3-AuNPs used previously[25]) and ability to prepare them
on a gram-scale. Additionally, HO-EG4-AuNPs were found to feature exceptional
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colloidal stability, where they can be stored in solution at -20°C for months with no
observed aggregation. Thus, these AuNPs represent very resilient substrates for further
modification as well as interfacial organic chemistry. Details of their synthesis can be
found in the Supporting Information (Section 3.6).
Following place exchange, Rhod-PPh3-EG4-AuNPs were purified from excess thiols and
disulfides via trituration with a 1:1 mixture of CH2Cl2/Et2O in which the AuNPs are not
soluble. It was important that any unbound or ‘free’ thiols and disulfides resulting from 5
were removed to provide a baseline of fluorescence from which we can monitor the
release event. The 1H NMR spectrum of the resulting treated AuNP sample (Figure 3.2,
bottom), when compared to the HO-EG4-AuNP starting material (Figure 3.2, top),
showed additional broad peaks in the aromatic region that correspond to surface-bound
ligand 5. The absence of sharp peaks in this region represents the absence of free 5 in
solution, thus indicating that the washing procedure employed was effective in removing
unbound thiols and disulfides. The
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P{1H} NMR spectrum of Rhod-PPh3-EG4-AuNPs

(see Figure S3.5) showed a broad signal at 41.4 ppm and a sharp signal at 33.7 ppm. As
discussed previously,[25] the broad signal at 41.4 ppm was assigned to the Staudingeractive phosphine ligand 5. The sharp signal at 33.7 ppm is a small amount of phosphine
oxide (P=O) generated from oxidation during the washing procedure. Rhod-(P=O)Ph3EG4-AuNPs (Scheme 3.2), which showed one sharp resonance at 33.7 ppm in its 31P{1H}
NMR spectrum, were also prepared to serve as a control as it will not undergo
Staudinger-Bertozzi ligation.
Thermogravimetric analysis (TGA) of Rhod-PPh3-EG4-AuNPs showed that 32% of the
total weight is from the organic corona (see Figure S3.7). Deconvolution of the derivative
plot showed that two ligands decompose at distinctly different temperatures (see Figure
S3.7): a large component at 270°C and a smaller component a 375°C. By comparing to
the TGA data of the HO-EG4-AuNP starting material (See Figure S3.3), the ligand
decomposing at 270 °C was assigned to HO-EG4-S– and corresponded to 83% of the
organic corona by mass, whereas the ligand decomposing at 375°C was assigned to 5 and
corresponded to the remaining 17%. Finally, from the deconvolution of the TGA curve,
31

P{1H} NMR spectrum, and the average gold core diameter (5 ± 1 nm) obtained from
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Figure 3.2. 1H NMR spectra of HO-EG4-AuNPs (top) and Rhod-PPh3-EG4-AuNPs
(bottom). *Denotes residual protium solvent. Spectra referenced against residual CD3OH.
transmission electron microscopy (TEM) images (see Figure S3.6), it was possible to
calculate a raw formula for Rhod-PPh3-EG4-AuNPs: Au3500[HO-EG4-S–]1400[Rhod-PPh3EG4-S–]40[Rhod-P(=O)Ph3-EG4-S–]5. More specifically, these AuNPs contain the payload
to be delivered at a concentration of 0.038 μmol mg-1 AuNP (for calculations, see Section
3.6). The concentration of 5 incorporated in this model system was chosen to strike a
balance between maintaining water solubility and allowing for enough incorporation for
characterization of the new functionalities. However, it is worth noting that the
concentration of ligand 5 can be tuned by increasing/decreasing the ratio of 5:AuNP
during the ligand exchange reaction or by increasing/decreasing reaction time as needed.
This ability to tune and determine the concentration of the payload with good precision
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using the protocol reported here is of particular importance for delivery and/or sensing
applications.
The final suspension of Rhod-PPh3-EG4-AuNPs retained only a very low level of
emission, which arose from the quenching of the Rhodamine B dye’s fluorescence by
proximity to the metallic core, thus providing a baseline from which the release event can
be monitored. To test our goal of azide-triggered release, azide 8 was introduced to a
solution of Rhod-PPh3-EG4-AuNPs in nanopure water and the reaction was monitored by
fluorescence spectroscopy (Figure 3.3). Azide 8 was selected for its water solubility and
structural resemblance to benzyl azide, a standard azide molecule employed in
bioorthogonal reaction studies.[20-21,25] An immediate increase in fluorescence emission
intensity after addition of an azide was observed. This enhancement in emission intensity
indicates effective release of the dye from the nanoparticle surface into the bulk solution,
reaching a plateau in 4–6 hours. It is worth noting that a high concentration of azide 8
(0.5 M) was used to trigger the release of the dye in this model study, however we’ve
previously demonstrated that the Staudinger-Bertozzi ligation proceeds even at
millimolar concentrations of azide on AuNPs and the same is true here.[25]
Following the addition of azide 8, the
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P{1H} NMR spectrum of the reacted AuNPs

showed only one component at 35 ppm corresponding to the P=O of the ligation product
(and overlapped P=O from previous, see Figure S3.10),[25] thus confirming that the
release mechanism observed here is due to the interfacial bioorthogonal reaction, which
proceeded quantitatively. Therefore, the emission intensity after 4–6 hours represents full
release of the cargo and the progression of the reaction can be monitored as a fraction of
emission intensity.
As a control, azide 8 was also introduced to a suspension of Rhod-(P=O)Ph3-EG4AuNPs, the phosphine oxide analogue to Rhod-PPh3-EG4-AuNPs. Due to the lack of the
phosphine moiety, these AuNPs do not undergo the interfacial Staudinger-Bertozzi
ligation. Even after 8 hours, no increase in fluorescence emission was observed, as
expected (Figure 3.3). This further confirmed that the release mechanism is in fact by
interfacial Staudinger-Bertozzi ligation in which the phosphine lone pair is required.[20]
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Figure 3.3. Top: Fluorescence emission spectra of an aqueous solution Rhod-PPh3-EG4AuNPs (from bottom to top) 0 min, 15 min, 30 min, 45 min, 1 h, 2 h, 3 h, 4 h, 5 h, and 6
h after addition of azide 8. Bottom: Fluorescence emission intensity of AuNPs at 585 nm
versus time. λex = 550 nm. Right: Vials depicting a solution of Rhod-PPh3-EG4-AuNPs
before and after addition of azide 8 accompanied by a scheme of the interfacial
Staudinger-Bertozzi ligation reaction.
Furthermore, as stated previously, AuNP-based delivery systems are prone to ligand
displacement by other thiol molecules. For example, GSH-mediated release is commonly
exploited in AuNP drug delivery systems in which intracellular concentrations (1–10
mM) of GSH can trigger ligand exchange.[7] This could potentially lead to loss of
specificity in which our cargo is released as a thiolate (i.e. thiolate of 5) as opposed to the
intended Rhodamine B alcohol derivative shown in Figure 3.3. To test this, Rhod-PPh3EG4-AuNPs were suspended in a 10 mM aqueous solution of GSH and the fluorescence
emission of the solution was monitored. No significant enhancement in emission was
observed (Figure 3.3) compared to the dramatic enhancement when azide 8 was
employed to trigger the payload release. Thus, ligand exchange is not a major contributor
to payload release. The high specificity of this nanocarrier system will allow for greater
control and selectivity of the release event compared to traditional ‘shotgun’-type
approaches.

93

3.3 Conclusion
In conclusion, to the best of our knowledge, we demonstrate for the first time a highly
specific AuNP-based controlled-release system based on the bioorthogonal interfacial
Staudinger-Bertozzi ligation. In our design, we exploit the efficient quenching effect of
metallic nanoparticles on fluorescent dyes when they are incorporated into the surfacebound monolayer. The resulting low level of dye emission provided the baseline of
fluorescence, which was used to monitor the release event. We observed – both
spectroscopically and visually – an immediate ‘turn on’ of fluorescence upon introduction
of an organic azide to a suspension of Rhod-PPh3-EG4-AuNPs, which corresponded to
dye release from the nanoparticle surface.
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P{1H} NMR data and control experiments

independently confirmed that interfacial Staudinger-Bertozzi ligation is the mechanism of
release.
Although the Staudinger-Bertozzi ligation represents a powerful organic transformation
that has been extensively used in small molecule chemistry for in vivo applications, it is
seldom exploited for its dual-purpose nature, especially on material surfaces. In our
methodology, we’ve provided a clean and simple route towards (1) chemically ligating
new material onto AuNP surfaces and (2) release of a molecular cargo from AuNP
nanocarriers, both of which can be achieved simultaneously within a single interfacial
transformation. This, along with the ease of installation of the azide functional group in
chemical biology, materials, and small molecule chemistry provides exciting
opportunities for new applications of this nanomaterial-based release platform. Lastly, the
molecular cargo can be designed to be a drug, fluorophore, or small molecule of interest
to further expand the scope of applications both in vivo and in the development of
functional nanomaterials. Further studies and applications of this novel controlled-release
system are currently underway.
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3.6 Supporting Information
General Methods. The following reagents, unless otherwise stated, were used as
received. Triethylene glycol monomethyl ether, tetraethylene glycol, 1-methyl-2aminoterephthalate, sodium azide, triphenylmethanethiol, triphenylphosphine, anhydrous
deuterated chloroform (CDCl3), anhydrous deuterated methanol (CD3OD), deuterium
oxide (D2O), tetrachloroauric acid trihydrate, sodium borohydride, p-Toluenesulfonyl
chloride,

triisopropylsilane

(TIPS),

N,N-Diisopropylethylamine

Benzotriazole-N,N,N',N'-tetramethyluronium-hexafluoro-phosphate

(DIEA),
(HBTU),

Oand

Rhodamine B were purchased from Sigma-Aldrich. All common solvents, triethylamine
(TEA), magnesium sulfate, sodium sulfate anhydrous, potassium iodide, sodium sulphite,
sodium bicarbonate, dry methanol, hydrochloric acid, trifluoroacetic acid, sodium
hydroxide, and sodium chloride were purchased from Caledon. Palladium(II) diacetate
trimer and diphenylphosphine were purchased from Alfa Aesar. Ethanol was purchased
from Commercial Alcohols. Glacial acetic acid (99.7%) and sodium nitrite were
purchased from BDH. Dialysis membranes (MWCO 6000-8000 Da) were purchased
from

Spectra/Por.

2-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)ethyl

4-

methylbenzenesulfonate and compound 1 were synthesized from 1-methyl-2aminoterephthalate according to a previously established protocol in our group (Org.
Biomol. Chem. 2015, 13, 4605–4612). Compound 3 was synthesized according to Org.
Lett. 2003, 5, 3245–3248.
1

H, 13C and 31P NMR spectra were recorded on an Inova 400 or 600 MHz spectrometers

using CDCl3, CD3OD, or D2O as solvent and were calibrated against the solvent or using
H3PO4 as a standard. Thermogravimetric analyses (TGA) were recorded by loading the
sample in a 70 μL ceramic crucible and heating from 25 ºC to 750 ºC at a rate of 10 ºC
min-1. The experiment was run under a nitrogen flow of 70 mL min-1 in a Mettler Toledo
TGA/SDTA 851 instrument. Transmission electron microscopy (TEM) images were
recorded from a TEM Philips CM10. The TEM grids (Formvar carbon film on 400 mesh
copper grids) were purchased from Electron Microscopy Sciences and prepared by
dropcasting a drop of nanoparticles solution directly onto the grid surface. The drop was
then carefully removed after 30 seconds with a soft tissue. ESI-MS spectra were recorded
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on a Micromass LCT mass spectrometer. Fluorescence spectroscopic studies were
performed on a Photon Technology International (PTI) fluorimeter.
Synthesis of compound 2. A solution of methyl 2-(diphenylphosphino)-4-((1,1,1triphenyl-5,8,11-trioxa-2-thiatridecan-13-yl)carbamoyl)benzoate 1 (834 mg, 1.07 mmol)
in argon purged 1 M NaOH solution in 95% ethanol (120 mL) was prepared under an
argon atmosphere and stirred vigourously at r.t. for 90 min. After, the mixture was
acidified with 1 M HCl(aq) (200 mL) and extracted with EtOAc (3 x 100 mL). The
combined organic layers was dried over Na2SO4 and concentrated in vacuo. The residue
was purified by column chromatography on silica gel using 1:6 iPrOH:CH2Cl2 as the
eluent to afford 2 (610 mg, 73%) as a pale yellow solid. 1H NMR (CDCl3, 400 MHz): δ
8.10 (dd, J = 8.2 Hz, 3.8 Hz, 1H), 7.74 (br, 1H), 7.41 – 7.16 (m, 26H), 6.56 (br, 1H), 3.62
– 3.48 (m, 10H), 3.42 (t, J = 4.4 Hz, 2H), 3.27 (t, J = 6.8 Hz, 2H), 2.40 (t, J = 7.0 Hz,
2H).

13

C{1H} NMR (CDCl3, 101 MHz): δ 169.2, 166.5, 144.8, 142.7, 142.5, 137.7,

137.2, 137.1, 135.3, 135.2, 134.0, 133.9, 132.8, 131.5, 129.6, 128.9, 128.6, 128.5, 127.8,
126.6, 70.5, 70.4, 70.2, 70.1, 69.6, 66.6, 39.8, 31.6. 31P{1H} NMR (CDCl3, 162 MHz): δ 4.04 (s). ESI-MS calcd for C47H47NO6PS+ [M + H]+ 784.2862, found 784.2876.
Synthesis of compound 4. To a solution of 2 (400 mg, 0.51 mmol), 3 (407 mg, 0.60
mmol), and HBTU (378 mg, 0.99 mmol) in MeCN (28 mL) was added DIEA (0.24 mL,
1.43 mmol) at r.t. under an argon atmosphere. The resulting solution was stirred for 18 h.
After, the solution was concentrated in vacuo and the residue was purified by column
chromatography on silica gel using 1:6 iPrOH:CH2Cl2 as the eluent to afford 4 (720 mg,
97%) as a purple solid. 1H NMR (CDCl3, 400 MHz): δ 8.06 (dd, J = 7.8 Hz, 3.7 Hz, 1H),
7.78 (dd, J = 7.8 Hz, 2.0 Hz, 1H), 7.70 – 7.63 (m, 2H), 7.56 – 7.49 (m, 1H), 7.43 – 7.16
(m, 29H), 6.94 (dd, J = 9.4 Hz, 2.7 Hz, 2H), 6.76 (d, J = 2.3 Hz, 2H), 6.54 (t, J = 5.1 Hz,
1H), 4.71 (t, J = 6.6 Hz, 2H), 3.66 – 3.48 (m, 18H), 3.45 – 3.40 (m, 2H), 3.40 – 3.30 (m,
br, 4H), 3.26 (t, J = 7.0 Hz, 2H), 2.40 (t, J = 7.0 Hz, 2H), 2.33 – 2.14 (m, br, 6H), 1.71 (t,
J = 7.0 Hz, 2H), 1.30 (t, J = 7.2 Hz, 12H).

13

C{1H} NMR (CDCl3, 101 MHz): δ 167.2,

166.3, 166.2, 157.6, 155.9, 155.5, 144.6, 140.9, 140.6, 137.2, 137.2, 137.1, 136.7, 136.6,
135.3, 133.8, 133.6, 132.9, 132.0, 131.81, 131.76, 130.6, 130.5, 130.0, 129.9, 129.7,
129.4, 128.7, 128.5, 128.4, 127.7, 127.4, 126.7, 126.5, 113.9, 113.6, 96.1, 70.3, 70.2,
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70.0, 69.9, 69.4, 66.4, 64.1, 63.5, 54.3, 45.9, 39.7, 31.5, 29.5, 25.5, 12.4. 31P{1H} NMR
(CDCl3, 162 MHz): δ -4.32 (s). ESI-MS calcd for C82H90N5O8PS2+ [M + H]2+ 1335.6242,
found 1335.6227.
Synthesis of compound 5. To a solution of 4 (50 mg, 0.03 mmol) in CH2Cl2 (18 mL)
was added TFA (0.6 mL, 7.8 mmol) dropwise at 0 °C under an argon atmosphere
followed by addition of iPr3SiH (16 μL, 0.08 mmol). Ar(g) was bubbled through the
reaction mixture for an additional 15 min. The flask was sealed and left to stir at 0 °C to
r.t. in the dark for 2 h. After, the solution was concentrated in vacuo and the residue was
purified by column chromatography on silica gel using 1:6 iPrOH:CH2Cl2 then 1:4
MeOH:CH2Cl2 as the eluent to afford 5 (31 mg, 75%) as a purple solid. 1H NMR
(CD3OD, 400 MHz): δ 8.02 (dd, J = 8.2 Hz, J = 3.5 Hz, 1H), 7.81 (dd, J = 8.2 Hz, J = 2.0
Hz, 1H), 7.79 – 7.73 (m, 2H), 7.67 –7.61 (m, 1H), 7.55 – 7.49 (m, 1H), 7.46 – 7.41 (m,
1H), 7.39 – 7.19 (m, 12H), 7.05 (dd, J = 9.6 Hz, J = 2.5 Hz, 2H), 6.95 (d, J = 2.3 Hz,
2H), 4.13 (t, J = 6.2 Hz, 2H), 3.71 – 3.50 (m, 20H), 3.46 (t, J = 5.5 Hz, 2H), 3.37 (s, br,
4H), 2.58 (t, J = 6.2 Hz, 2H), 2.32 (t, J = 7.0 Hz, 2H), 2.22 (s, br, 4H), 1.70 (quintet, J =
7.0 Hz, 2H), 1.28 (t, J = 7.0 Hz, 12H).

13

C{1H} NMR (CD3OD, 101 MHz): δ 169.4,

169.3, 168.0, 159.4, 157.3, 157.0, 142.1, 141.9, 139.2, 139.1, 138.8, 138.7, 136.6, 135.3,
135.1, 134.8, 133.6, 132.3, 131.8, 131.7, 131.5, 131.4, 130.3, 129.9, 129.0, 128.1, 115.5,
115.0, 97.5, 74.2, 71.73, 71.66, 71.4, 71.2, 70.5, 64.9, 64.4, 56.9, 55.7, 47.0, 41.2, 31.7,
31.2, 26.0, 25.4, 24.8, 13.1.

31

P{1H} NMR (CD3OD, 162 MHz): δ -4.34 (s). ESI-MS

calcd for C63H76N5O8PS2+ [M + H]2+ 1093.5147, found 1093.5127.
Synthesis of compound 6. To a solution of 4 (57 mg, 0.04 mmol) in CHCl3 (5 mL) was
added 10 mL 3% H2O2(aq) while stirring. The mixture was heated to 45 °C and left to stir
for 3 h. After, the reaction mixture was extracted with CH2Cl2 (3 x 10 mL) and the
combined organic fractions were dried over Na2SO4 and concentrated to give 6 as a
purple solid (58 mg, quant. yield), which was used in the next step without further
purification. 1H NMR (CDCl3, 400 MHz): δ 8.09 – 8.02 (m, 2H), 7.86 (dd, J = 7.8 Hz, J
= 3.1 Hz, 1H), 7.69 – 7.15 (m, 31H), 7.07 (t, J = 5.5 Hz, 1H), 6.92 (dd, J = 9.8 Hz, 2.7
Hz, 2H), 6.75 (d, J = 2.3 Hz, 2H), 3.93 (t, J = 6.6 Hz, 2H), 3.65 – 3.51 (m, 18H), 3.43 –
3.28 (m, 6H), 3.25 (t, J = 6.6 Hz, 2H), 2.38 (t, J = 7.0 Hz, 2H), 2.28 – 2.10 (m, br, 6H),
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1.53 (m, 2H), 1.29 (t, J = 7.3 Hz, 12H).

13

C{1H} NMR (CDCl3, 101 MHz): δ 167.3,

166.7, 165.6, 157.7, 156.2, 155.6, 144.7, 138.4, 136.6, 136.5, 135.5, 133.4, 133.3, 133.2,
131.9, 131.8, 130.6, 130.5, 130.1, 129.8, 129.6, 128.5, 128.3, 127.8, 127.5, 126.6, 114.1,
113.8, 96.1, 70.5, 70.3, 70.2, 70.1, 69.5, 69.4, 66.5, 64.0, 54.3, 53.4, 53.0, 52.3, 47.6,
46.0, 41.7, 40.0, 31.6, 29.7, 25.1, 12.6.

31

P{1H} NMR (CDCl3, 162 MHz): δ 31.2 (s).

ESI-MS calcd for C82H89N5O9PS+ [M]+ 1350.6113, found 1350.6115.
Synthesis of compound 7. To a solution of 6 (50 mg, 0.03 mmol) in CH2Cl2 (20 mL)
was added TFA (1.4 mL, 18 mmol) dropwise at 0 °C under an argon atmosphere
followed by addition of iPr3SiH (20 μL, 0.10 mmol). Ar(g) was bubbled through the
reaction mixture for an additional 15 min. The flask was sealed and left to stir at 0 °C to
r.t. in the dark for 2 h. After, the solution was concentrated in vacuo and the residue was
purified by column chromatography on silica gel using 1:6 iPrOH:CH2Cl2 then 1:4
MeOH:CH2Cl2 as the eluent to afford 7 (29 mg, 80%) as a purple solid. 1H NMR
(CD3OD, 600 MHz): δ 8.69 (t, J = 5.5 Hz, 1H), 8.14 (d, J = 8.2 Hz, 1H), 8.01 (dd, J = 7.6
Hz, J = 3.5 Hz, 1H), 7.86 (m, 1H), 7.80 – 7.77 (m, 2H), 7.73 (m, 1H), 7.80 – 7.50 (m,
11H), 7.26 (d, J = 9.4 Hz, 2H), 7.07 (dd, J = 9.4 Hz, J = 2.3 Hz, 2H), 6.97 (d, J = 2.3 Hz,
2H), 4.04 (t, J = 5.9 Hz, 2H), 3.71 – 3.59 (m, 26H), 3.14 – 2.78 (m, br, 6H), 2.59 (t, J =
6.4 Hz, 2H), 1.86 (s, br, 2H), 1.30 (t, J = 7.6 Hz, 12H).

13

C{1H} NMR (CD3OD, 150

MHz): δ 169.4, 168.2, 168.2, 168.1, 159.4, 157.4, 156.9, 139.92, 139.86, 138.6, 138.4,
136.0, 135.3, 135.2, 133.9, 133.9, 133.7, 133.3, 133.1, 133.0, 132.6, 132.5, 132.3, 132.23,
132.15, 132.1, 132.0, 131.7, 131.5, 130.2, 130.1, 129.0, 119.8, 116.9, 115.5, 115.0, 97.5,
74.2, 71.74, 71.66, 71.4, 71.2, 70.5, 64.9, 64.4, 55.7, 49.2, 47.1, 41.3, 39.5, 25.4, 24.8,
13.0.

31

P{1H} NMR (CD3OD, 243 MHz): δ 33.8 (s). ESI-MS calcd for C63H75N5O9PS+

[M]+ 1108.5018, found 1108.5041.
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Scheme S3.1. Synthesis of sodium 4-(azidomethyl)benzoate 8.
Synthesis of compound 8. To a suspension of 4-(bromomethyl)benzoic acid (2.0 g, 9.3
mmol) in MeCN (30 mL) was added NaN3 (800 mg, 12.3 mmol). The mixture was heated
to 85°C and stirred under reflux for 14 h. After, the solvent was removed by rotary
evaporation and CH2Cl2 (50 mL) was added followed by extraction by H2O (50 mL x 2)
to remove unreacted NaN3. The organic phase was dried over Na2SO4 and concentrated.
The residue was moved forward to the next step without any further purification.
The residue was dissolved in 4 mL acetone and added to a stirring solution of NaOH(aq)
(247 mg, 6.17 mmol) in H2O (10 mL). The resulting mixture was stirred vigorously at
room temperature for 18 h. After, the remaining solid was removed by filtration and the
filtrate was concentrated under reduced pressure to afford 8 as a white solid (926 mg,
50%). 1H NMR (CDCl3, 400 MHz): δ 7.86 (d, J = 8.2 Hz, 2H), 7.43 (d, J = 8.2 Hz, 2H),
4.44 (s, 2H).

Scheme S3.2. Synthesis of HO-EG4-SH thiol ligand 9.
Synthesis

of

compound

9.

To

a

solution

of

2-(2-(2-(2-

hydroxyethoxy)ethoxy)ethoxy)ethyl 4-methylbenzenesulfonate (5 g, 14.6 mmol) in
acetone (75 mL) was added potassium thioacetate (1.71 g, 15.0 mmol) while stirring. The
solution was heated to 50 °C and stirred under reflux for 18 h. After, the solid was
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removed by gravity filtration and the filtrate was concentrated in vacuo. The crude
product was purified by column chromatography using 3:1 CH2Cl2:acetone as the eluent
to afford 9 as a yellow oil (3.03 g, 84%). 1H NMR (CDCl3, 400 MHz): δ 3.74 (m, 2H)
3.67 (m, 12H) 3.10 (t, J = 12 Hz, 2H), 2.34 (s, 3H). 13C{1H} NMR (CDCl3, 101 MHz): δ
195.5, 72.5, 70.61, 70.45, 70.32, 70.23, 69.7, 61.7, 30.5, 28.8. CI-HRMS: calcd for
C10H20O5S [M+H+]: 253.1031, found 253.1105.
Synthesis of compound 10. To a solution of 8 (3.03 g, 0.012 mmol) in anhydrous
CH3OH (20 mL) was added 12 mL of 1 M NaOH in EtOH under an argon atmosphere
while stirring. In a separate flask, argon was bubbled through a 2 M HCl(aq) solution.
After 20 min, 12 mL of HCl(aq) was added to the reaction flask and left to react for 5
min. After, the product was extracted into CH2Cl2 (20 mL x 5). The combined organic
fractions were dried over Mg2SO4 and concentrated in vacuo. The crude product was
purified by column chromatography using 2:1 CH2Cl2:acetone as the eluent to afford 9 as
a pale yellow oil (2.38 g, 94%). 1H NMR (CDCl3, 400 MHz): δ 3.73 (m, 2H) 3.68 (m,
12H) 2.70 (m, 2H), 2.39 (bs, 1H), 1.63 (t, J = 16 Hz, 1H).

13

C{1H} NMR (CDCl3, 101

MHz): δ 72.89, 72.47, 70.63, 70.48, 70.33, 70.17, 61.7, 24.2. CI-HRMS: calcd for
C8H19NO3S [M+H+]: 211.0926, found 211.0996.
Synthesis of HO-EG4-AuNPs. HAuCl4·3H2O (1.4564 g, 3.7 mmol, 1.0 eq.) was
dissolved in a mixture of dry methanol (503 mL) and glacial acetic acid (83 mL). To this
yellow solution was added HO-EG4-SH (10) (2.3 g, 11 mmol, 3.0 eq.). The bright yellow
solution was stirred vigorously for 1 h and the solution color faded slightly. A solution of
NaBH4 (1.3997 g, 37 mmol, 10.0 eq.) in nanopure H2O (96 mL) was added dropwise to
the reaction mixture under vigorous stirring. The mixture turned dark brown
immediately. After overnight stirring at ambient temperature, the solution was
concentrated in vacuo. The resulting film of AuNPs was washed with toluene (3x) and
the film was remade by dissolving the AuNPs in methanol followed by rotary
evaporation to remove the solvent. This washing procedure was repeated 6 times. Next,
the crude HO-EG4-AuNPs were dissolved in nanopure water and centrifuged at 6000 rpm
for 10 min to remove insoluble solid impurities. The crude HO-EG4-AuNPs were then
further purified by overnight dialysis in H2O.
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Figure S3.1. 1H NMR spectrum of HO-EG4-AuNPs in CD3OD. *Denotes residual
protium solvent. Spectrum referenced against residual CD3OH.

Figure S3.2. TEM images of HO-EG4-AuNPs.
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Figure S3.3. TGA characterization of HO-EG4-AuNPs.
Synthesis of Rhod-PPh3-EG4-AuNPs. To a solution of HO-EG4-AuNPs (84 mg) in
MeOH (5 mL) was added a solution of thiol (5) (27 mg, 0.02 mmol) in MeOH (5 mL)
under an argon atmosphere in the dark. The resulting mixture was stirred vigorously for
18 h in the dark. After, the solution was concentrated in vacuo and the resulting film was
washed with argon purged 1:1 CH2Cl2:Et2O until washings were nearly colorless. The
film was remade by dissolving in MeOH and concentrating in vacuo. The washes were
then repeated until the washings were no longer colored or fluorescent under a UV lamp.
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Figure S3.4. 1H NMR spectrum of Rhod-PPh3-EG4-AuNPs in CD3OD. *Denotes
residual protium solvent. Spectrum referenced against residual CD3OH.
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Figure S3.5. 31P{1H} NMR spectrum of Rhod-PPh3-EG4-AuNPs in CD3OD. Spectrum
referenced against H3PO4 as a standard.
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Figure S3.6. TEM images of Rhod-PPh3-EG4-AuNPs.

Figure S3.7. TGA characterization of Rhod-PPh3-EG4-AuNPs.
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Synthesis of Rhod-P(=O)Ph3-EG4-AuNPs (control). To a solution of HO-EG4-AuNPs
(21 mg) in MeOH (5 mL) was added a solution of thiol (7) (9 mg, 7 μmol) in MeOH (2.5
mL) under an argon atmosphere in the dark. The resulting mixture was stirred vigorously
for 18 h in the dark. After, the solution was concentrated in vacuo and the resulting film
was washed with argon purged 1:1 CH2Cl2:Et2O until washings were nearly colorless.
The film was remade by dissolving in MeOH and concentrating in vacuo. The washes
were then repeated until the washings were no longer colored or fluorescent under a UV
lamp.
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Figure S3.8. 1H NMR spectrum of Rhod-(P=O)Ph3-EG4-AuNPs in CD3OD. *Denotes
residual protium solvent. Spectrum referenced against residual CD3OH.
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Figure S3.9. 31P{1H} NMR spectrum of Rhod-(P=O)Ph3-EG4-AuNPs in CD3OD.
Spectrum referenced against H3PO4 as a standard.
Calculation of the nanoparticles raw formula
From the deconvolution of the TGA derivative (see Figure S3.7, bottom) it is possible to
calculate the weight amount of template ligand (HO-EG4-S–) and phosphine ligand 5 per
milligram of Rhod-PPh3-EG4-AuNP. A fraction of ligand 5 is present as phosphine oxide
(12 % from the 31P{1H} NMR spectrum). It is possible to calculate the amount, in grams,
of oxidized phosphine ligand (mgP=O) and active phosphine (mgP:) per milligram of
AuNP from the following equations:

mg P: =

M TGA( P:+ P=O )  MWP:  n% P:
MWP:  n% P: + MWP =O  n% P =O

mg P=O = M TGA( P:+ P =O ) − mg P:
Where:
MTGA(P:+P=O) = mass of phosphine ligand (P: + P=O) per milligram of AuNP from TGA
MWP: = molecular weight of phosphine ligand
MWP=O = molecular weight of phosphine oxide ligand

108

n%P: = molar percentage of phosphine ligand from 31P{1H} NMR
n%P=O = molar percentage of phosphine oxide ligand from

31

P{1H} NMR (normalized to

1)
Knowing the molecular weights of the three different ligands (HO-EG4-S-; thiolate of 5;
oxidized thiolate of 5), it is possible to know the molar percentage of each ligand per
milligram of nanoparticles.
The number of gold atoms (NAu) can be calculated from the following formula3:
𝑁𝐴𝑢

𝜋𝜌𝑑 3 𝑁𝐴
=
6𝑀𝐴𝑢

Where:

 = density of face centered cubic(fcc) gold lattice (19.3 g cm-1)
d = average diameter of nanoparticles in centimeters (from TEM images)
NA = Avogadro constant
MAu = mole atomic weight of gold (196.9665 g mol-1)
This is assuming that the AuNPs are spherical and that their size is monodispersed.

The total number of ligands (NL) can be calculated using the following formula:
𝑁𝐿 =

𝑁𝐴𝑢 𝑀𝐴𝑢 𝑀𝑇𝐺𝐴
(1 − 𝑀𝑇𝐺𝐴 )(𝑀𝑊𝑃: 𝑛%𝑃: + 𝑀𝑊𝑂𝐻 𝑛%𝑂𝐻 + 𝑀𝑊𝑃=𝑂 𝑛%𝑃=𝑂 )

Where:
MTGA = organic percentage from TGA
MWOH = molecular weight of HO-EG4-S- ligand
n%OH = molar percentage of HO-EG4-S- ligand

From the number of ligands per particle, the number of gold atoms per particles, and the
molar percentage of the three different ligands it is possible to obtain the nanoparticles
raw formula.
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Fluorescence spectroscopic studies of Rhod-PPh3-EG4-AuNPs. To a suspension of
Rhod-PPh3-EG4-AuNPs (10 mg) in 116.7 μL nanopure H2O was added 50 μL of 1.727 M
sodium 4-(azidomethyl)benzoate 8 in nanopure H2O. The reaction was monitored by
fluorescence spectroscopy. After every stated interval, 5 μL of the mixture was diluted by
a factor of 1.5 x 103 and fluorescence emission and excitation spectra of these solutions
were recorded. λex = 550 nm, λem = 600 nm.

80

60
40
Chemical Shift (ppm)

20

0

Figure S3.10. 31P{1H} NMR spectrum of Rhod-PPh3-EG4-AuNPs in D2O after treatment
with sodium 4-(azidomethyl)benzoate. Spectrum referenced against H3PO4 as a standard.

Fluorescence spectroscopic studies of Rhod-P(=O)Ph3-EG4-AuNPs. To a suspension
of Rhod-(P=O)Ph3-EG4-AuNPs (10 mg) in 116.7 μL nanopure H2O was added 50 μL of
1.727 M sodium 4-(azidomethyl)benzoate 8 in nanopure H2O. The reaction was
monitored by fluorescence spectroscopy. After every stated interval, 5 μL of the mixture
was diluted by a factor of 1.5 x 103 and fluorescence emission and excitation spectra of
these solutions were recorded. λex = 550 nm, λem = 600 nm.
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Fluorescence spectroscopic studies of Rhod-PPh3-EG4-AuNPs in GSH. To a
suspension of Rhod-PPh3-EG4-AuNPs (10 mg) in 116.7 μL nanopure H2O was added 50
μL of 33.3 mM GSH in nanopure H2O to give a final concentration of 10 mM GSH(aq).
The reaction was monitored by fluorescence spectroscopy. After every stated interval, 5
μL of the mixture was diluted by a factor of 1.5 x 103 and fluorescence emission and
excitation spectra of these solutions were recorded. λex = 550 nm, λem = 600 nm.
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Chapter 4

4

Dual-Bioorthogonal Molecular Tool: “Click-to-Release”
and “Double-Click” Reactivity on Small Molecules and
Material Surfaces

Reprinted with permission from Bioconjugate Chem. 2019, 30, 1140–1149, with minor
formatting changes to maintain consistency throughout thesis. Figure S4.X refers to
Supporting Information (Section 4.6).

4.1 Introduction
The ability to cleanly and selectively form and break chemical bonds in complex,
biological media is an important tool in the fields of chemical biology, medicine, and
increasingly nanotechnology as it enables selective (and often, site-specific) manipulation
of biomolecules, cells, particles and surfaces. The development of bioorthogonal
chemistries has enabled researchers to monitor biomolecular dynamics and processes in
their native environment, i.e. in vivo, due to several key features: (1) these reactions
proceed in physiological conditions in water and neutral pH; (2) they form robust
covalent bonds; and (3) they are chemoselective and bioorthogonal, i.e. they are not
perturbed by native biological functionalities (nucleophiles, electrophiles, reducing or
oxidizing conditions).[1-2] As a result, many widely used bioorthogonal ligation strategies
have been developed over the last two decades: the Staudinger-Bertozzi ligation (SBL),[3]
strain-promoted alkyne-azide cycloaddition (SPAAC),[4] strain-promoted alkyne-nitrone
cycloaddition (SPANC),[5] tetrazene ligation,[6] and tetrazole ‘photo-click’,[7] to name a
few.
More recently, there has been a focus on the development of ‘click-to-release’ strategies,
wherein a bioorthogonal ligation reaction results in the concomitant release of a drug,
fluorophore, or small molecule of interest. Several of these systems involve an
intramolecular Diels-Alder (DA) click, which is designed to trigger the release of carbon
monoxide (CO) or sulfur dioxide (SO2) as a prodrug.[8-10] Pluth and coworkers designed a
tetrazene click-based system that releases carbonyl sulfide (COS), which is enzymatically
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hydrolyzed to hydrogen sulfide (H2S) — a biologically relevant gasotransmitter — by
carbonic anhydrase.[11] Other strategies that enable more complex payloads to be released
have also been developed. Wang and coworkers demonstrated a cascade prodrug system
in which an inverse-electron demand DA click and subsequent lactonization resulted in
the release of CO, a drug, and fluorescent byproduct.[12] Chatterjee and coworkers
reported a chemoselective rapid azo-coupling reaction between 5-hydroxyindoles and
aromatic diazonium ions.[13] Although this ligation strategy does not result in concomitant
release of a payload, the otherwise stable azo-linkage can be “unclicked” by treatment
with dithionite to afford a release product. Robillard and coworkers demonstrated a
tetrazene ligation in which the 1,4-dihydropyridazine product undergoes an electron
cascade mechanism to extrude CO2 and the carbamate-installed payload.[14-15] Recently,
Taran and coworkers reported a novel [3+2] cycloaddition between iminosydnones and
strained cyclooctynes, in which the cycloaddition product undergoes unimolecular
fragmentation to afford a ligation product and a release product.[16] Although effective,
many of these click-to-release strategies face challenges with incomplete conversion, use
of additional harsh exogenous reagents to “unclick”, or suffer from limitations regarding
synthetic accessibility or amenability of the desired cargo.
Our group has recently revisited the SBL — a classic in the field of bioorthogonal
chemistry as a powerful transformation for amide bond formation through organic azides
— as a click-to-release strategy off gold nanoparticles (AuNPs) by utilizing an
electrophilic ester as a cargo scaffold.[17] Prior to this, the dual-purpose nature (chemical
ligation and release) of this highly specific transformation was seldom recognized or
utilized. Florent and coworkers demonstrated a SBL-based release strategy that featured
rearrangement of the intermediate aza-ylide to a phenol anion, which subsequently
underwent a 1,6-quinone methide rearrangement and hydrolysis to liberate the phosphine
oxide, CO2, a drug, and urea byproduct (Scheme 4.1a).[18] They reported yields
approaching 90%, but this multicomponent system remains synthetically complex and
lacks the ease-of-use offered by the traditional SBL. In contrast to their work, where the
azide is destined to be liberated as a urea, in our design, retaining the ‘click’ aspect of the
SBL was desired. Instead, we demonstrated installation of the cargo via the ester
electrophilic trap (Scheme 4.1b), which is liberated as an alcohol following the classic
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Scheme 4.1. Conceptual blueprint for SBL-based click-to-release strategies.
SBL mechanism. This methodology worked effectively as demonstrated by the tethering
and release of a Rhodamine B dye from a AuNP nanocarrier.[17]
However, as in many existing click-to-release strategies, synthetic accessibility and
amenability remains a real challenge. These systems typically require arduous synthetic
pathways that must be taken for each payload of interest to be suitable for a specific
application. Instead, we propose a single dual-bioorthogonal molecular tool that can
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undergo multiple controlled bioorthogonal reaction pathways, which can be applied to
small molecules and material surfaces (Scheme 4.1c). In this design, we envisioned an
electrophilic ester-bound strained cyclooctyne that is capable of covalently “catching” a
general payload via 1,3-dipolar cycloaddition (SPAAC depicted, SPANC can be
employed as well). The resulting triazole- or isoxazoline-tethered cargo can then be
liberated via SBL “click-to-release” with an exogenous azide molecule. Additionally, we
propose a secondary “double-click” reaction sequence that can be employed for multiple
ligations within the single moiety (Scheme 4.1c). Sundhoro et al. recently reported a
modified Staudinger reaction between aryl phosphines and perfluoroaryl azides
(abbreviated PFAA-SR) that affords a uniquely stable iminophosphorane “click” product
that doesn’t undergo the cyclization and hydrolysis steps of typical SBL reactions.[19-20]
We utilize the PFAA-SR as a secondary click reaction and alternative to click-to-release,
which provides unprecedented versatility and full molecular control of bond-forming and
bond-breaking reactions within a small molecule or material surface system. We
successfully demonstrate this dual-bioorthogonal click-to-release and double-click
reactivity and its implementation on a model material (AuNPs) for cell-surface labelling.

4.2 Results and Discussion
Design and Synthesis of Dual-Action Molecular Tool.
The design of a dual-bioorthogonally reactive moiety needed to address several
considerations: (i) stability of the strained cyclooctyne under various synthetic
conditions; (ii) relative reactivity kinetics between cyclooctyne and phosphine towards an
azide, as cycloaddition via SPAAC should proceed first; and (iii) its amenability towards
incorporation onto surfaces to expand its applicability in materials science and
nanotechnology. To this end, we employed a photocaged dibenzocyclooctyne (hνDIBO)
moiety as our cyclooctyne precursor of choice for its exceptional stability and ability to
liberate CO to generate the parent dibenzocyclooctyne (DIBO) upon irradiation with
UVA light.[21] We previously demonstrated its utility and versatility on AuNPs, in which
interfacial DIBO reacted cleanly and effectively with various 1,3-dipoles,[22] thus making
it the perfect candidate for covalently tethering a general cargo. Additionally, bimolecular
rate constants illustrate at least a 10-fold preference for SPAAC between DIBO[21] and
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benzyl azide (BnN3) versus SBL between a triarylphosphine[20] and BnN3, which we
envisioned would be key in enabling cycloaddition to proceed first, as per our design for
the click-to-release pathway outlined in Scheme 4.1c. We designed the multicomponent
ligand 5 (Scheme 4.2, top) to bear several key features: 1) a hνDIBO moiety tethered by
an ester electrophilic trap, where CO liberation can be spatiotemporally controlled and
allows for covalent cargo catching via SPAAC/SPANC of the resulting cyclooctyne; the
limited lifetime of strained alkynes in aqueous solutions and their incompatibility with
nucleophilic thiols make this photo-caging strategy necessary; 2) triaryl phosphine
moiety capable of undergoing either SBL to trigger click-to-release or PFAA-SR for
‘double-click’ reactivity; and 3) a thiol moiety as a representative functional handle for
materials modification or small molecule manipulation. Thiols are highly amenable to
materials incorporation, e.g. metallic surfaces (2D or nanoparticles) via S-M (where M =
metal) bond formation[23] or polymers and organic nanoscale materials via thiol-ene or
thiol-Michael addition click reactions.[24-25]
The synthesis of 5 was achieved via a convergent approach (Scheme 4.2, top).
Cyclpropenone 1[26] was alkylated with 3-bromo-1-propanol to give alcohol 2, which
underwent DCC-mediated coupling with phosphine 3[17] to afford ester 4 in moderate
yields. Cleavage of the S-trityl protecting group of 4 by trifluoroacetic acid in CH2Cl2
gave thiol 5 in excellent yield. Prescher and coworkers recently reported a new
bioorthogonal ligation that proceeds efficiently between cyclopropenones and
triarylphosphines bearing nucleophiles (–OH, –NH2, and –SH),[27] which drew attention
to 5 potentially being self-reactive in this manner. However, we observed no
bioorthogonal self-reactivity, likely due to the dibenzocyclooctyl-fused cyclopropenone
offering additional steric protection, rendering the cyclopropenone sterically and
conformationally unavailable to the phosphine. As the dibenzocyclooctyne was
photocaged, we also observed no self-reactivity via attack from the nucleophilic thiol.
Thiol 5 is stable for months under standard storage conditions at -20°C in the freezer.
Click-to-release and double-click reactivity.
Upon confirming the synthetic accessibility of the ligand 5, we investigated the dualbioorthogonal reactivity of 4, which lacks the nucleophilic –SH of 5 and avoids undesired
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Scheme 4.2. Synthesis of multicomponent thiol ligand 5 (top) and multi-bioorthogonal
reactivity of compound 4 (bottom).
self-reactivity upon alkyne generation. Irradiation of a solution of 4 in CH3OH at 22°C
with 14 x 8 W UVA (350 nm) lamps afforded alkyne 6 cleanly within minutes (Scheme
4.2, bottom). Upon decarbonylation, 1H NMR spectral analysis showed disappearance of
the signal at 7.93 ppm and a decrease in the 6.88 ppm signal followed by appearance of
signals at 7.20 ppm and 6.74 ppm (Figure 4.1A). The Fourier transform infrared (FT-IR)
spectrum of 6 showed disappearance of the characteristic C=O absorption band (1843 cm1

) resulting from the cyclopropenone in 4. These results are consistent with generation of
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Figure 4.1. Spectroscopic analysis of small molecules 4, 6, 7a/7b, 9, 11a/11b, and
13a/13b. (A) 1H NMR spectra obtained in CDCl3 and referenced to residual CHCl3. Blue
arrows ( ) designate expected signal decrease and red arrows ( ) designate expected
signal increase resulting from decarbonylation. Blue highlight ( ) designates 1H from
ethylene bridge of cycloctyl ring. Red highlight ( ) designates –C(1H)3 from butyl group.
Green star ( ) designates triazole-derived benzylic 1H and blue star ( ) designates
isoxazoline Cα-1H. (B) UV-Vis spectroscopic analysis obtained in CH3OH. (C) 31P{1H}
NMR spectra obtained in CDCl3 and referenced to H3PO4. *Inset obtained in DMSO-d6.
the alkyne species.[20] Addition of 1 equiv. of BnN3 to 6 in CH2Cl2 (1.70 mM, equimolar)
provided the cycloaddition products 7a and 7b as a pair of inseparable regioisomers
within 8 h.

31

P{1H} NMR analysis of the crude mixture showed no reaction at the

phosphine center (i.e. no conversion of P: to P=O via SBL), which indicated reaction
selectivity of SPAAC over SBL, as envisioned. The 1H NMR spectrum of 7a/7b provided
clear evidence of regioisomerism (Figure 4.1A): proton environments in proximity of the
triazole-phosphine moiety showed split signals for 7a and 7b. Namely, the –CH3 of the
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butyl group of 7a and 7b can be seen as two distinct triplets at 0.99 and 0.95 ppm. In
addition, the ethylene bridge of 6 (3.19 and 2.45 ppm) appears as four broad signals at
3.25, 2.98, 2.83, and 2.68 ppm in 7a/7b, characteristic of triazole formation. Lastly,
triazole-bound benzylic protons at 5.54 ppm are diagnostic for successful SPAAC with
BnN3.[22] Cycloaddition of 6 with nitrones can also be achieved with greater precision due
to the orthogonality of SPANC versus SBL. Addition of nitrone 12 to alkyne 6 in CH2Cl2
(0.65 mM, equimolar) provided quantitative conversion to isoxazolines 13a and 13b
within 8 h. As with 7a/7b, the 1H NMR spectrum of 13a/13b showed distinct peaks for
each regioisomer as well as a diagnostic Cα–H of isoxazolines at 4.97 ppm (Figure 4.1A).
Reactivity of the hνDIBO moiety can also be monitored via UV-vis spectroscopy, in
which 4 displays a characteristic absorption band at 331–347 nm (Figure 4.1B).[21]
Decarbonylation of 4 to give 6 results in a hypsochromic shift to a 302–320 nm
absorption band. Upon cycloaddition with BnN3 or nitrone 12 (Scheme 4.2, bottom), we
observed bleaching of the 302–320 nm absorption, which is consistent with consumption
of the alkyne species via SPAAC and SPANC, respectively (Figure 4.1B).[21]
Treatment of a solution of 7a/7b in CH2Cl2 with excess BnN3 and H2O resulted in
liberation of 8a/8b cleanly via SBL click-to-release within 16 h (Scheme 4.2, bottom).
Isomers 8a and 8b could be separated and isolated alongside the click product 9, thus
illustrating the efficacy of the dual-bioorthogonal click-to-release strategy outlined in
Scheme 4.1c. Similarly, treatment of isoxazolines 13a/13b with BnN3 under similar
conditions resulted in liberation of 14a/14b as a pair of inseparable isomers and the click
product 9. Furthermore, we tested the reactivity of phosphines 7a and 7b towards
perfluoroaryl azide 10 as an alternate reaction pathway to click-to-release (Scheme 4.2,
bottom). Remarkably, we observed rapid and clean conversion to iminophosphoranes 11a
and 11b within minutes. The iminophosphorane linkage of 11a/11b proved to be
exceptionally robust under various conditions, including being left in water-containing
solvent for weeks and being heated to 80°C in DMSO with no hydrolysis or
fragmentation observed. Thus, this represents a robust dual-bioorthogonal double-click
strategy that, in addition to click-to-release, provides opportunities for bioorthogonal
multiplex labelling.[28,29]
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31P

NMR Investigation.

One key feature offered by this dual-bioorthogonal moiety is the ability to track the
reaction species by

31

P NMR spectroscopy, thus allowing for ease of analysis even in

complex mixtures (Figure 4.1C). Upon decarbonylation of 4 to 6, we observe no change
in the
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P environment (-4.33 ppm), as expected. However, treatment of 6 with BnN3

resulted in two equal phosphine signals at -4.32 and -4.36 ppm belonging to regioisomers
7a and 7b. Similarly, treatment of 6 with nitrone 12 results in a spectrum with phosphine
signals at

-4.28 and -4.30 ppm belonging to regioisomers 13a and 13b. Upon triggered

release by SBL, this regioisomeric information is lost (and passed on to 8a/8b and
14a/14b, respectively) as both yield the click product 9, which displays only a single 31P
signal at 31.9 ppm corresponding to the phosphine oxide.[30] Furthermore, when
employing the double-click pathway, generation of the iminophosphorane products
11a/11b from 7a/7b results in a spectrum that shows a single triplet (JPF = 4.5 Hz) at
11.51 ppm in CDCl3, a chemical shift that is characteristic of iminophosphoranes.[19]
Although we did not observe two distinct regioisomers for 11a/11b in CDCl3 (as in
7a/7b), obtaining the spectrum in DMSO-d6 allowed us to resolve the two species with
triplet signals at 11.73 and 11.67 ppm. These results highlight a key advantage of this
dual-bioorthogonal system in that the ability to monitor reaction species and progress
with diagnostic
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P signals represents an extremely powerful and useful tool, especially

as researchers utilize bioorthogonal chemistry with structurally complex molecules
(enzymes, proteins, antibodies, etc.) — as they often do — rendering traditional
spectroscopic analyses unfeasible or difficult to interpret.
AuNP Incorporation and Implementation.
After confirming the click-to-release and double-click functionality of 4, we investigated
the efficacy of this dual-bioorthogonal tool on the surface of AuNPs as a model material
substrate. For the last two decades, interest in metal-free click chemistry on surfaces has
increased dramatically due to their ease-of-use for fabricating multifunctional materials
and biosensors in a clean, bottom-up approach.[31] We envisioned that the highly versatile
moiety demonstrated here would find useful application on material surfaces. Thus, we
incorporated thiol 5 into the monolayer of 5 nm hydroxyl-terminated AuNPs (HO-EG4AuNPs) via a ligand displacement reaction. These HO-EG4-AuNPs were synthesized via
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a modified Brust-Schriffin method, where HAuCl4·3H2O is reduced by NaBH4 in the
presence

of

hydroxyl-terminated

thiol

(tetraethylene,

HO-EG4-SH)

to

afford

nanoparticles with Au core diameter of 5 ± 1 nm, as confirmed by TEM.[17] These AuNPs
represent an ideal model substrate due to their amphiphilicity (high solubility in both
water and organic solvents), ease-of-characterization by spectroscopy (NMR, UV-vis,
and IR), and offers an inert and stable nanoscale platform for our investigation.
Functionalization of 5 onto AuNPs was achieved via a stirring solution of 5 and HO-EG4AuNPs in CH2Cl2/CH3OH at 22°C for 16 h (Scheme 4.3), followed by trituration of a
AuNP film (prepared by rotary evaporation, see Supporting Information) by 2:1
Et2O:CH2Cl2 to remove excess 5, displaced thiols and disulfides. The derivatized AuNPs,
hνDIBO-PPh3-EG4-AuNPs, were characterized by 1H and 31P{1H} NMR, UV-vis, and IR
spectroscopy as well as thermogravimetric analysis to confirm successful incorporation
of 5.
The 1H NMR spectrum of hνDIBO-PPh3-EG4-AuNPs showed characteristic broad peaks
that correspond to ligand 5 (Figure S4.36) and a broad signal at ~40 ppm in the
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P{1H}

NMR spectrum typical of phosphine-based monolayers on AuNPs (Figure S4.39).[17,30]
UV-vis spectroscopy showed a characteristic absorption band at 331–347 nm
corresponding to the hνDIBO moiety of AuNP-bound 5 (Figure S4.40). Lastly,
thermogravimetric analysis (TGA) provided proof of two ligands decomposing at
distinctly different temperatures (250 and 375°C, see Figure S4.35) corresponding to the
hydroxyl-terminated ligand and ligand 5 at a ratio of 47:53, respectively. From
deconvolution of the TGA curve, the ligand concentration of 5 was determined to be
0.367 μmol mg-1 AuNP. This data also allows us to determine ligand density based on Au
core size (TEM), organic content of AuNPs (TGA curve), and bilayer composition (TGA
curve deconvolution). The AuNP raw formula was calculated to be Au3500[HO-EG4S]685[hνDIBO-PPh3-EG4-S]760, which assumes that particles are spherical and
monodispersed (see Supporting Information for calculations). This stoichiometric
information can be utilized to carefully control the amount of cargo that is to be
immobilized on the nanocarrier surface. Together, these results confirm successful
incorporation of ligand 5 into the AuNP monolayer.
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“CLICK”

“CLICK TO RELEASE”

Scheme 4.3. Synthesis of AuNPs and ‘click-to-release’ on AuNPs via SPAAC/SPANC
and SBL. Reaction conditions: a) 1 equiv. BnN3, CH2Cl2; b) excess BnN3, H2O,
CH2Cl2/CH3OH; c) nitrone 12, CH2Cl2.
A solution of hνDIBO-PPh3-EG4-AuNPs in methanol decarbonylated cleanly upon
photoirradiation (UVA) within minutes to afford DIBO-PPh3-EG4-AuNPs (Scheme 4.3).
As with the conversion of 4 to 6, we observed new signals in the 1H NMR spectrum at
7.19 ppm and 6.72 ppm corresponding to interfacial DIBO (Figure S4.36) as well as a
hypsochromic shift to 302–320 nm in UV-vis absorption (Figure S4.40). In addition, the
FT-IR spectrum of DIBO-PPh3-EG4-AuNPs showed the disappearance of the
characteristic C=O absorption band at 1843 cm-1 resulting from the cyclopropenone
(Figure S4.37). DIBO-PPh3-EG4-AuNPs were then evaluated for their ability to
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interfacially tether a cargo via cycloaddition by treatment with BnN3 and nitrone 12
separately as models (Scheme 4.3). In both cases, characteristic peaks in the 1H NMR
spectra of treated AuNPs provided clear evidence of triazole or isoxazoline formation
(Figure S4.38). Namely, benzylic protons at 5.54 ppm and Cα–H proton at 4.97 ppm are
consistent with the analogous compounds 7a/7b and 13a/13b, respectively, and are
diagnostic of effective cycloaddition between DIBO-PPh3-EG4-AuNPs and the respective
cargo. This was also seen by UV-vis spectroscopy, in which the treated AuNPs showed
bleaching of the 302-320 nm absorption that is consistent with consumption of the
interfacial alkyne species (Figure S4.36).
Throughout irradiation and subsequent cycloaddition of hνDIBO-PPh3-EG4-AuNPs,
31

P{1H} NMR analysis displayed no significant changes in chemical shift (Figure S4.39).

Although spectral broadening was observed after cycloaddition, this is likely due to the
regioisomerism of cycloadducts and is consistent with that observed in 7a/7b and
13a/13b. When treated with excess BnN3 to trigger click-to-release (Scheme 4.3), the
31

P{1H} NMR spectra of both release experiments (from (benzyl)triazole-PPh3-EG4-

AuNPs and isoxazoline-PPh3-EG4-AuNPs) displayed a single sharp signal at 37.9 ppm
corresponding to the phosphine oxide click product formed by interfacial SBL,
benzylamide-P(=O)Ph3-EG4-AuNPs (Figure S4.39).[17,27] Trituration of the AuNP
samples with 2:1 EtOAc/hexanes after click-to-release to remove unbound molecules
revealed the presence of the release products 8a/8b and 14a/14b from their respective
AuNPs (Figures S4.41 and S4.42), thus confirming the successful implementation of this
dual-bioorthogonal click-to-release system on a material surface. Importantly, this clickto-release system represents a powerful pseudo “transclick” reaction on materials as it
exchanges functionality from the primary click product (green sphere, Scheme 4.3) to a
secondary click functionality from the incoming azide (blue star, Scheme 4.3), which
occurs readily and cleanly at room temperature. This is advantageous to existing
transclick methodologies in which high temperatures (>100°C)[32] or UV light[33] is
needed to initiate the exchange reaction.
To further illustrate the utility and ease-of-use of this molecular tool on a surface, we
employed the double-click pathway on hνDIBO-PPh3-EG4-AuNPs to prepare a
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multifunctional AuNP template. However, we opted to subject hνDIBO-PPh3-EG4AuNPs to PFAA-SR first, followed by photouncaging and subsequent SPAAC. Unlike
click-to-release, in which the method requires that the cargo be installed first via
SPAAC/SPANC then released by SBL, the double-click features two bond-forming
reactions that are not restricted to a specific sequence; i.e., it can proceed via
photouncaging, SPAAC/SPANC, then PFAA (as in Scheme 4.2) or PFAA-SR,
photouncaging, then SPAAC/SPANC (as in Scheme 4.4) to achieve the same result. To
highlight this flexibility, hνDIBO-PPh3-EG4-AuNPs were treated with a perfluoroaryl
azido Rhodamine B derivative (17, see Supporting Information) to afford the interfacial
iminophosphorane

product,

hνDIBO-P(=N-Rhodamine)Ph3-EG4-AuNPs,

via

the

modified Staudinger reaction (Scheme 4.4). Excess 17 was removed by dialysis in
CH3OH/H2O for 2 days to ensure that no unbound molecules remained. After
purification, we observed a significant shift in the
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P{1H} NMR spectrum from a broad

signal at ~40 ppm to a sharp signal at 11.6 ppm corresponding to the iminophosphorane
(Figure S4.44).[19] UV-vis spectroscopy also confirmed the presence of AuNP-bound
rhodamine, which showed the characteristic absorbance of Rhodamine B at 560 nm as
well as the 331–347 nm absorption band typical of hνDIBO in the spectrum (Figure
S4.46). This highlights two key aspects of this double-click strategy: (1) the hνDIBO
moiety allows for temporal control of the photoclick, thus allowing the PFAA-SR click to
truly proceed orthogonally and (2) this double-click strategy can therefore be done in
reverse order, i.e. PFFA-SR and SPAAC/SPANC can be utilized interchangeably as the
primary or secondary click, thus offering a higher degree of modularity and control to the
multifunctionalization reaction sequence.
A solution of hνDIBO-P(=N-Rhodamine)Ph3-EG4-AuNPs decarbonylated cleanly in
methanol to liberate the alkyne, which was treated with a commercially available azidePEG3-biotin conjugate (CAS 875770-34-6, Sigma Aldrich) to afford the triazole via
SPAAC (Scheme 4.4). Excess biotin was removed by dialysis in CH3OH/H2O to provide
clean

(biotin)-triazole-P(=N-Rhodamine)Ph3-EG4-AuNPs.

Effective

secondary

functionalization with biotin was confirmed by UV-vis spectroscopy, which showed a
hypsochromic shift from 331–347 nm absorption to 302–320 nm upon irradiation,
followed by bleaching of the 302–320 nm absorption to indicate triazole formation with
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“DOUBLE CLICK”

Scheme 4.4. Double-click reactivity of AuNPs and reoxidation of (biotin)-triazole-P(=NRhodamine)Ph3-EG4-AuNPs by molecular I2. ESI-MS calcd for C116H142F4N12O20PS3+
[M]+ 2225.92992, found 2225.93351; difference -1.61 ppm. Values for m/z main peaks
were enlarged for clarity (full figure available in Supporting Information). Reaction
conditions: a) perfluoroaryl azido Rhodamine 17 (see Supporting Information),
CH2Cl2/CH3OH; b) hν (350 nm), CH3OH, 6 min; c) azide-PEG3-biotin conjugate,
CH3OH.
biotin (Figure S4.46). Remarkably, the iminophosphorane proved to be robust through
multiple overnight dialysis steps and irradiation with UVA light as indicated by 31P{1H}
and

19

F{1H} NMR analysis (Figures S4.44 and S4.45). It is worth noting that these

transformations (SPAAC, SPANC, SBL, and PFAA-SR) were all found to proceed
quantitatively even on AuNPs. For interfacial SPAAC/SPANC, bleaching of the 302–320
nm absorption band was followed by UV-vis spectroscopy until the alkyne species was
fully consumed. For SBL and PFAA-SR, disappearance of the broad signal at ~40 ppm in
the 31P{1H} NMR spectrum (P: of active phosphine) was monitored until completion and
concurrently with the appearance of a sharp signal at 37.9 ppm for SBL (P=O of ligated
phosphine oxide) or 11.6 ppm for PFAA-SR (P=N of iminophosphorane).
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To further confirm successful formation of the double-clicked product, (biotin)-triazoleP(=N-Rhodamine)Ph3-EG4-AuNPs were reoxidized by molecular iodine to afford a
mixture of Au(I) and Au(III) complexes, which liberated organic ligands as disulfides
(Scheme 4.4).[22,34] The mixture of disulfides was examined by ESI-MS to determine the
exact mass of the disulfide molecule most likely to form. The experimental m/z matched
with that calculated for the proposed disulfide 19, thus confirming successful
implementation of this double-click strategy on AuNPs. This ability to implement two
robust click reactions on a surface using structurally complex substrates (e.g. dyes, drugs,
and other biologically relevant macromolecules) in a highly controlled and orthogonal
manner — enabled by a single moiety — represents a powerful tool for preparing
multifunctional materials under mild and biocompatible reaction conditions.
AuNP Targeting on Human Fibroblast Cells.
Lastly, we aim to demonstrate the utility of (biotin)-triazole-P(=N-Rhodamine)Ph3-EG4AuNPs — which contains both a targeting and an imaging agent — as a proof-of-concept
model for AuNP-based pretargeted delivery. Due to the high affinity of biotin to bind
avidin and streptavidin, the avidin-biotin system is widely used in immunohistochemistry
(IHC), enzyme-linked immunosorbent assay, and molecular biology.[35] We modified
human fibroblast cells that contain vimentin — the epitope — via common IHC protocols
to display avidin on the cell surface (see cartoons, Figure 4.2).[36] Briefly, cell samples
were fixed and incubated with a primary goat anti-vimentin antibody, washed, then
treated with a secondary biotinylated donkey anti-goat IgG antibody. A solution of avidin
in PBS was then introduced for binding to the fixed cells, which contained available
binding sites for AuNP recognition. Although Rhodamine B emission is known to quench
on metallic particle surfaces,[17,37] we envisioned that residual emission would provide
sufficient contrast for visualization by fluorescence microscopy. Thus, we incubated
avidin-modified human fibroblast cells with (biotin)-triazole-P(=N-Rhodamine)Ph3-EG4AuNPs followed by 4′,6-diamidino-2-phenylindole (DAPI) nuclear staining. Unbound
AuNPs and DAPI were washed with PBS in triplicate with each step. Separately, control
experiments in which either AuNP-bound biotin or avidin was excluded from the
protocol were carried out. Visualization by fluorescence microscopy (λex = 532 nm)
confirmed successful targeting of (biotin)-triazole-P(=N-Rhodamine)Ph3-EG4-AuNPs
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Figure 4.2. Fluorescence microscopy (λex = 532 nm) of human fibroblast cells (A–D)
accompanied by schematic cartoon of IHC protocol. White arrow indicates cytosol,
where labeling would occur. (A) Human fibroblast cells incubated with secondary
antibody bearing Alexa Fluor 568 (B) Human fibroblast cells incubated with avidin and
(biotin)-triazole-P(=N-Rhodamine)Ph3-EG4-AuNPs. (C) Human fibroblast cells
incubated with avidin and hνDIBO-P(=N-Rhodamine)Ph3-EG4-AuNPs. (D) Human
fibroblast cells incubated with only (biotin)-triazole-P(=N-Rhodamine)Ph3-EG4-AuNPs,
no avidin. Scale bar = 50 μm.
towards avidin-modified cells (Figure 4.2B), which gave similar results to the positive
control (Figure 4.2A). In the absence of AuNP-bound biotin — i.e. when hνDIBO-P(=NRhodamine)Ph3-EG4-AuNPs were incubated instead — we observed no significant
binding (Figure 4.2C). Similarly, when avidin was excluded, non-specific binding of
(biotin)-triazole-P(=N-Rhodamine)Ph3-EG4-AuNPs was not observed (Figure 4.2D).
Although IHC imaging has now become routine, efforts to combine chemical imaging
and IHC to develop new imaging technologies are ongoing.[36] This proof-of-concept
model for AuNP-based pretargeted delivery of a fluorophore highlights 1) the ease-of-use
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of this dual-bioorthogonal molecular tool on a surface, and 2) its applicability in the
development of multifunctional materials via a single moiety in a facile manner.

4.3 Conclusion
In this work, we report the design, synthesis, and implementation of a dual-bioorthogonal
molecular tool that features clean reactivity under mild conditions. It was demonstrated
both on small molecules and a material surface that this tool enables researchers to
interchangeably utilize four bioorthogonal transformations (SPAAC, SPANC, SBL, and
PFAA-SR) to attach, release, and replace functionalities in a facile and highly modular
manner. Importantly, the applicability of the click-to-release and double-click reaction
pathways — based on simple yet highly specific recognition events — is complemented
and reinforced by the widespread use and commercialization of organic and biologically
relevant azides. Additionally, this dual-bioorthogonal moiety represents a highly versatile
tool that provides multiple avenues for implementing and monitoring the attachment or
release of molecules even in complex mixtures. Specifically, the ability to employ
NMR spectroscopy to monitor reaction species and progress via diagnostic
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P
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P signals

represents a key advantage when utilizing structurally complex reaction partners that
would render traditional spectroscopic analyses either unfeasible or difficult to interpret.
The dual-bioorthogonal molecular tool described herein thus enables the design and
production of molecular and material systems with unique, modular, and tunable
dynamic properties. This was demonstrated for metallic nanoparticles, as exemplified
with the preparation of multifunctional AuNPs and pretargeted delivery into human
fibroblast cells, but we believe this moiety and its associated chemistries will become
useful for many applications in materials science and nanotechnology. Additional
development of applications of this dual-bioorthogonal moiety on surfaces is currently
underway.
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4.6 Supporting Information
Material and Methods.
All reagents, unless otherwise stated, were purchased from Sigma-Aldrich and used as
received. All common solvents, triethylamine (TEA), sodium sulfate anhydrous, and
trifluoroacetic acid were purchased from Caledon. Benzyl azide was purchased from Alfa
Aesar. Ethanol was purchased from Commercial Alcohols. Dialysis membranes (MWCO
6000-8000 Da) were purchased from Spectra/Por. Compound 1 was synthesized
according to a literature procedure (Chem. Commun. 2014, 50, 5307–5309). Compound 3
was synthesized from 1-methyl-2-aminoterephthalate according to a previously
established protocol in our group (Org. Biomol. Chem. 2015, 13, 4605–4612). Azides 10
and 16 were synthesized according to procedures developed by Sunhoro et al (Angew.
Chem. Int. Ed. 2017, 56, 12117–12121). Rhodamine B derivative 15 was prepared from a
previous protocol (Synlett 2015, 26, 1169–1174). Azide-PEG3-biotin conjugate 18 was
purchased from Sigma-Aldrich.
1

H, 13C{1H}, 31P{1H}, and
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F{1H} NMR spectra were recorded on Varian INOVA 400

(or 600) or Bruker AvIII HD 400 spectrometers using CDCl3 or CD3OD as solvent. FTIR spectra were recorded using an attenuated total reflectance (ATR) attachment using a
Bruker Vector 33 FT-IR spectrometer. Ultraviolet (UV)-visible spectra were recorded
using a Varian Cary 300 Bio spectrometer. Thermogravimetric analyses (TGA) were
recorded by loading the sample in a 70 μL ceramic crucible and heating from 25ºC to
750ºC at a rate of 10 ºC min-1. The experiment was run under a nitrogen flow of 70 mL
min-1 in a Mettler Toledo TGA/SDTA 851 instrument. Transmission electron microscopy
(TEM) images were recorded from a TEM Philips CM10. The TEM grids (Formvar
carbon film on 400 mesh copper grids) were purchased from Electron Microscopy
Sciences and prepared by dropcasting a drop of nanoparticles solution directly onto the
grid surface. The drop was then carefully removed after 30 seconds with a soft tissue.
ESI-MS spectra were recorded on a Micromass LCT mass spectrometer. Photolyses were
conducted in a Luzchem LZC-4V photoreactor equipped with 14 UVA (350 nm) 8 watt
lamps. Fluorescence spectroscopic studies were performed on a Photon Technology
International (PTI) fluorimeter. Fluorescence microscopy was performed using a Nikon
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ECLIPSE Ti2 Inverted Research Microscope. Palmar fascia tissue samples were resected
from patients with Dupuytren’s disease undergoing surgery at the Roth McFarlane Hand
and Upper Limb clinic in London, Ontario, Canada. All patients were provided written
informed consent and tissue samples were collected with the approval of the University
of Western Ontario Research Ethics Board for Health Sciences Research involving
Human Subjects. Primary fibroblasts were derived from surgically resected palmar fascia
tissues of Dupuytren’s disease patients. Fibroblast cultures were incubated in Dulbecco’s
Modified Eagle Medium (D-MEM) supplemented with 10% fetal bovine serum albumin
(Invitrogen), 1% L-glutamine and antibiotic-antimycotic solution (Sigma-Aldrich). Cell
cultures were serially passaged at confluency up to 6 passages for analysis; otherwise,
cells were discarded.
Immunocytochemistry
Primary fibroblasts were split and 1 x 105 cells were plated into each well on 8 well μslide (Cat. # 80826, Ibidi) and incubated for 72 hours at 37 ˚C. Cells were then washed,
fixed with 4% paraformaldehyde at room temperature for 10 minutes, thoroughly washed
and permeabilized with 0.1% Triton X-100 in PBS for 5 minutes at room temperature and
blocked with serum free Background Sniper for 10 minutes. Primary goat polyclonal
vimentin antibody was incubated over night at 4 ˚C followed by incubation with
biotinylated donkey anti-goat IgG (H + L) antibody at room temperature for 45 minutes.
Wells were washed with PBS and incubated with avidin at room temperature for 15
minutes. After, avidin-labeled fibroblast cells were incubated with a PBS solution of
AuNPs (0.23 mg AuNP mL-1) at room temperature (15 minutes) for binding. Wells were
washed 3 times with PBS, DAPI stained, and visualized under a fluorescence
microscope. In two separate control experiments, either avidin or AuNP-bound biotin
was excluded from the procedure.
Synthesis of compound 2. To 1 (0.132 g, 0.412 mmol) and K2CO3 (0.285 g, 2.06 mmol)
in a flask was added CH3CN (10 mL) followed by 3-bromopropanol (0.19 mL, 2.06
mmol) at r.t. while stirring. The resulting mixture was heated to 80 °C and stirred for 16
h. After, CH3CN was removed by rotary evaporation and replaced with 2:1
CH2Cl2/CH3OH (10 mL). Solids were removed by gravity filtration and the filtrate was
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concentrated by evaporation in vacuo. The crude product was purified by column
chromatography on silica gel using 10% CH3OH in CH2Cl2 as the eluent to afford
compound 2 as a white solid (0.116 g, 74%). 1H NMR (CDCl3, 400 MHz): δ 7.93 (d, J =
9 Hz, 1H), 7.88 (d, J = 8.5 Hz, 1H), 6.90 – 6.84 (m, 4H), 4.20 (t, J = 6 Hz, 2H), 4.04 (t, J
= 6.5 Hz, 2H), 3.89 (t, J = 6 Hz, 2H), 3.37 – 3.24 (m, 2H), 2.65 – 2.53 (m, 2H), 2.47 (s,
OH), 2.08 (tt, J = 6 Hz, J = 6 Hz, 2H), 1.84 – 1.75 (m, 2H), 1.56 – 1.46 (m, 2H), 0.99 (t, J
= 7.5 Hz, 3H).
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C{1H} NMR (CDCl3, 101 MHz): δ 162.1, 161.8, 153.8, 147.8, 142.2,

141.9, 135.8, 135.7, 116.4, 116.23, 116.17, 116.1, 112.33, 112.32, 68.0, 65.5, 59.6, 37.12,
37.11, 32.0, 31.2, 19.2, 13.8. FT-IR (ATR, ν, cm-1): 3382, 2955, 2937, 2873, 1845, 1605,
1557, 1501, 1486, 1471, 1456, 1432, 1360, 1319, 1319, 1276, 1251, 1179, 1167, 1141,
1094, 1063, 1025. ESI-MS calcd for C24H27O4+ [M + H]+ 379.19093, found 379.19035;
difference +1.5 ppm.
Synthesis of compound 4. To a flask containing 2 (0.120 g, 0.317 mmol), 3 (0.206 g,
0.264 mmol), DCC (0.065 g, 0.317 mmol), and DMAP (0.007 g, 0.0573 mmol) under an
Ar(g) atmosphere was added dry THF (25 mL) at r.t.. The resulting mixture was stirred
for 16 h. After, solids were removed by filtration and the filtrate was concentrated by
evaporation in vacuo. The crude product was purified by column chromatography on
silica gel using EtOAc as the eluent to afford compound 4 as a pale yellow solid (0.160 g,
53%). 1H NMR (CDCl3, 400 MHz): δ 8.02 (dd, J = 8 Hz, J = 3.5 Hz, 1H), 7.88 (d, J = 9
Hz, 1H), 7.87 (d, J = 8 Hz, 1H), 7.74 (dd, J = 8 Hz, J = 2 Hz, 1H), 7.43 – 7.07 (m, 26H),
6.88 – 6.74 (m, 4H), 6.50 (t, J = 5 Hz, NH), 4.33 (t, J = 6 Hz, 2H), 4.00 (t, J = 6.5 Hz,
2H), 3.94 (t, J = 6 Hz, 2H), 3.60 – 3.42 (m, 10H), 3.41 – 3.34 (m, 2H), 3.31 – 3.23 (m,
2H), 3.22 (t, J = 6.5 Hz, 2H), 2.65 – 2.48 (m, 2H), 2.36 (t, J = 6.5 Hz, 2H), 2.04 (tt, J = 6
Hz, J = 6 Hz, 2H), 1.80 – 1.70 (m, 2H), 1.53 – 1.41 (m, 2H), 0.96 (t, J = 7.5 Hz, 3H).
C{1H} NMR (CDCl3, 101 MHz): δ 166.33, 166.31, 166.2, 162.0, 161.4, 153.6, 147.6,
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144.7, 142.3, 141.9, 140.9, 140.6, 137.4, 137.1, 137.0, 136.7, 135.6, 135.5, 133.8, 133.6,
132.8, 130.72, 130.69, 129.5, 128.9, 128.6, 128.5, 127.8, 126.7, 126.5, 116.43, 116.2,
116.1, 116.06, 112.20, 112.17, 70.4, 70.3, 70.1, 70.0, 69.5, 69.4, 67.9, 66.5, 64.5, 62.1,
39.7, 37.05, 37.03, 31.5, 31.0, 28.3, 19.1, 13.7. 31P{1H} NMR (CDCl3, 162 MHz): δ -4.34
(s). FT-IR (ATR, ν, cm-1): 3321, 3055, 2957, 2931, 2870, 1843, 1716, 1652, 1600, 1561,
1486, 1471, 1443, 1435, 1351, 1319, 1276, 1249, 1165, 1183, 1130, 1094, 1055, 1027.
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ESI-MS calcd for C71H71NO9PS+ [M + H]+ 1144.45872, found 1144.46015; difference 1.25 ppm.
Synthesis of compound 5. To a solution of 4 (0.100 g, 0.0872 mmol) in CH2Cl2 (24 mL)
was added trifluoroacetic acid (1.995 g, 17.4 mmol) and triisopropylsilane (0.042 g,
0.265 mmol) under an Ar(g) atmosphere while stirring at r.t.. The resulting mixture was
stirred for 30 min and the solvent was removed by rotary evaporation. The crude product
was purified by column chromatography on silica gel using 7% CH3OH in EtOAc as the
eluent to afford compound 5 as a pale yellow oil (0.074 g, 94%). 1H NMR (CDCl3, 400
MHz): δ 8.08 (dd, J = 8 Hz, J = 3.5 Hz, 1H), 7.98 – 7.90 (m, 2H), 7.80 (dd, J = 8 Hz, J =
2 Hz, 1H), 7.40 – 7.22 (m, 11H), 6.93 – 6.79 (m, 4H), 6.48 (s, br, NH), 4.38 (t, J = 6 Hz,
2H), 4.05 (t, J = 6.5 Hz, 2H), 4.00 (t, J = 6 Hz, 2H), 3.68 – 3.49 (m, 14H), 3.39 – 3.24
(m, 2H), 2.64 (dt, J = 8 Hz, J = 6.5 Hz, 2H), 2.68 – 2.53 (m, 2H), 2.09 (tt, J = 2 Hz, J = 2
Hz, 2H), 1.86 – 1.75 (m, 2H), 1.56 (t, J = 8 Hz, SH), 1.56 – 1.46 (m, 2H), 1.00 (t, J = 7.5
Hz, 3H).
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C{1H} NMR (CDCl3, 101 MHz): δ 166.4, 166.2, 162.1, 161.5, 153.8, 147.8,

142.2, 141.8, 141.0, 140.7, 137.4, 137.2, 137.1, 136.8, 135.8, 133.9, 133.7, 132.9, 130.8,
128.9, 128.7, 128.6, 126.8, 116.3, 166.2, 166.16, 116.0, 112.3, 112.2, 72.8, 70.5, 70.4,
70.1, 70.05, 69.5, 67.9, 64.5, 62.1, 39.8, 37.0, 31.1, 28.3, 24.1, 19.1, 13.7. 31P{1H} NMR
(CDCl3, 162 MHz): δ -4.34 (s). FT-IR (ATR, ν, cm-1): 3335, 3054, 2955, 2933, 2870,
1843, 1716, 1652, 1600, 1557, 1505, 1471, 1434, 1354, 1319, 1275, 1248, 1165, 1115,
1055, 1026. ESI-MS calcd for C52H57NO9PS+ [M + H]+ 902.34917, found 902.34774;
difference +1.58 ppm.
Synthesis of compound 6. A solution of 4 (0.060 g, 0.0523 mmol) in CH3OH was
irradiated in a Luzchem (LZC-4V) photoreactor equipped with 14 UVA (350 nm) lamps
for 3 min at r.t. The solution was concentrated in vacuo and purified by column
chromatography on silica gel using 2:1 EtOAc:hexanes as the eluent to afford compound
6 as a pale yellow oil (0.058 g, 99%). 1H NMR (CDCl3, 400 MHz): δ 8.07 (dd, J = 8 Hz,
J = 3.5 Hz, 1H), 7.77 (dd, J = 8 Hz, J = 2 Hz, 1H), 7.45 – 7.15 (m, 28H), 6.89 (d, J = 2
Hz, 1H), 6.84 (d, J = 2 Hz, 1H), 6.77 (dd, J = 8 Hz, J = 2 Hz, 1H), 6.71 (dd, J = 8 Hz, J =
2 Hz, 1H), 6.40 (t, J = 5 Hz, NH), 4.37 (t, J = 6 Hz, 2H), 3.99 (t, J = 6.5 Hz, 2H), 3.94 (t,
J = 6 Hz, 2H), 3.65 – 3.48 (m, 10H), 3.46 – 3.39 (m, 2H), 3.28 (t, J = 7 Hz, 2H), 3.24 –
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3.13 (m, 2H), 2.51 – 2.39 (m, 2H), 2.41 (t, J = 6.5 Hz, 2H), 2.06 (tt, J = 6 Hz, J = 6 Hz,
2H), 1.84 – 1.74 (m, 2H), 1.57 – 1.46 (m, 2H), 0.99 (t, J = 7.5 Hz, 3H).
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C{1H} NMR

(CDCl3, 101 MHz): δ 166.4, 166.2, 158.7, 158.1, 154.8, 144.7, 141.1, 140.8, 137.3,
137.2, 137.1, 137.07, 136.9, 133.9, 133.7, 132.8, 130.8, 130.76, 129.5, 128.9, 128.7,
128.6, 127.8, 126.7, 126.6, 126.58, 116.7, 116.6, 116.4, 111.8, 110.5, 110.2, 70.5, 70.4,
70.2, 70.1, 69.6, 69.5, 67.7, 66.6, 64.3, 62.4, 39.8, 36.61, 36.58, 31.6, 31.3, 28.4, 19.2,
13.8.
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P{1H} NMR (CDCl3, 162 MHz): δ -4.33 (s). FT-IR (ATR, ν, cm-1): 3336, 3054,

2955, 2929, 2870, 1716, 1661, 1609, 1562, 1559, 1489, 1471, 1444, 1434, 1387, 1335,
1277, 1264, 1250, 1232, 1183, 1154, 1108, 1055. ESI-MS calcd for C70H71NO8PS+ [M +
H]+ 1116.46380, found 1116.46207; difference +1.55 ppm.
Synthesis of compounds 7a and 7b. To a solution of 6 (0.057 g, 0.0511 mmol) in
CH2Cl2 (2 mL) was added a solution of benzyl azide (0.0068 g, 0.0511 mmol) in CH2Cl2
(1 mL) at r.t. while stirring. The resulting solution was stirred for 8 h then concentrated in
vacuo. The crude product was purified by column chromatography on silica gel using
EtOAc as the eluent to afford a 1:1 mixture of compounds 7a and 7b as a pale yellow oil
(0.056 g, 88%). 1H NMR (CDCl3, 400 MHz): δ 8.11 – 8.00 (m, 1H), 7.82 – 7.74 (m, 1H),
7.50 – 7.16 (m, 29H), 7.14 – 7.03 (m, 2H), 7.01 – 6.94 (m, 2H), 6.84 – 6.60 (m, 4H), 6.54
– 6.43 (m, NH), 5.64 – 5.43 (m, 2H), 4.42 – 4.27 (m, 2H), 4.02 – 3.81 (m, 4H), 3.67 –
3.47 (m, 10H), 3.47 – 3.38 (m, 2H), 3.34 – 3.20 (m, 3H), 3.05 – 2.91 (m, 1H), 2.90 – 2.76
(m, 1H), 2.73 – 2.61 (m, 1H), 2.47 – 2.36 (m, 2H), 2.13 – 1.96 (m, 2H), 1.81 – 1.68 (m,
2H), 1.55 – 1.40 (m, 2H), 1.04 – 0.92 (m, 3H).
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C{1H} NMR (CDCl3, 101 MHz): δ

166.41, 166.39, 166.37, 166.3, 166.2, 160.0, 159.5, 158.7, 158.2, 146.8, 146.6, 144.7,
143.2, 143.1, 141.0, 140.7, 139.1, 139.0, 137.4, 137.3, 137.22, 137.18, 137.1, 137.07,
136.9, 135.6, 133.9, 133.7, 133.6, 132.9, 132.8, 130.8, 130.2, 129.6, 128.94, 128.9, 128.6,
128.6, 128.56, 128.0, 127.8, 127.4, 127.3, 126.8, 126.7, 126.6, 122.7, 122.3, 118.7, 118.2,
116.4, 116.3, 115.6, 115.5, 112.5, 112.4, 112.2, 112.1, 70.5, 70.4, 70.2, 70.1, 69.6, 69.5,
67.7, 67.5, 66.6, 64.2, 64.1, 62.43, 62.38, 52.1, 39.8, 36.5, 32.9, 31.6, 31.3, 31.2, 28.4,
19.2, 13.8. 31P{1H} NMR (CDCl3, 162 MHz): δ -4.32 (s), -4.35 (s). FT-IR (ATR, ν, cm1

): 3361, 3061, 2955, 2924, 2853, 1733, 1698, 1683, 1661, 1652, 1646, 1608, 1568, 1558,

1539, 1516, 1489, 1455, 1437, 1379, 1313, 1280, 1245, 1162, 1120, 1104, 1087, 1061,
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1029, 1018. ESI-MS calcd for C77H77N4NaO8PS+ [M + Na]+ 1271.50974, found
1271.50929; difference +0.35 ppm.
Synthesis of compounds 8a, 8b, and 9. To a solution of compounds 7a and 7b (0.020 g,
0.0160 mmol) in CH2Cl2 (3 mL) was added H2O (0.1 mL) and benzyl azide (0.0197 g,
0.160 mmol) at r.t. while stirring. The resulting mixture was stirred for 16 h then
concentrated in vacuo. The crude products were purified by column chromatography on
silica gel using 3:1 EtOAc as the eluent to afford compounds 8a (Rf = 0.55) and 8b (Rf =
0.45), then 10% CH3OH in CH2Cl2 to elute compound 9.
Compound 8a (yellow oil, 3 mg, 78%): 1H NMR (CDCl3, 400 MHz): δ 7.46 (d, J = 8.5
Hz, 1H), 7.31 – 7.24 (m, 3H), 7.12 – 7.06 (m, 2H), 6.98 (m, J = 8 Hz, 1H), 6.81 (d, J =
2.5 Hz, 1H), 6.76 (dd, J = 5 Hz, J = 2.5 Hz, 1H), 6.74 (dd, J = 5 Hz, J = 2.5 Hz, 1H), 6.66
(d, J = 2.5 Hz, 1H), 5.62 – 5.45 (m, 2H), 4.12 (dt, J = 6 Hz, J = 2.5 Hz, 2H), 3.92 (t, J =
6.5 Hz, 2H), 3.90 – 3.84 (m, 2H), 3.34 – 3.20 (m, 1H), 3.05 – 2.91 (m, 1H), 2.89 – 2.77
(m, 1H), 2.74 – 2.61 (m, 1H), 2.05 (tt, J = 6 Hz, J = 6 Hz, 2H), 1.77 – 1.69 (m, 2H), 1.69
– 1.62 (s, br, OH), 1.52 – 1.41 (m, 2H), 0.95 (t, J = 7.5 Hz, 3H).13C{1H} NMR (CDCl3,
101 MHz): δ 159.6, 158.7, 146.8, 143.3, 139.0, 135.7, 133.6, 132.9, 130.3, 128.7, 128.1,
127.4, 122.4, 118.8, 116.4, 115.6, 112.5, 112.2, 67.5, 65.6, 60.2, 52.1, 36.5, 32.9, 31.9,
31.3, 19.2, 13.8. FT-IR (ATR, ν, cm-1): 3355, 3064, 3031, 2954, 2930, 2872, 1607, 1574,
1515, 1489, 1472, 1455, 1430, 1393, 1361, 1345, 1305, 1280, 1257, 1243, 1208, 1175,
1118, 1103, 1062, 1028, 1008. ESI-MS calcd for C30H34N3O3+ [M + H]+ 484.26002,
found 484.25875; difference +2.62 ppm.
Compound 8b (yellow oil, 3.5 mg, 90%): 1H NMR (CDCl3, 400 MHz): δ 7.47 (d, J =
8.5 Hz, 1H), 7.31 – 7.23 (m, 3H), 7.12 – 7.06 (m, 2H), 6.97 (d, J = 8.5 Hz, 1H), 6.81 –
6.75 (m, 2H), 6.73 (dd, J = 8.5 Hz, J = 2.5 Hz, 1H), 6.68 (d, J = 2.5 Hz, 1H), 5.63 – 5.45
(m, 2H), 4.09 (t, J = 6 Hz, 2H), 3.95 (dt, J = 6.5 Hz, J = 2 Hz, 2H), 3.88 – 3.80 (m, 2H),
3.33 – 3.20 (m, 1H), 3.05 – 2.91 (m, 1H), 2.89 – 2.78 (m, 1H), 2.73 – 2.61 (m, 1H), 2.02
(tt, J = 6 Hz, J = 6 Hz, 2H), 1.81 – 1.71 (m, 2H), 1.55 – 1.45 (m, 2H), 0.99 (t, J = 7 Hz,
3H).

13

C{1H} NMR (CDCl3, 101 MHz): δ 160.0, 158.3, 146.7, 143.1, 139.2, 135.7,

133.8, 133.0, 130.2, 128.7, 128.0, 127.4, 122.9, 118.3, 116.4, 115.6, 112.5, 112.2, 67.7,
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65.6, 60.5, 52.1, 36.6, 32.9, 31.9, 31.2, 19.2, 13.8. FT-IR (ATR, ν, cm-1): 3363, 3065,
3032, 2955, 2929, 2872, 1607, 1577, 1575, 1558, 1516, 1489, 1471, 1455, 1429, 1362,
1345, 1306, 1281, 1257, 1243, 1208, 1176, 1163, 1119, 1105, 1062. ESI-MS calcd for
C30H34N3O3+ [M + H]+ 484.2600, found 484.2586.; difference +2.9 ppm.
Compound 9 (yellow oil, 13 mg, 92%): 1H NMR (CDCl3, 400 MHz): δ 9.10 (t, J = 5.5
Hz, NH), 8.06 (dd, J = 8 Hz, J = 3.5 Hz, 2H), 7.96 (dt, J = 8 Hz, J = 1.5 Hz, 1H), 7.73 –
7.57 (m, 7H), 7.55 – 7.46 (m, 4H), 7.45 – 7.38 (m, 6H), 7.33 – 7.18 (m, 13H), 6.80 (t, J =
5.5 Hz, NH), 4.12 (d, J = 5.5 Hz, 2H), 3.65 – 3.51 (m, 10H), 3.48 – 3.42 (m, 2H), 3.29 (t,
J = 7 Hz, 2H), 2.41 (t, J = 6.5 Hz, 2H).

13

C{1H} NMR (CDCl3, 101 MHz): δ 166.53,

166.49, 165.4, 144.7, 143.4, 143.3, 137.4, 135.7, 135.6, 132.9, 132.7, 132.59, 132.56,
132.0, 131.9, 131.8, 131.7, 131.0, 130.8, 130.2, 129.9, 129.8, 129.6, 128.9, 128.8, 128.5,
128.0, 127.9, 127.2, 126.6, 70.5, 70.4, 70.3, 70.1, 69.6, 69.5, 66.6, 44.1, 39.9, 31.6.
P{1H} NMR (CDCl3, 162 MHz): δ 34.91 (s). FT-IR (ATR, ν, cm-1): 3274, 3055, 3030,
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2921, 2866, 1656, 1652, 1645, 1598, 1557, 1538, 1486, 1455, 1438, 1349, 1307, 1277,
1265, 1252, 1142, 1118, 1100, 1070, 1028. ESI-MS calcd for C54H53N2NaO6PS+ [M +
Na]+ 911.32596, found 911.32537; difference +0.65 ppm.
Synthesis of compounds 11a and 11b. To a solution of compounds 7a and 7b (0.020 g,
0.0160 mmol) in CH2Cl2 (3 mL) was added perfluoroaryl azide 103 (0.005 g, 0.020
mmol) at r.t. while stirring. A temporary change from a colorless solution to a yellow
solution was observed. Within several minutes, it returned to a colorless solution. After
20 min, the solvent was evaporated in vacuo. The crude products were purified by
column chromatography on silica gel using EtOAc as the eluent to afford a 1:1 mixture of
compounds 11a and 11b as a colorless oil (0.022 g, 93%). 1H NMR (CDCl3, 400 MHz): δ
8.26 – 8.14 (m, 1H), 8.06 – 7.99 (m, 1H), 7.91 – 7.81 (m, 1H), 7.74 – 7.62 (m, 4H), 7.55
– 7.36 (m, 13H), 7.32 – 7.16 (m, 12H), 7.14 – 7.06 (m, 2H), 7.03 – 6.83 (m, 2H), 6.83 –
6.56 (m, 4H), 5.64 – 5.45 (m, 2H), 4.05 – 3.88 (m, 4H), 3.88 – 3.84 (m, 3H), 3.79 – 3.52
(m, 12H), 3.46 – 3.40 (m, 2H), 3.34 – 3.21 (m, 3H), 3.06 – 2.91 (m, 1H), 2.90 – 2.78 (m,
1H), 2.74 – 2.62 (m, 1H), 2.40 (t, J = 6.5 Hz, 2H), 1.87 – 1.67 (m, 4H), 1.56 – 1.41 (m,
2H), 1.03 – 0.92 (m, 3H).

13

C{1H} NMR (CDCl3, 101 MHz): δ 166.42, 166.39, 166.31,

166.29, 165.3, 165.2, 160.0, 159.4, 158.7, 158.2, 146.8, 146.6, 144.7, 143.2, 143.1, 139.2,
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139.0, 138.2, 138.1, 138.13, 138.11, 138.0, 136.82, 136.78, 136.71, 136.67, 135.7, 135.6,
133.83, 133.76, 133.7, 133.6, 132.9, 132.2, 132.13, 132.09, 132.0, 131.9, 130.89, 130.86,
130.8, 130.7, 130.4, 130.33, 130.30, 130.2, 129.80, 129.76, 129.6, 128.8, 128.7, 128.65,
128.6, 128.0, 127.8, 127.4, 127.3, 126.6, 122.8, 122.4, 118.7, 118.2, 116.3, 115.6, 112.5,
112.3, 112.2, 112.1, 70.5, 70.33, 70.27, 70.1, 69.52, 69.45, 67.7, 67.5, 66.6, 64.0, 63.8,
62.82, 62.80, 52.22, 52.20, 52.1, 40.1, 36.51, 36.49, 32.90, 32.88, 31.6, 31.3, 31.2, 29.7,
27.9, 19.2 13.8.
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P{1H} NMR (CDCl3, 162 MHz): δ 11.51 (t, JPF = 4.5 Hz).
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P{1H}

NMR (DMSO-d6, 162 MHz): δ 11.73 (t, JPF = 4.5 Hz), 11.67 (t, JPF = 4.5 Hz).
19

F{1H}NMR (CDCl3, 377 MHz): δ -143.1 (m), -152.8 (m). FT-IR (ATR, ν, cm-1): 3335,

3059, 3031, 2952, 2929, 2871, 1722, 1661, 1637, 1608, 1557, 1519, 1516, 1486, 1435,
1413, 1361, 1347, 1254, 1206, 1171, 1107, 1062, 1015. ESI-MS calcd for
C85H81F4N5O10PS+ [M + H]+ 1470.53779, found 1470.53946; difference -1.14 ppm.
Synthesis of compound 12. To a solution of 4-formylbenzonitrile (0.150 g, 1.14 mmol)
in CH3CN (20 mL) was added N-methylhydroxylamine hydrochloride (0.196 g, 2.35
mmol, 2.35 mmol) and Et3N (0.65 mL, 4.69 mmol) at r.t. while stirring. After, Na2SO4
(0.100 g) was added to the stirring reaction mixture to absorb the H2O byproduct. The
mixture was stirred at r.t. for 16 h. Solids were removed by filtration and the filtrate was
concentrated by evaporation in vacuo. The crude product was purified by column
chromatography on silica gel using EtOAc as the eluent to afford compound 12 as a
white solid (0.145 g, 79%). 1H NMR (CDCl3, 400 MHz): δ 8.31 (d, J = 8.5 Hz, 2H), 7.69
(d, J = 8.5 Hz, 2H), 7.46 (s, 1H), 3.93 (s, 3H).

13

C{1H} NMR (CDCl3, 101 MHz): δ

134.2, 133.4, 132.2, 128.2, 118.4, 113.0, 55.0. FT-IR (ATR, ν, cm-1): 3165, 3086, 3039,
2991, 2933, 2223, 1585, 1549, 1442, 1421, 1402, 1396, 1318, 1275, 1267, 1261, 1184,
1166, 1096, 947. ESI-MS calcd for C9H8N2O+ [M]+ 160.06366, found 160.06341;
difference -1.56 ppm.
Synthesis of compounds 13a and 13b. To a solution of 6 (0.029 g, 0.0260 mmol) in
CH2Cl2 (4 mL) was added nitrone 12 (0.005 g, 0.0312 mmol) at r.t. while stirring. The
resulting mixture was stirred for 4 h and the solvent was removed by evaporation in
vacuo. The crude product was purified by column chromatography on silica gel using 2:1
EtOAc:hexanes as the eluent to afford a 1:1 mixture of compounds 13a and 13b as a pale
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yellow oil (0.032 g, 96%). 1H NMR (CDCl3, 400 MHz): δ 8.09 – 8.00 (m, 1H), 7.80 –
7.72 (m, 1H), 7.60 – 7.52 (m, 2H), 7.52 – 7.16 (m, 29H), 7.06 – 6.98 (m, 1H), 6.74 – 6.56
(m, 4H), 6.47 – 6.40 (m, 1H), 5.02 – 5.01 (m, 1H), 4.37 – 4.28 (m, 2H), 3.95 – 3.82 (m,
4H), 3.66 – 3.47 (m, 10H), 3.47 – 3.39 (m, 2H), 3.36 – 3.23 (m, 3H), 3.13 (s, 3H), 3.08 –
2.96 (m, 1H), 2.96 – 2.85 (m, 1H), 2.76 – 2.66 (m, 1H), 2.41 (t, J = 6.5 Hz, 2H), 2.07 –
1.96 (m, 2H), 1.78 – 1.64 (m, 2H), 1.52 – 1.40 (m, 2H), 1.00 – 0.92 (m, 3H).

13

C{1H}

NMR (CDCl3, 101 MHz): δ 166.38, 166.37, 166.3, 159.2, 158.7, 158.1, 157.6, 146.9,
146.7, 146.6, 144.7, 142.64, 142.56, 141.1, 141.0, 140.79, 140.75, 140.65, 137.35,
137.33, 137.2, 137.1, 136.9, 133.9, 133.7, 132.8, 132.3, 131.31, 131.28, 130.80, 130.78,
129.6, 129.0, 128.9, 128.7, 128.6, 127.8, 126.9, 126.8, 126.6, 126.0, 125.7, 124.0, 123.6,
119.9, 119.5, 118.9, 116.2, 116.1, 115.1, 115.0, 112.5, 112.4, 112.3, 112.2, 111.0, 108.4,
108.2, 79.8, 70.5, 70.4, 70.2, 70.1, 69.6, 69.5, 67.5, 66.6, 64.1, 62.5, 62.4, 46.8, 39.8,
36.80, 36.77, 32.93, 32.90, 31.6, 31.3, 31.2, 28.4, 28.3, 19.2, 19.1, 13.81, 13.77. 31P{1H}
NMR (CDCl3, 162 MHz): δ -4.29 (s), -4.30 (s). FT-IR (ATR, ν, cm-1): 3331, 3054, 2957,
2929, 2870, 2227, 1716, 1661, 1605, 1505, 1471, 1444, 1435, 1393, 1347, 1278, 1241,
1173, 1161, 1110, 1055. ESI-MS calcd for C79H78N3NaO9PS+ [M + Na]+ 1298.50941,
found 1298.50959; difference -0.14 ppm.
Synthesis of compounds 14a and 14b, and 9. To a solution of compounds 13a and 13b
(0.012 g, 0.0094 mmol) in CH2Cl2 (2 mL) was added a solution of benzyl azide (0.0125
g, 0.0939 mmol) in CH2Cl2 (1 mL) followed by H2O (0.1 mL) at r.t. while stirring. The
resulting mixture was stirred for 8 h and concentrated in vacuo. Excess benzyl azide was
removed by washing with hexanes. The resulting crude residue was purified by column
chromatography on silica gel using EtOAc to elute 14a and 14b as a 1:1 mixture (Rf =
0.8) followed by 10% CH3OH in CH2Cl2 to elute 9.
Compound 14a/14b mixture (colorless oil, 4.2 mg, 88%): 1H NMR (CDCl3, 400
MHz): δ 7.57 (d, J = 8.5 Hz, 2H), 7.46 (d, J = 8.5 Hz, 2H), 7.42 (dd, J = 8.5 Hz, J = 3.5
Hz, 1H), 7.02 (dd, J = 8.0 Hz, J = 5.0 Hz, 1H), 6.74 – 6.61 (m, 4H), 5.01 (s, 1H), 4.10 –
4.04 (m, 2H), 3.90 (t, J = 6.5 Hz, 2H), 3.84 (dt, J = 6.5 Hz, J = 6.0 Hz, 2H), 3.65 (t, J =
6.5 Hz, OH), 3.36 – 3.25 (m, 1H), 3.13 (s, 3H), 3.07 – 2.97 (m, 1H), 2.95 – 2.86 (m, 1H),
2.76 – 2.66 (m, 1H), 2.07 – 1.97 (m, 2H), 1.78 – 1.67 (m, 2H), 1.53 – 1.40 (m, 2H), 0.99
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– 0.92 (m, 3H).

13

C{1H} NMR (CDCl3, 101 MHz): δ 159.2, 158.8, 158.1, 157.7, 146.9,

146.7, 146.6, 142.7, 142.6, 140.8, 140.7, 132.3, 131.4, 131.3, 129.1, 129.0, 128.8, 126.9,
124.2, 123.6, 120.0, 119.5, 118.9, 116.1, 115.11, 115.07, 112.5, 112.3, 112.2, 111.0,
108.4, 108.2, 79.9, 77.2, 67.5, 65.6, 65.5, 60.5, 60.3, 46.8, 36.8, 32.9, 31.93, 31.87, 31.3,
31.2, 19.23, 19.18, 13.83, 13.79. FT-IR (ATR, ν, cm-1): 3396, 3035, 2956, 2930, 2872,
2227, 1671, 1605, 1569, 1505, 1471, 1456, 1429, 1398, 1343, 1279, 1241, 1175, 1128,
1109, 1063. ESI-MS calcd for C32H34N2NaO4+ [M + Na]+ 533.24163, found 533.24131;
difference +0.60 ppm.
Compound 9 (yellow oil, 7.5 mg, 90%): Characterizations matched data from previous
release experiment with compounds 7a/7b.

Scheme S4.1. Synthesis of perfluoroaryl azide 17.
Synthesis of compound 17. To a solution of 16 (0.100 g, 0.301 mmol) in CH2Cl2 (15
mL) was added a solution of Rhodamine B derivative 15 (0.226 g, 0.361 mmol) and Et3N
(0.061 g, 0.602 mmol) in CH2Cl2 (5 mL) at r.t. while stirring. The resulting solution was
stirred in the dark for 3 h. After, the solvent was removed by evaporation in vacuo. The
resulting crude residue was purified by column chromatography on silica gel using 10%
CH3OH in CH2Cl2 as the eluent to afford 17 as a dark purple solid (0.190 g, 75%). 1H
NMR (CD3OD, 400 MHz): δ 7.86 – 7.71 (m, 3H), 7.57 – 7.50 (m, 1H), 7.33 – 7.22 (m,
2H), 7.13 – 7.04 (m, 2H), 6.99 – 6.92 (m, 2H), 3.85 – 3.53 (m, 12H), 3.14 (s, br, 4H),
1.33 (t, J = 7.0 Hz, 12H).

13

C{1H} NMR (CD3OD, 101 MHz): δ 169.5, 162.9, 159.3,

157.3, 156.8, 147.1 – 146.8 (m), 144.6 – 144.3 (m), 143.3 – 143.0 (m), 140.9 – 140.5

141

(m), 135.7, 133.1, 132.5, 131.9, 131.7, 131.5, 128.9, 123.1 – 122.8 (m), 115.5, 114.9,
112.9, 97.5, 47.0, 44.3, 39.7, 13.0. 19F{1H}NMR (CD3OD, 377 MHz): δ -76.8 (s), -143.1
– -143.3 (m), -153.7 – -154.0 (m). FT-IR (ATR, ν, cm-1): 3392, 2978, 2932, 2872, 2718,
2125, 1645, 1584, 1529, 1486, 1464, 1411, 1393, 1334, 1273, 1246, 1197, 1178, 1159,
1131, 1073. ESI-MS calcd for C39H38F4N7O3+ [M – CF3COO]+ 728.2972, found
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728.2993; difference -2.86 ppm.
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Figure S4.1. 1H NMR spectrum of compound 2 obtained in CDCl3 and referenced to
residual CHCl3. *Denotes residual solvent signal.
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Figure S4.2. 13C{1H} NMR spectrum of compound 2 obtained in CDCl3 and referenced
to CDCl3.
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Figure S4.3. 1H NMR spectrum of compound 4 obtained in CDCl3 and referenced to
residual CHCl3.
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Figure S4.6. 1H NMR spectrum of compound 5 obtained in CDCl3 and referenced to
residual CHCl3. *Denotes residual solvent signal.

200

180

Figure S4.7.
to H3PO4.

160

31

140

120

100

80
60
Chemical Shift (ppm)

40

20

0

-20

-40

P{1H} NMR spectrum of compound 5 obtained in CDCl3 and referenced

8.5

8.0

7.5

7.0

6.5

6.0

0.91 0.92 30.30 2.05 2.01 0.90

5.5

5.0
4.5
4.0
Chemical Shift (ppm)

3.56
3.55
3.55
3.20
3.54
3.17
3.28
2.46
2.47
2.43
2.41
2.39
2.10 2.08
2.05 2.06
1.81
1.75 1.79
1.77
1.52
1.50
1.02
0.98

80

3.5

1.00

3.59
3.59

120
100
Chemical Shift (ppm)

3.43

140

3.61

7.27

160

4.39
4.38
4.36
4.36 4.00
3.99
3.94
3.93

7.40

180

6.40

7.25
7.22
7.20

7.42

200

7.18 6.89 7.18
6.89
6.85
6.84
6.78
6.73

8.09
8.08
8.06
8.06
7.78
7.78

116.30

3.0

60
40

2.5

2.0

28.27

31.05

72.75
70.37
70.05

2.014.18 11.042.21 2.13 2.08 4.23 2.06 2.041.98

1.5

13.73

24.11
19.10

39.77
37.04

69.48
64.53 67.92
62.14

116.13
112.16

130.74
126.80

147.76
137.34
137.13
137.02

153.74

166.32
162.07
161.49

77.00

133.88
133.67
128.91 128.62
128.55

145

20
0

Figure S4.8. 13C{1H} NMR spectrum of compound 5 obtained in CDCl3 and referenced
to CDCl3.
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Figure S4.9. 1H NMR spectrum of compound 6 obtained in CDCl3 and referenced to
residual CHCl3.
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Figure S4.10. 31P{1H} NMR spectrum of compound 6 obtained in CDCl3 and referenced
to H3PO4.
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Figure S4.11. 13C{1H} NMR spectrum of compound 6 obtained in CDCl3 and referenced
to CDCl3.
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Figure S4.12. 1H NMR spectrum of compounds 7a/7b obtained in CDCl3 and referenced
to residual CHCl3.
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Figure S4.13. 31P{1H} NMR spectrum of compounds 7a/7b obtained in CDCl3 and
referenced to H3PO4.
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Figure S4.14. 13C{1H} NMR spectrum of compounds 7a/7b obtained in CDCl3 and
referenced to CDCl3.
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Figure S4.15. 1H NMR spectrum of compound 8a obtained in CDCl3 and referenced to
residual CHCl3.
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Figure S4.16. 13C{1H} NMR spectrum of compound 8a obtained in CDCl3 and
referenced to CDCl3.
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Figure S4.17. 1H NMR spectrum of compound 8b obtained in CDCl3 and referenced to
residual CHCl3.

200

180

160

140

120
100
Chemical Shift (ppm)

80

60

40

19.21

13.83

36.55
32.91
31.94
31.24

52.10

67.69
65.63
60.54

122.88
118.28 116.37
115.57
112.51
112.22

135.67
132.96
130.21

146.65
143.11

160.03
158.28

128.66
127.42

77.00

150

20

0

8

7

6

5
Chemical Shift (ppm)

2.43
2.39

2.41

3.47 3.57
3.29
3.27

1.94 10.11 2.17 2.12
4

3

2.07
1.85
1.84
1.30
1.28
1.28
1.26
0.91

4.14

0.91 0.98 0.97 0.03 7.03 0.05 4.08 0.05 6.17 0.02 14.47 0.95
9

3.63
3.62

4.13
4.12

7.23
7.21
7.20
7.19
7.19
6.81
6.80
6.79

8.05
8.04
7.97
7.71
7.69
7.68 7.67
7.49 7.63

9.12
9.10
9.09

7.42

7.26

7.42
7.40

7.28
7.28

3.61

Figure S4.18. 13C{1H} NMR spectrum of compound 8b obtained in CDCl3 and
referenced to CDCl3.
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Figure S4.19. 1H NMR spectrum of compound 9 obtained in CDCl3 and referenced to
residual CHCl3. *Denotes residual solvent signal.
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Figure S4.20. 31P{1H} NMR spectrum of compound 9 obtained in CDCl3 and referenced
to H3PO4.
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Figure S4.21. 13C{1H} NMR spectrum of compound 9 obtained in CDCl3 and referenced
to CDCl3.
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Figure S4.22. 1H NMR spectrum of compounds
11a/11b obtained in CDCl3 and
referenced to residual CHCl3. *Denotes residual solvent signal.
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Figure S4.23. 31P{1H} NMR spectrum of compounds 11a/11b obtained in CDCl3 and
referenced to H3PO4.
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Figure S4.24. 13C{1H} NMR spectrum of compounds 11a/11b obtained in CDCl3 and
referenced to CDCl3.
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Figure S4.25. 1H NMR spectrum of compound 12 obtained in CDCl3 and referenced to
residual CHCl3. *Denotes residual solvent signal.
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Figure S4.26. 13C{1H} NMR spectrum of compound 12 obtained in CDCl3 and
referenced to CDCl3.
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Figure S4.27. 1H NMR spectrum of compounds 13a/13b obtained in CDCl3 and
referenced to residual CHCl3. *Denotes residual solvent signal.
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Figure S4.28. 31P{1H} NMR spectrum of compounds 13a/13b obtained in CDCl3 and
referenced to H3PO4.
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Figure S4.29. 13C{1H} NMR spectrum of compounds 13a/13b obtained in CDCl3 and
referenced to CDCl3.
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Figure S4.30. 1H NMR spectrum of compounds 14a/14b obtained in CDCl3 and
referenced to residual CHCl3. *Denotes residual solvent signal.
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Figure S4.31. 13C{1H} NMR spectrum of compounds 14a/14b obtained in CDCl3 and
referenced to CDCl3.
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Figure S4.32. 1H NMR spectrum of compound 17 obtained in CD3OD and referenced to
residual CD3OH.

Figure S4.33. 13C{1H} NMR spectrum of compound 17 obtained in CD3OD and
referenced to CD3OD.
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Figure S4.34. 19F{1H} NMR spectrum of compound 17 obtained in CD3OD and
referenced against trifluoroacetic acid.

Synthesis of HO-EG4-AuNPs. HAuCl4·3H2O (1.4564 g, 3.7 mmol, 1.0 eq.) was
dissolved in a mixture of dry methanol (503 mL) and glacial acetic acid (83 mL). To this
yellow solution was added HO-EG4-SH (10) (2.3 g, 11 mmol, 3.0 eq.). The bright yellow
solution was stirred vigorously for 1 h and the solution color faded slightly. A solution of
NaBH4 (1.3997 g, 37 mmol, 10.0 eq.) in nanopure H2O (96 mL) was added dropwise to
the reaction mixture under vigorous stirring. The mixture turned dark brown
immediately. After overnight stirring at ambient temperature, the solution was
concentrated in vacuo. The resulting film of AuNPs was washed with toluene (3x) and
the film was remade by dissolving the AuNPs in methanol followed by rotary
evaporation to remove the solvent. This washing procedure was repeated 6 times. Next,
the crude HO-EG4-AuNPs were dissolved in nanopure water and centrifuged at 6000 rpm
for 10 min to remove insoluble solid impurities. The crude HO-EG4-AuNPs were then
further purified by overnight dialysis.
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Synthesis of hvDIBO-PPh3-EG4-AuNPs. To a solution of thiol 5 (0.060 g, 0.0665
mmol) in 1:1 CH2Cl2:CH3OH (6 mL) was added a solution of HO-EG4-AuNPs2 in 1:1
CH2Cl2:CH3OH (6 mL) under an Ar(g) atmosphere and vigorous stirring at r.t. The
resulting solution was stirred for 16 h. After, solvents were removed by rotary
evaporation to deposit a film of AuNPs inside a 500 mL round bottom flask. This film
was washed 3x by trituration with 2:1 Et2O:CH2Cl2 to remove excess 5, displaced thiols
and disulfides. The AuNP film was remade by dissolving in 1:1 CH2Cl2:CH3OH followed
by rotary evaporation. This washing procedure was repeated 4x to afford clean hvDIBOPPh3-EG4-AuNPs (dark brown solid, 0.065 g).

Calculation of nanoparticle raw formula.
The number of gold atoms (NAu) can be calculated from the following formula2:
𝑁𝐴𝑢

𝜋𝜌𝑑 3 𝑁𝐴
=
6𝑀𝐴𝑢

Where:

 = density of face centered cubic(fcc) gold lattice (19.3 g cm-1)
d = average diameter of nanoparticles in centimeters (from TEM images)
NA = Avogadro constant
MAu = mole atomic weight of gold (196.9665 g mol-1)
This is assuming that the AuNPs are spherical and that their size is monodispersed.
The total number of ligands (NL) can be calculated using the following formula:
𝑁𝐿 =

𝑁𝐴𝑢 𝑀𝐴𝑢 𝑀𝑇𝐺𝐴
(1 − 𝑀𝑇𝐺𝐴 )(𝑀𝑊𝑃: 𝑛%𝑃: + 𝑀𝑊𝑂𝐻 𝑛%𝑂𝐻 )

Where:
MTGA = organic percentage from TGA
MWOH = molecular weight of HO-EG4-S- ligand
n%OH = molar percentage of HO-EG4-S- ligand
From the number of ligands per particle, the number of gold atoms per particles, and the
molar percentage of the three different ligands it is possible to obtain the nanoparticles
raw formula.
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Quantitative analysis of hvDIBO-PPh3-EG4-AuNPs.

Figure S4.35. Thermogravimetric analysis (left) and derivative plot (right) of hvDIBOPPh3-EG4-AuNPs.
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Figure S4.36. 1H NMR spectra of thiol 5, hvDIBO-PPh3-EG4-AuNPs, and DIBO-PPh3EG4-AuNPs obtained in CDCl3 and referenced to residual CHCl3. Blue arrows designate
expected shifts from hvDIBO-PPh3-EG4-AuNPs to DIBO-PPh3-EG4-AuNPs after
photochemical decarbonylation.
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Figure S4.37. FT-IR spectra of hvDIBO-PPh3-EG4-AuNPs (left) and DIBO-PPh3-EG4AuNPs (right) acquired on a PerkinElmer Spectrum Two FTIR spectrometer with an
attenuated total reflectance (ATR) attachment and a single reflection diamond.
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Figure S4.38. 1H NMR spectra of 13a/13b, isoxazoline-PPh3-EG4-AuNPs, 7a/7b, and
(benzyl)triazole-PPh3-EG4-AuNPs obtained in CDCl3 and referenced to residual CHCl3.
Dashed lines indicate correlation between AuNPs and the analogous ‘free’ unbound
molecules.
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Figure S4.39. 31P{1H} NMR spectra of thiol 5 and AuNPs obtained in CDCl3 and
referenced to H3PO4.
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Figure S4.40. UV-vis spectra of AuNPs obtained in CH3OH.
Synthesis of DIBO-PPh3-EG4-AuNPs. A solution of hvDIBO-PPh3-EG4-AuNPs (0.059
g) in 1:1 CH2Cl2:CH3OH (450 mL) was irradiated in a Luzchem photoreactor equipped
with 14 x 8 W UVA (350 nm) lamps for 3 min at r.t. while stirring vigorously. The
solvents were removed by rotary evaporation to afford DIBO-PPh3-EG4-AuNPs (dark
brown solid, 0.059 g).
Synthesis of (benzyl)triazole-PPh3-EG4-AuNPs. To a solution of DIBO-PPh3-EG4AuNPs (0.032 g, estimated 11.74 μmol interfacial DIBO) in CH2Cl2 was added a solution
of benzyl azide in CH2Cl2 (1 mL, 11.7 mM) at r.t. while stirring. The resulting solution
was stirred for 16 h. The solvent was removed by rotary evaporation to afford
(benzyl)triazole-PPh3-EG4-AuNPs (dark brown solid, 0.033 g).
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Synthesis of isoxazoline-PPh3-EG4-AuNPs. To a solution of DIBO-PPh3-EG4-AuNPs
(0.028 g, estimated 10.28 μmol interfacial DIBO) in CH2Cl2 was added a solution of
nitrone 12 in CH2Cl2 (1 mL, 20.6 mM) at r.t. while stirring. The resulting solution was
stirred for 16 h. The solvent was removed by rotary evaporation to afford isoxazolinePPh3-EG4-AuNPs (dark brown solid, 0.030 g).
Release experiment for (benzyl)triazole-PPh3-EG4-AuNPs. To a solution of
(benzyl)triazole-PPh3-EG4-AuNPs (0.015 g) in 1:1 CH2Cl2:CH3OH (1 mL) was added
H2O (0.1 mL) and a solution of benzyl azide in CH2Cl2 (0.5 mL, 0.11 M, ~10 equiv.) at
r.t. The mixture was left for 16 h. After, the solvents were removed by rotary evaporation
and resulting AuNP film was washed with 2:1 EtOAc:hexanes (3x). The film was remade
by dissolving in 1:1 CH2Cl2:CH3OH followed by rotary evaporation. This washing
procedure was repeated 2x and the washes were combined, concentrated, and analyzed by
1

H NMR spectroscopy.
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Figure S4.41. 1H NMR spectral overlay of 8a/8b and 2:1 EtOAc:hexanes washes from
release experiment with (benzyl)triazole-PPh3-EG4-AuNPs. All spectra obtained in
CDCl3 and referenced to residual CHCl3 (7.27 ppm). Signals at 1.26 and 0.88 ppm
correspond to residual hexanes.
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Release experiment for isoxazoline-PPh3-EG4-AuNPs. To a solution of isoxazolinePPh3-EG4-AuNPs (0.015 g) in 1:1 CH2Cl2:CH3OH (1 mL) was added H2O (0.1 mL) and
a solution of benzyl azide in CH2Cl2 (0.5 mL, 0.11 M, ~10 equiv.) at r.t. The mixture was
left for 16 h. After, the solvents were removed by rotary evaporation and resulting AuNP
film was washed with 2:1 EtOAc:hexanes (3x). The film was remade by dissolving in 1:1
CH2Cl2:CH3OH followed by rotary evaporation. This washing procedure was repeated 2x
and the washes were combined and analyzed by 1H NMR spectroscopy.
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Figure S4.42. 1H NMR spectral overlay of 14a/14b and 2:1 EtOAc:hexanes washes from
release experiment with isoxazoline-PPh3-EG4-AuNPs. All spectra obtained in CDCl3
and referenced to residual CHCl3 (7.27 ppm). Signals at 1.26 and 0.88 ppm correspond to
residual hexanes.

Synthesis of hvDIBO-P(=N-Rhodamine)Ph3-EG4-AuNPs. To a solution of hvDIBOPPh3-EG4-AuNPs (0.038 g, estimated 13.95 μmol interfacial phosphine) in 1:1
CH2Cl2:CH3OH (2 mL) was added azide 17 (0.035 g, 41.8 μmol) and left to stir for 16 h
at r.t. After, solvent was evaporated and crude AuNPs were dialyzed in 70% CH3OH in
H2O over 2 days (solvent changed 4x) until washings no longer became pink. Solvent
was then removed by rotary evaporation to afford hvDIBO-P(=N-Rhodamine)Ph3-EG4AuNPs (dark brown-purple solid, 0.037 g).
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Synthesis of DIBO-P(=N-Rhodamine)Ph3-EG4-AuNPs. A solution of hvDIBO-P(=NRhodamine)Ph3-EG4-AuNPs (0.023 g) in 1:1 CH2Cl2:CH3OH (200 mL) was irradiated in
a Luzchem photoreactor equipped with 14 x 8 W UVA (350 nm) lamps for 6 min at r.t.
while stirring vigorously. The solvents were removed by rotary evaporation to afford
DIBO-P(=N-Rhodamine)Ph3-EG4-AuNPs (dark brown-purple solid, 0.023 g).
Synthesis of (biotin)triazole-P(=N-Rhodamine)Ph3-EG4-AuNPs. To a solution of
DIBO-P(=N-Rhodamine)Ph3-EG4-AuNPs (0.019 g, estimated 6.97 μmol interfacial
DIBO) in CH3OH (1 mL) was added azide-PEG3-biotin conjugate 18 (0.006 g, 13.5
μmol) at r.t. while stirring. This mixture was stirred for 6 h and the solvent was removed
by rotary evaporation. Crude AuNPs were dialyzed in 50% CH3OH in H2O overnight
(solvent changed 3x) and the clean AuNP solution was concentrated in vacuo to afford
(biotin)triazole-P(=N-Rhodamine)Ph3-EG4-AuNPs (dark brown-purple solid, 0.022 g).

Figure S4.43. 1H NMR spectral overlay of multifunctional AuNPs obtained in CD3OD
and referenced to residual CD3OH (3.31 ppm).
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Figure S4.44. 31P{1H} NMR spectral overlay of multifunctional AuNPs obtained in
CD3OD and referenced to H3PO4.

Figure S4.45. 19F{1H} NMR spectral overlay of multifunctional AuNPs obtained in
CD3OD and referenced to CFCl3.
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Figure S4.46. UV-Vis spectroscopic analysis of multifunctional AuNPs in CH3OH.
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Figure S4.47. ESI-MS analysis of disulfide 19.

Figure S4.48. TEM images of a) hvDIBO-PPh3-EG4-AuNPs, b) benzylamide(P=O)Ph3EG4-AuNPs, and c) (biotin)triazole-P(=N-Rhodamine)Ph3-EG4-AuNPs.

172

λem = 562 nm
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Merged

Figure S4.49. Additional images at 60x magnification of fibroblast cells labeled with
multifunctional AuNPs. Scale bar = 100 μm.
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Chapter 5

5

Contributions of the Studies and Outlook

5.1 Contributions of the Studies
The ability to reliably engineer target functionalities onto material surfaces to program
and tune their properties and reactivity in different environments represents an important
challenge in nanomaterials chemistry. This thesis examines the use of two prototypical
bioorthogonal reactions — originally designed to form bonds cleanly and selectively in
complex biological environments — as a chemical tool to effectively derivatize gold
nanoparticles (AuNPs) as a model nanomaterial. In addition to their ease-of-synthesis and
processability, AuNPs feature high stability, rich surface chemistry, and characterizability
by various techniques (e.g. NMR, IR, and UV-Vis spectroscopies, TGA, TEM) that
permit the precise determination of their composition and monitoring of their interfacial
chemistry. Furthermore, their widespread use in diagnostic imaging, therapeutics, and
catalysis makes AuNPs an interesting and relevant nanoplatform to investigate.
Specifically, this work describes:
1. New methodologies to cleanly incorporate strained alkyne (SA) and cargobearing triarylphosphine derivatives onto AuNPs to afford well-defined reactive
interfaces that undergo bioorthogonal transformations.
2. A new method to release molecules off AuNP nanocarriers, initiated by a highly
specific reaction between phosphines and azides.
3. Methods

to

quantitatively and

qualitatively

determine

these

chemical

functionalities on AuNPs and monitor interfacial reactivity of their monolayers.
4. An innovative strategy towards deploying multiple bioorthogonal reactions
independently on AuNPs via a single ligand, enabled by a combinatorial approach
using phosphine and strained alkyne reactivity.
5. New approaches for simple, clean, reliable, and versatile reactivity on AuNPs
under mild conditions to provide surfaces that are derivatized with target
molecules.
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The strain-promoted cycloaddition of 1,3-dipoles (e.g. azides and nitrones) onto alkynes
is one of the most important reactions in the click and bioorthogonal toolkit. It offers a
rapid, clean (no byproduct), and selective route towards forming robust covalent bonds.
However, the incorporation of SAs into AuNP monolayers is nontrivial; the strained C–C
triple bond is susceptible to thiol-yne addition, thus a SA-bearing thiol ligand cannot be
stably obtained and used. Chapter 2 addresses this deficiency through the use of
cyclopropenones, which feature exceptional stability and inertness towards thiols, as a
photochemical cyclooctyne precursor (Scheme 5.1). A cyclopropenone-bearing thiol
ligand was synthesized and allowed for direct incorporation of the cyclooctyne precursor
into the AuNP monolayer via ligand displacement. It was shown that the interfacial
cyclopropenone decarbonylates quantitatively (and rapidly, <10 min) under UV
irradiation to uncage dibenzocylooctyne, which reacts with various azides and a nitrone
to afford a library of derivatized AuNPs. Kinetic investigation of the interfacial SPAAC
between benzyl azide and dibenzocyclooctyne-AuNPs revealed no significant difference

Scheme 5.1. Generalized overview of AuNP surface derivatization by employing a
cyclopropenone-precursor strategy followed by interfacial SPAAC and SPANC with
azides and nitrones, respectively. Shapes represent a general functionality of interest.
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in reaction rate relative to the analogous reaction of unbound molecules. Modified
AuNPs were decomposed by I2 and the decomposition products were analyzed by mass
spectrometry to further confirm the presence of products resulting from successful
SPAAC and SPANC reactivity. This work represents an important advancement to AuNP
derivatization as it enables the incorporation of SA precursors directly into their
monolayer — without the aid of additional reagents or generation of byproducts —
followed by clean and rapid “shine & click” chemistry.
The Staudinger-Bertozzi ligation (SBL), as its name suggests, is a powerful chemical tool
to form bonds between two abiotic functionalities: azide and phosphine. However, its
ability to liberate an alcohol in the process is seldom utilized or recognized. Thus,
Chapter 3 serves to reinforce the SBL as a viable dual-purpose transformation (chemical
ligation and release) to demonstrate the release of molecules off AuNPs, triggered only
by a highly specific interaction with azides. The electrophilic ester trap, almost invariably
a methyl ester, was synthetically modified to tether a Rhodamine B dye as a model cargo
(Scheme 5.2). This cargo-bearing phosphine was successfully incorporated into AuNP
monolayers via a terminal thiol. Upon treatment with a water-soluble benzyl azide
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Scheme 5.2. Demonstrative release of molecules off AuNP surfaces using the SBL as a
bioorthogonal cleavage reaction. Shapes represent a general functionality of interest.
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variant, modified AuNPs underwent SBL to afford the ligated AuNP product and
liberated a cargo — in this case, a Rhodamine B alcohol. Due to the choice of cargo, the
release process could be monitored by fluorescence spectroscopy: as AuNP-bound dye
molecules are released from the surface, their previously quenched emission is recovered
(“turn-on”), which can be observed visually and spectroscopically. A control experiment
using the analogous phosphine oxide (P=O) modified AuNPs (which do not undergo
SBL) exhibited no release upon treatment with azide. Similarly, no significant release via
ligand displacement was observed when AuNPs were dispersed in intracellular
concentrations (1–10 mM) of glutathione. Thus, it was shown that the SBL represents the
only significant release mechanism among the conditions examined. This work is the first
time the SBL is utilized on a material surface to release molecules, enabled only by a
highly specific transformation. To facilitate the visualization of the release process, a
fluorescent dye was investigated as the cargo; however, the ester linkage is easily
synthetically accessible and represents a versatile chemical handle for tethering different
cargos such as drugs or biomolecules. Therefore, this work underscores the SBL as a
versatile chemical tool for tailoring AuNP surface functionalities via ligation and release
mechanisms.
The versatility of the SBL for chemical ligation and release on materials led to a major
shift in this thesis work to focus on addressing the challenge of multifunctionality —
wherein a single molecule or material can perform multiple chemical functions (or
reactions) independently. Multifunctionality on AuNPs can be achieved using multiple
functional thiols concurrently. However, the ligand ratios of the resulting multi-mixed
monolayers are difficult to control and quantitate, which hinders our understanding of the
final AuNP composition. To address this challenge, a single thiol ligand bearing multiple
functionalities can be employed. Chapters 2 and 3 demonstrated reliable methodologies
for incorporating SAs and cargo-carrying phosphines onto AuNPs to afford well-defined
mixed monolayers of known ligand concentrations. Chapter 4 extends this development
via a combinatorial approach: a cylooctyne precursor tethered via an electrophilic ester
trap to the triarylphosphine (Scheme 5.3). This cyclooctyne, once uncaged, represents a
“reactive tether” that enables a cargo to be immobilized onto AuNPs interfacially (via
SPAAC or SPANC with azides and nitrones, respectively) without having to
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Scheme 5.3. Generalized overview of highly modular reactivity on AuNPs.
Bioorthogonal ligation and cleavage reactions can be used interchangeably to afford
reliable and clean derivatization of AuNP surfaces. Shapes represent a general
functionality of interest.
synthetically introduce it in the thiol synthesis stage. Consequently, stability of the cargo
towards thiols, which was necessary in Chapter 3, is not necessitated in this new design.
This dual-bioorthogonal molecular tool exhibits the bioorthogonal reactivity of both
phosphine and SA functionalities: SPAAC or SPANC via the alkyne, and SBL or the
modified perfluoroaryl azide Staudinger reaction (PFAA-SR) via the phosphine. This
unique design enables two reaction pathways: “click-to-release”, which proceeds via
SPAAC/SPANC then SBL, or “double-click”, which proceeds via SPAAC/SPANC then
PFAA-SR (or reverse order).
A thiol ligand bearing this multifunctional moiety was synthesized and incorporated into
the AuNP monolayer successfully. Despite its structural complexity, reactivity at each
site can be carefully monitored via NMR (1H and 31P), IR, and UV-vis spectroscopies to
understand the AuNP composition at each step. Both click-to-release and double-click
strategies were successfully employed on the modified AuNPs. Biotin- and Rhodamine B
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dye-modified AuNPs (obtained via double-click) were used to demonstrate targeted
labelling of human fibroblast cells. This work represents significant advancement in
AuNP derivatization for two reasons: 1) it offers a modular and highly controlled method
to attach, release, and replace molecules as well as access multifunctional AuNPs from a
single template, and 2) it constitutes an important combinatorial prototype that is key to
achieving multifunctionality on materials in a controlled manner. As outlined in Sections
1.2.1 and 1.3.4, applications of nanomaterials typically require multiple functionalities
(e.g. targeting agent, imaging agent, therapeutics, or biomolecules) on their surface to be
effective, which highlights the importance of reliable and controlled derivatization
methodologies. The combination of bioorthogonal moieties that react in a modular and
mutually orthogonal manner overcomes the challenges associated with multifunctionality
and provides access to materials that are complex but still well-defined.
Overall this thesis work examines ways in which AuNP monolayers can be modified
effectively using two prototypical bioorthogonal reactions. Indeed, surface derivatization
of AuNPs has been achieved for decades — with varying levels of success — using
direct ligand binding approaches or other interfacial organic reactions (e.g. EDC/NHS
coupling). However, the resulting mixed monolayers are often ill-defined with respect to
their chemical composition and ligand concentrations. Instead, this work provides the
means to modify AuNP monolayers using reactions that proceed cleanly, rapidly,
selectively, and to completion under mild conditions (Scheme 5.4, Route A). The
underlying objective is two-fold: 1) conserving the AuNP core diameter and size
distribution during modification and 2) precisely determining and conserving the
concentration of target functionalities within the AuNP monolayer in each step. Although
seemingly trivial, the control of these two parameters can be highly consequential.
Properties of AuNPs are significantly affected by their size and shape, while their ligand
composition governs their interactions and activity inside different environments.
Existing applications that use derivatized AuNPs demonstrate that their methods work —
e.g. adding a targeting agent increased cellular uptake or the release of a drug off AuNP
monolayers led to decreased cell viability — but rarely investigate how well it works.
Continued advancement in nanotechnology using AuNPs (and other materials) will
require systematic

investigations

where the determination of

precise ligand
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Scheme 5.4. Conceptual scheme depicting the advantages of utilizing interfacial
bioorthogonal chemistry on AuNPs (Route A) versus other organic reactions (Route B).
concentrations is important to answer questions such as: How does varying the
concentration of surface peptides affect cellular uptake? If the drug loading in the
monolayer was increased/decreased to X mmol mg-1 AuNP, will it have an effect on cell
viability? Using other organic reactions, which suffer from the generation of byproducts,
incomplete or side reactivity, need for high temperature or pressure, use of a catalyst, or
incompatibility with in vivo use, can lead to AuNPs of changed core diameter, greater
size distribution, presence of impurities (both AuNP-bound and unbound), and ill-defined
monolayers that hinder systematic investigations (Scheme 5.4, Route B). The AuNPs
reported in this work represent not only a versatile platform on which surface
modifications can be achieved, but allows for careful tuning, determination, and
conservation of AuNP size and ligand concentrations due to the advantages associated
with bioorthogonal reactivity. Lastly, widespread commercialization of organic azides —
ranging from small molecules to large biomolecules — will result in further ease in
achieving surface modifications even by non-experts using the AuNPs reported in this
thesis.
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5.2

Outlook

The methodologies described in this thesis serve only as a stepping stone towards the
realization of multifunctional nanomaterials with well-defined interfaces. The
transposition of bioorthogonal chemistry to materials science is a relatively young field,
where existing methodologies are more application-oriented with less emphasis on
investigating the derivatized interface. Thus, future work in this field should address one
of the following two challenges:
1.

Continuing to demonstrate and expand the viability of bioorthogonal reactions
on nanomaterials to achieve controlled modifications. The bioorthogonal toolkit is
extensive and prolific, where new reactions are reported every year, each with their
own advantages with respect to stability of reactants, reaction kinetics, orthogonality
to other bioorthogonal reactions, and biocompatibility.[1] Methodologies for
incorporating these chemical functionalities onto materials, as well as quantifying
them, will be an important and necessary advancement in nanotechnology to fully
understand their composition-function relationship.

2.

Developing other combinatorial approaches to deploying bioorthogonal
chemistry on materials. The engineering of nanomaterials that can perform multiple
chemical functions (or reactions) independently is challenging, with emphasis on the
difficulties associated with controlling and fine-tuning the incorporation of multiple
target functionalities concurrently on a single material. As demonstrated in Chapter
4, the combination of bioorthogonal chemical functionalities that are mutually
orthogonal can serve to overcome these challenges via a modular approach wherein
each bioorthogonal reaction is executed independently and sequentially to afford a
well-defined multifunctional interface.

With respect to the work specifically described in this thesis, our group’s short-term goals
include expanding the methodologies developed here to other nanomaterials. Initially,
AuNPs were investigated due to their rich surface chemistry, high stability, and
characterizability by various techniques that permitted careful monitoring of their
monolayer composition and reactivity. Next steps include transposing and adapting these
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bioorthogonal strategies to other nanomaterials, e.g. Au nanorods (AuNRs), carbon-based
nanoparticles (or carbon dots), and carbon nanotubes (CNTs). Compared to AuNPs,
AuNRs exhibit higher absorbance of near-infrared (NIR) light, which features greater
utility for therapeutic applications involving photothermal heating and fluorescence
imaging.[2-3] In addition, we wish to further expand the application of bioorthogonal
chemistry onto carbon-based nanomaterials, which are far less studied. Carbon dots
feature low toxicity and exciting emissive properties, while CNTs are effective
nanocarriers for drugs and biomolecules and has potential for photothermal therapy.[4-5]
However, due to their general inertness, well-defined modifications on carbon dots and
CNTs are challenging to achieve. Our group has recently started investigating these
methods on CNTs, using protocols we previously developed for introducing chemical
functionality.[6-7] Lastly, new click-to-release and double-click strategies that involve
different bioorthogonal chemical functionalities will be further explored.
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